
<html lang="en"     class="pb-page"  data-request-id="0b18d699-f8aa-41e4-a89c-1a17dd1af0ec"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.8b01943;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2019.62.issue-9"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib" /></meta><meta name="dc.Creator" content="Min Jae  Lee" /></meta><meta name="dc.Creator" content="Deepak  Bhattarai" /></meta><meta name="dc.Creator" content="Jisu  Yoo" /></meta><meta name="dc.Creator" content="Zach  Miller" /></meta><meta name="dc.Creator" content="Ji Eun  Park" /></meta><meta name="dc.Creator" content="Sukyeong  Lee" /></meta><meta name="dc.Creator" content="Wooin  Lee" /></meta><meta name="dc.Creator" content="James J.  Driscoll" /></meta><meta name="dc.Creator" content="Kyung Bo  Kim" /></meta><meta name="dc.Description" content="Over the past 15 years, proteasome inhibitors (PIs), namely bortezomib, carfilzomib (Cfz) and ixazomib, have significantly improved the overall survival and quality-of-life for multiple myeloma (MM..." /></meta><meta name="Description" content="Over the past 15 years, proteasome inhibitors (PIs), namely bortezomib, carfilzomib (Cfz) and ixazomib, have significantly improved the overall survival and quality-of-life for multiple myeloma (MM..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 9, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b01943" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01943" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b01943" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01943" /></link>
        
    
    

<title>Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b01943" /></meta><meta property="og:title" content="Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0010.jpeg" /></meta><meta property="og:description" content="Over the past 15 years, proteasome inhibitors (PIs), namely bortezomib, carfilzomib (Cfz) and ixazomib, have significantly improved the overall survival and quality-of-life for multiple myeloma (MM) patients. However, a significant portion of MM patients do not respond to PI therapies. Drug resistance is present either de novo or acquired after prolonged therapy through mechanisms that remain poorly defined. The lack of a clear understanding of clinical PI resistance has hampered the development of next-generation PI drugs to treat MM patients who no longer respond to currently available therapies. Here, we designed and synthesized novel epoxyketone-based PIs by structural modifications at the P1′ site. We show that a Cfz analog, 9, harboring a hydroxyl substituent at its P1′ position was highly cytotoxic against cancer cell lines displaying de novo or acquired resistance to Cfz. These results suggest that peptide epoxyketones incorporating P1′-targeting moieties may have the potential to bypass resistance mechanisms associated with Cfz and to provide additional clinical options for patients resistant to Cfz." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b01943"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01943">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b01943&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b01943&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b01943&amp;href=/doi/10.1021/acs.jmedchem.8b01943" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 9</span><span class="cit-fg-pageRange">, 4444-4455</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/9" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01936" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b01978" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Min Jae Lee</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Min Jae Lee</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40536, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Min+Jae++Lee">Min Jae Lee</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Deepak Bhattarai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Deepak Bhattarai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40536, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Deepak++Bhattarai">Deepak Bhattarai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jisu Yoo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jisu Yoo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jisu++Yoo">Jisu Yoo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zach Miller</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zach Miller</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40536, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zach++Miller">Zach Miller</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ji Eun Park</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ji Eun Park</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ji+Eun++Park">Ji Eun Park</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sukyeong Lee</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sukyeong Lee</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sukyeong++Lee">Sukyeong Lee</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wooin Lee</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wooin Lee</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wooin++Lee">Wooin Lee</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James J. Driscoll</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James J. Driscoll</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Internal Medicine, Division of Hematology and Oncology and University of Cincinnati Cancer Institute, Cincinnati, Ohio 45267, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James+J.++Driscoll">James J. Driscoll</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Kyung Bo Kim</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kyung Bo Kim</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40536, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#39525b5250540b794c5240175c5d4c"><span class="__cf_email__" data-cfemail="bfd4ddd4d6d28dffcad4c691dadbca">[email protected]</span></a>. Phone: 1-859-257-5301.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kyung+Bo++Kim">Kyung Bo Kim</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4744-2466" title="Orcid link">http://orcid.org/0000-0003-4744-2466</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01943&amp;href=/doi/10.1021%2Facs.jmedchem.8b01943" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 9</span><span class="cit-pageRange">, 4444–4455</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 9, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>12 December 2018</li><li><span class="item_label"><b>Published</b> online</span>9 April 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 May 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b01943" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01943</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4444%26pageCount%3D12%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMin%2BJae%2BLee%252C%2BDeepak%2BBhattarai%252C%2BJisu%2BYoo%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D9%26contentID%3Dacs.jmedchem.8b01943%26title%3DDevelopment%2Bof%2BNovel%2BEpoxyketone-Based%2BProteasome%2BInhibitors%2Bas%2Ba%2BStrategy%2BTo%2BOvercome%2BCancer%2BResistance%2Bto%2BCarfilzomib%2Band%2BBortezomib%26numPages%3D12%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4455%26publicationDate%3DMay%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b01943"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1793</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">7</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b01943" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Min&quot;,&quot;last_name&quot;:&quot;Jae Lee&quot;},{&quot;first_name&quot;:&quot;Deepak&quot;,&quot;last_name&quot;:&quot;Bhattarai&quot;},{&quot;first_name&quot;:&quot;Jisu&quot;,&quot;last_name&quot;:&quot;Yoo&quot;},{&quot;first_name&quot;:&quot;Zach&quot;,&quot;last_name&quot;:&quot;Miller&quot;},{&quot;first_name&quot;:&quot;Ji&quot;,&quot;last_name&quot;:&quot;Eun Park&quot;},{&quot;first_name&quot;:&quot;Sukyeong&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;Wooin&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;J. Driscoll&quot;},{&quot;first_name&quot;:&quot;Kyung&quot;,&quot;last_name&quot;:&quot;Bo Kim&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;09&quot;,&quot;issue&quot;:&quot;9&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;4444-4455&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b01943&quot;},&quot;abstract&quot;:&quot;Over the past 15 years, proteasome inhibitors (PIs), namely bortezomib, carfilzomib (Cfz) and ixazomib, have significantly improved the overall survival and quality-of-life for multiple myeloma (MM) patients. However, a significant portion of MM patients do not respond to PI therapies. Drug resistance is present either de novo or acquired after prolonged therapy through mechanisms that remain poorly defined. The lack of a clear understanding of clinical PI resistance has hampered the development of next-generation PI drugs to treat MM patients who no longer respond to currently available therapies. Here, we designed and synthesized novel epoxyketone-based PIs by structural modifications at the P1′ site. We show that a Cfz analog, 9, harboring a hydroxyl substituent at its P1′ position was highly cytotoxic against cancer cell lines displaying de novo or acquired resistance to Cfz. These results suggest that peptide epoxyketones incorporating P1′-targeting moieties may have the potential to bypass resistance me&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01943&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01943" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01943&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01943" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01943&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01943" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01943&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01943&amp;href=/doi/10.1021/acs.jmedchem.8b01943" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b01943" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b01943" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b01943%26sid%3Dliteratum%253Aachs%26pmid%3D30964987%26genre%3Darticle%26aulast%3DLee%26date%3D2019%26atitle%3DDevelopment%2Bof%2BNovel%2BEpoxyketone-Based%2BProteasome%2BInhibitors%2Bas%2Ba%2BStrategy%2BTo%2BOvercome%2BCancer%2BResistance%2Bto%2BCarfilzomib%2Band%2BBortezomib%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D9%26spage%3D4444%26epage%3D4455%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291750" title="Hydroxyls">Hydroxyls</a>,</li><li><a href="/action/doSearch?ConceptID=292519" title="Cancer therapy">Cancer therapy</a>,</li><li><a href="/action/doSearch?ConceptID=292227" title="Drug resistance">Drug resistance</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/9" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/jmcmar.2019.62.issue-9/20190509/jmcmar.2019.62.issue-9.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/medium/jm-2018-019434_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01943&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Over the past 15 years, proteasome inhibitors (PIs), namely bortezomib, carfilzomib (Cfz) and ixazomib, have significantly improved the overall survival and quality-of-life for multiple myeloma (MM) patients. However, a significant portion of MM patients do not respond to PI therapies. Drug resistance is present either <i>de novo</i> or acquired after prolonged therapy through mechanisms that remain poorly defined. The lack of a clear understanding of clinical PI resistance has hampered the development of next-generation PI drugs to treat MM patients who no longer respond to currently available therapies. Here, we designed and synthesized novel epoxyketone-based PIs by structural modifications at the P1′ site. We show that a Cfz analog, <b>9</b>, harboring a hydroxyl substituent at its P1′ position was highly cytotoxic against cancer cell lines displaying <i>de novo</i> or acquired resistance to Cfz. These results suggest that peptide epoxyketones incorporating P1′-targeting moieties may have the potential to bypass resistance mechanisms associated with Cfz and to provide additional clinical options for patients resistant to Cfz.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54686" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54686" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Since the FDA approval of bortezomib (Btz) in 2003, proteasome inhibitors (PIs) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A) have become critical components of many MM treatment regimens. Compared to the pre-PI era, the use of PIs, either as single agents or in combination with an immunomodulatory agent, has significantly improved the 5-year overall survival rate for MM patients.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Despite these remarkable successes, MM remains nearly universally incurable due to <i>de novo</i> or acquired drug resistance. Since 2015, the FDA has approved three non-PI drugs, daratumumab (a monoclonal antibody (mAb) targeting CD38), elotuzumab (mAb targeting SLAMF7), and panobinostat (HDAC inhibitor). Although these non-PI drugs offer additional options for MM patients relapsed on current PI-based therapies, their response rates vary widely. Results from recent clinical trials show that responses to these non-PI drugs are rather transient with a median duration of ∼7–20 months before relapsing.<a onclick="showRef(event, 'ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4">(2−4)</a> Thus, there is an urgent unmet medical need for new agents that can yield durable responses for MM patients who have exhausted current treatment options.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/medium/jm-2018-019434_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Structures of proteasome inhibitors in clinical use. The gray-colored markings denote the functional groups that are proposed to form favorable interactions with the specificity pockets (S1–4) of a proteasome catalytic subunit. (B) Schematic representation of a prototypical proteasome substrate or substrate-like inhibitor bound to a proteasome catalytic subunit showing the unprimed residues (P1, P2, P3, and P4) located <i>N</i>-terminal to the cleavage site of the proteasome catalytic subunit (shown as an arrow) and the primed P1′ residue located C-terminal to the cleavage site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01943&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The ubiquitin-proteasome system (UPS) is responsible for maintaining protein homeostasis via controlled degradation of numerous intracellular proteins. The UPS furthermore plays a critical role in regulating cellular signaling pathways and several key processes described as the original hallmarks of cancer by Hanahan and Weinberg (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The fundamental importance of the UPS to cancer cells is further reflected by the recent inclusion of the proteotoxic stress as an additional hallmark of cancer.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/medium/jm-2018-019434_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Ubiquitin-proteasome system (UPS) and its association with various hallmarks of cancer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01943&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The UPS presumably remains essential for cancer cells regardless of resistance to existing PI drugs. The UPS components upstream of the proteasome (e.g., deubiquitinases, ubiquitin E3 ligases) are being explored as potential anticancer therapeutic targets,<a onclick="showRef(event, 'ref7 ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9 ref10 ref11">(7−11)</a> but clinical success is yet to be achieved. Alternatively, it remains to be seen whether the proteasome itself can be subsequently retargeted to achieve further therapeutic gains for MM patients relapsed on existing PI drugs. Although there are several new PIs in commercial development pipelines (e.g., delanzomib, oprozomib, marizomib), early clinical data indicate that those PIs may not be beneficial for patients with acquired resistance to existing PIs due to issues such as low response rates in high-risk populations and prevalent cross-resistance with existing PIs.<a onclick="showRef(event, 'ref12 ref13 ref14 ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15 ref16 ref17">(12−17)</a></div><div class="NLM_p">Until now, nearly all PIs have been developed through optimization of amino acid side chains (P1, P2, P3), which interact with the conventional substrate binding pockets (S1, S2, S3, etc.) of proteasome catalytic subunits (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B) located <i>N</i>-terminal to the cleavage site. This binding configuration is further stabilized by the formation of an antiparallel β-sheet configuration via hydrogen bonding interactions between the inhibitor’s peptide backbone and the conserved backbone residues such as Thr21, Gly47, and Ala49 of proteasome catalytic subunits.<a onclick="showRef(event, 'ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20">(18−20)</a> When combined with a C-terminal warhead, which targets the catalytic Thr1 residue, this strategy typically yields potent inhibitors including the three FDA-approved PIs: Btz, Ixz (peptide boronic acids), and Cfz (a peptide epoxyketone). However, this strategy might have unintentionally contributed to an increased incidence of cross-resistance among them. A potential strategy to circumvent PI cross-resistance is to identify and exploit a structural niche not utilized by existing PIs. In that regard, previously unexplored are P1′ binding sites, which lie on the C-terminal side of the proteasome catalytic subunit’s cleavage site (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B).</div><div class="NLM_p last">Here, we have developed peptide epoxyketones bearing a P1′-targeting moiety. The anticancer efficacy of these compounds was superior to their non-P1′-targeting parent compounds when evaluated against models of intrinsic and acquired Cfz resistance. The identified lead compound, <b>9</b>, an analog of Cfz containing a hydroxyl group at the P1′ position, displayed potent proteasome inhibitory activity and cytotoxicity in both Cfz-sensitive and Cfz-resistant cancer cell lines.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64782" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64782" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">The final compounds (<b>5</b>, <b>7</b>–<b>12</b>) were prepared as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. TBDPS (<i>t</i>-butyldiphenylsilyl) and methyl-protected alkenes <b>1a</b> and <b>1b</b> were synthesized in three steps following a known method starting from Boc-serine methyl ester.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Boc-serine methyl ester was treated with dimethyl methylphosphonate in the presence of <i>n</i>-butyllithium (<i>n</i>-BuLi) to yield a phosphoryl intermediate, which upon combination of Wittig–Horner and Baylis–Hillman-type one-pot reactions furnished the hydroxymethyl-substituted enone in a good yield. Protection of a hydroxyl group with TBDPS or a methyl group was carried out in TBDPS-Cl/DIEA or methyl iodide/silver oxide, respectively. Hydrogen peroxide was used to prepare epoxide <b>2a</b> and <b>2b</b> from the respective enones. Intermediates <b>3</b> and <b>4</b> were prepared using a conventional amide coupling reaction. Deprotection of TBDPS from the intermediate <b>4</b> in the presence of TBAF (t-butylammonium fluoride) yielded the final compound <b>5</b> as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>A. For Cfz P1′ derivatives, the left-hand peptide backbone of Cfz <b>6</b> was separately prepared in three steps fromBoc-serine using a series of amide coupling reactions in good yields. Another amide coupling reaction between benzyl deprotected <b>6</b> and Boc deprotected <b>2a</b> or <b>2b</b> gave the final compounds <b>7</b> and <b>8</b>. Deprotection of TBDPS from <b>7</b> yielded the final compound <b>9</b>. Compounds <b>10</b>, <b>11</b>, and <b>12</b> were prepared from compound <b>9</b> using the respective alkylating agents in the presence of organic base DIEA as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>B. UK101 and UK102 were used from in-house compound library.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/medium/jm-2018-019434_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0009.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis Scheme of <b>5</b> (UK101-OH) and <b>9</b> (Cfz–OH)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01943&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (A) (a) (i) CH<sub>3</sub>PO(OCH<sub>3</sub>)<sub>2</sub>, n-BuLi, THF, −78 °C, 2 h, Boc-serine methylester, THF, −78 °C, 3 h, 55%; (ii) Aqueous solution of formaldehyde, K<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O, rt, 4 h, 59%; (iii) TBDMS-Cl, imidazole, DCM, rt, 30 min, 71% or iodomethane, Ag<sub>2</sub>O, MeCN, rt, 24 h, 51%; (b) benzonitrile, H<sub>2</sub>O<sub>2</sub>, DIEA, MeOH, 0 °C, 3 h, 35–41%; (c) heptanoic acid, HBTU, HOBt, DIEA, DCM, rt, 18 h, 82%; (d) (i) H<sub>2</sub>, Pd/C, methanol, 1 h, (ii) Boc-deprotected 2a, HBTU, HOBt, DIEA, DCM, rt, 18 h, 91%; (e) TBAF, DCM, 2 h, 70%. (B) (a) (i) Phenylalanine benzyl ester hydrochloride, HBTU, HOBt, DIEA, DCM, rt, 18 h, 81%; (ii) TFA, DCM, rt, 1 h then evaporation and drying, Boc-homoPhe-OH, HBTU, HOBt, DIEA, DCM, rt, 18 h, 79%; (iii) TFA, DCM, rt, 1 h then evaporate and dried, morpholin-4-yl-acetic acid hydrochloride, HBTU, HOBt, DIEA, DCM, rt, 18 h, 65%; (b) (i) H<sub>2</sub>/Pd, C, methanol, 1 h; (ii) 2a or 2b, HBTU, HOBt, DIEA, DCM, rt, 18 h, 45% and 48%, respectively; (c) TBAF, DCM, 2 h, 64%; (d) MOM-Cl or MEM-Cl or methanesulfonyl chloride, DIEA, DCM, overnight, 60–64%.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Initial Screening for PIs That Can Overcome <i>de Novo</i> Resistance to Cfz</h3><div class="NLM_p">We recently noted that H727 cells derived from human lung adenocarcinoma are intrinsically resistant to Cfz (IC<sub>50</sub> of 611 nM, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01943/suppl_file/jm8b01943_si_001.pdf" class="ext-link">Supporting Information S1</a>) compared to a panel of cancer cell lines (IC<sub>50</sub>’s in the low nM range). Our mechanistic investigation via chemical and genetic modulation of proteasome catalytic subunits suggests that proteasome catalytic subunit composition contributes to the <i>de novo</i> resistance of H727 cells to Cfz.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Therefore, we envisioned that H727 cells can serve as an initial screening system in identifying PIs that can overcome <i>de novo</i> resistance to Cfz (currently there is no MM model with <i>de novo</i> resistance to Cfz). We hypothesized that alternative PIs with distinct structural features may interact differentially with proteasomes in H727 cells to induce proteasome inhibition and consequent cell death. As a control, we used another lung cancer cell, H23, which is highly sensitive to Cfz (IC<sub>50</sub> of 18 nM). We compared the cytotoxic effects of PIs with differing pharmacophores including P1′-targeted peptide epoxyketones (UK101 and UK102 previously developed in our laboratory)<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> in H727 and H23 cells (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/medium/jm-2018-019434_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Structures of UK101 and UK102. (B) Comparison of the cytotoxic potency (72-h IC<sub>50</sub> values) of H727 and H23 cells to carfilzomib, bortezomib, MG-132, UK101, UK102, and lactacystin. Data are reported as the mean ± SD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01943&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Btz (a peptide boronic acid) and MG-132 (a peptide aldehyde) displayed a comparable cytotoxicity in H727 and H23 cells. UK101 and UK102 were also not cross-resistant to Cfz, displaying similar IC<sub>50</sub> values in H727 cells and H23 cells. On the other hand, lactacystin (a lactone) was not as effective in H727 cells as in H23 cells. These results suggest that proteasome inhibition using alternative compounds can still be a viable therapeutic option even in the presence of resistance to Cfz.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Anticancer Efficacy of PIs with P1′ Moieties (UK101 and UK102) Is Not Attenuated by Acquired Cfz Resistance in Cancer Cells</h3><div class="NLM_p">As a next step to examine the effectiveness of P1′-targeting epoxyketones in cancer cells, we examined whether these compounds can overcome acquired Cfz resistance, a major clinical challenge facing Cfz-based therapies.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> We utilized a Cfz-resistant subline of RPMI8226 (derived from human MM cells), which had been adapted to escalating concentrations of Cfz over several months.</div><div class="NLM_p">As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A, the Cfz-resistant RPMI8226 cells displayed a marked (greater than 35-fold) increase in IC<sub>50</sub> values and elevated expression of the efflux transporter P-glycoprotein (P-gp), similar to the previous reports.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> The use of the P-gp inhibitor reversin 121 almost completely restored Cfz sensitivity (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01943/suppl_file/jm8b01943_si_001.pdf" class="ext-link">Supporting Information S2</a>), suggesting the predominant contribution of P-gp in the current model of acquired Cfz resistance. While both Cfz and epoxomicin (also reported as a P-gp substrate<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a>) displayed a marked increase in IC<sub>50</sub> values, UK101 and UK102 showed minimal changes in IC<sub>50</sub> values in Cfz-resistant RPMI 8226 cells compared to the parental control (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B).</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/medium/jm-2018-019434_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Effects of carfilzomib (Cfz) on the viability of an RPMI8266 cell line with acquired Cfz resistance (RPMI8266/CfzR) in comparison to the parental cell line. Cell viability was measured by MTS assay after 72 h drug treatment (left). Immunoblotting analysis showing a marked increase of P-gp expression in RPMI8226 Cfz-resistant cells in comparison to parental cells (right). (B) Comparison of the sensitivity (72-h IC<sub>50</sub> values) of RPMI8226 parental and Cfz-resistant cells to Cfz, epoxomicin, UK101, and UK102. Data are reported as the mean ± SD. For epoxomicin and carfilzomib, the SD values were obtained from three independent experiments. For UK101 and UK102, the SD values were from nonlinear regression analysis using three replicates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01943&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Anticancer Efficacy of UK101 and UK102 Is Not Impaired by Acquired Btz Resistance in Primary MM Samples</h3><div class="NLM_p">We next investigated whether UK101 and UK102 can be effective in primary MM samples from patients who do not respond to Btz (We were not able to obtain MM samples from patients who are resistant to Cfz, but it was previously reported that patients with MM refractory to or relapsed on Btz are often cross-resistant to Cfz.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a>). Using primary MM samples from 14 different donors (6 from PI-naïve patients and 8 from patients relapsed on Btz therapy), their sensitivity to Cfz was assessed. The results indicated varying degrees of sensitivity to Cfz, but the MM samples from the patients who relapsed on Btz tended to be less responsive to Cfz than those from patients from the PI-naïve group (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). Because of the limited quantities of primary MM samples from five patients (#5–8 and #14), we utilized only nine primary MM samples (4 Btz-resistant and 5 PI-naïve) to examine the effect of UK101 or UK102. When nine primary MM samples treated with UK101 or UK102 for 48 h, the results indicated that cytotoxic effects of UK101 or UK102 were similar. Although the current sample size was small, the lack of apparent cross-resistance between Cfz/Btz and UK101/UK102 was encouraging.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/medium/jm-2018-019434_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of carfilzomib (Cfz), UK101, and UK102 on cell viability of primary MM samples from 14 different donors, six from Btz/Cfz-naïve patients and eight from patients relapsed on Btz therapy. Primary MM cells were treated with Cfz (A, 50 nM), UK101 (B, 10 μM), or UK102 (C, 10 μM) for 48 h. Cell viability was measured using an ATP-based luminescent assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01943&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Introduction of Hydrophilic Residues at P1′ Position of Peptide Epoxyketones Improves Proteasome Inhibitory Potency</h3><div class="NLM_p">To improve the potency of UK101 and UK102 and obtain structure–activity relationship (SAR) information, we first utilized docking models of UK101 bound to β1i and β5, known targets of UK101. UK101 was initially identified as a selective inhibitor of the β1i subunit at nanomolar concentration ranges.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Later, UK101 was also found to inhibit the β5 subunit (chymotrypsin-like (CT-L) activity) at micromolar concentration ranges.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Docking structures shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> were generated by Autodock Vina using the previously reported X-ray structures from mouse 20S proteasomes complexed with ONX 0914<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and were used as a guide to our optimization effort at the P1′ position. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A, the P1–P3 residues of UK101 were predicted to occupy the S1–S3 pockets located deep inside of the active sites of the β1i and β5 subunits.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/medium/jm-2018-019434_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Predicted docking models of UK101 and carfilzomib (Cfz) bound to β5 or β1i. The location of UK101’s TBDMS group positioned within putative P1′ pockets is highlighted using a purple-colored circle. β5 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UNB">3UNB</a>) and β1i (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UNF">3UNF</a>) from mammalian 20S proteasomes were used as templates. In cartoon presentation, β1i (gray, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UNF">3UNF</a>) was superposed to β5 (yellow, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UNB">3UNB</a>) and only different amino acid residues are shown in stick model. (B) Comparison of UK101 and <b>5</b>(UK101-OH) in terms of their potency (IC<sub>50</sub> values) against proteasome chymotrypsin-like activity (in RPMI8226 cell lysate), β1i/LMP2 catalytic activity (in 20S purified human immunoproteasome), and against H23, H727, and Cfz-resistant RPMI8226 cells as measured by MTS cell viability assay. Data are reported as the mean ± SD. Docking model of UK101-OH bound to β1i (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UNF">3UNF</a>). The P1′–OH of UK101-OH (<b>5</b>) is perfectly positioned to form hydrogen bonds with Ser168 and Ser21.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01943&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">However, unlike Cfz bound to β5, docking models indicated that UK101 occupies an additional binding pocket (S1′) of the β5 as well as β1i subunits via its P1′ group (highlighted in purple circles, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A), which is not occupied by Cfz or Btz.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Although the P1′ group (<i>t</i>-butyldimethylsilyl, TBDMS) of UK101 points toward the surface of β1i, it is predicted to contribute to a favorable hydrogen bonding interaction with the hydroxyl side chain of Ser168 within the S1′ pocket (bottom-left, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). In the case of UK101 bound to β5, the amino acid residue changes within the S1′ pocket (especially, β1i-Ser168 → β5-Tyr169) are predicted to abolish this additional hydrogen bonding interaction with the TBDMS (top-left, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A).</div><div class="NLM_p last">The resulting change in amino acid residues of the S1′ pocket is also predicted to force the large hydrophobic TBDMS group to be surrounded by the polar amino acids (Asp17, Thr21, Ser130) within the S1′ pocket, a plausible contributing factor toward UK101’s low potency against the β5 subunit.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> On the basis of this prediction, we hypothesized that the introduction of small polar groups at the P1′ position could provide energetically favorable hydrogen bonding interactions with the polar amino acid residues within the S1′ pockets of β1i and β5, potentially improving potency against both subunits. To test this, we replaced the bulky hydrophobic P1′ substituent (TBDMS) of UK101 with a hydroxyl group (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>A) and assessed its impact. This simple P1′ substitution increased <i>in vitro</i> 20S proteasome inhibitory potency by ∼4–10-fold (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). This experimental result is consistent with the docking models of UK101-OH (<b>5</b>) bound to β1i (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UNF">3UNF</a>), in which the P1′ hydroxyl group of UK101-OH (<b>5</b>) is perfectly positioned to form hydrogen bonds with the oxygen of Ser168 carbonyl backbone and the hydroxyl side chain of Ser21. Consequently, the P1′ hydroxyl group also considerably improved the cytotoxic activity of compound <b>5</b> in cancer cell lines, including our models of both <i>de novo</i> and acquired Cfz resistance. On the basis of this result, we suspect that the P1′ residue of peptide epoxyketones may play an important role in overcoming the resistance of cancer cells to Cfz.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Development of 9 (Cfz–OH) with an Improved Potency in Models of <i>de Novo</i> and Acquired Cfz Resistance</h3><div class="NLM_p">In our efforts to further optimize <b>5</b>, we considered that the P1–P4 groups of Cfz have already been thoroughly optimized for the S1–S4 pockets of β5 and β5i (as well as β1i, to a lesser extent, based on the largely β1i/β5 superimposed model, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). We thus decided to attach several different P1′ moieties to Cfz (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Our hypothesis was that Cfz analogs bearing a P1′-targeting group could overcome cross-resistance to Cfz. We also expected that a Cfz analog containing a polar P1′ moiety may have an improved inhibitory potency against both β5 and β1i compared to Cfz due to additional P1′:S1′ interactions (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B). We prepared Cfz analogs having a series of P1′ moieties varying from bulky hydrophobic to small hydrophilic residues (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>B). We subsequently measured their activity against cell lysates to measure CT-L (β5/β5i) inhibition and against 20S purified immunoproteasomes to measure β1i inhibition. As predicted by <i>in silico</i> docking analysis, <b>9</b> and <b>12</b> having small polar moieties were most potent <i>in vitro</i> with IC<sub>50</sub> values similar to that of Cfz. When these two compounds were tested using Cfz-resistant H727 cells, <b>12</b> was less potent than Cfz against H727. On the other hand, <b>9</b> (Cfz–OH, a Cfz analog with a hydroxyl group at the P1′ position) demonstrated an improved potency by ∼10-fold relative to Cfz. When tested against RPMI8226 with acquired Cfz resistance, <b>9</b> demonstrated an almost three-fold improvement in potency against Cfz-resistant RPMI8226 cells as compared to Cfz (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/medium/jm-2018-019434_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0007.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Potency (IC<sub>50</sub> values) for compounds with various substitutions at the P1′site against proteasome chymotrypsin-like activity (RPMI8226 cell lysate), β1i/LMP2 activity (purified human 20S immunoproteasome), and cell viability of H23, H727, and Cfz-resistant RPMI8226 cells. Data reported as the mean ± SD (carfilzomib, <i>n</i> = 3 independent experiments) or from a single experiment (3 replicates, <b>7</b>, <b>9</b>, and <b>12</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01943&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Compound <b>9</b> (Cfz–OH) Has Improved Metabolic Stability Compared to Its Close Structural Analog, Cfz</h3><div class="NLM_p">Cfz is rapidly metabolized <i>in vivo</i> with plasma half-lives of less than 1 h,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> likely contributing to its lack of efficacy against solid cancers especially those with poorly developed vasculature.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The metabolic inactivation of Cfz is reported to be mediated mainly by microsomal epoxide hydrolase (mEH) and peptidases.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> In the case of mEH, the active site harbors two conserved tyrosine residues which may contribute to substrate specificity and orientation of substrates within the active site.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35,36)</a> The prototypical substrates of mEH include planar hydrophobic compounds such as various epoxides of polycyclic aromatic hydrocarbons and steroids.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> It is thus expected that the epoxide ring of Cfz occupies the active site of mEH with a position suitable for hydrolysis to yield Cfz-diol (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A). We hypothesized that the addition of a hydroxyl group adjacent to the epoxide ring of Cfz (compound <b>9</b>) may hinder the hydrolysis of the epoxide ring by inhibiting access to the active site of mEH. When the metabolic stability of <b>9</b> was examined in rat liver homogenates, <b>9</b> was indeed more stable than Cfz (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B).</div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/medium/jm-2018-019434_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0008.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Schematic depicting the rapid metabolism of Cfz by microsomal epoxide hydrolase (mEH) to the inactive diol. (B) Quantification of the remaining levels of Cfz or <b>9</b> following the incubation with rat liver homogenate containing active mEH and peptidase activities for 5, 10, and 20 min, respectively. Data presented as mean ± SD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01943&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48510" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48510" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In expanding the clinical utility of existing PI drugs, cancer resistance, either <i>de novo</i> or acquired, remains a major obstacle. Currently, MM patients who do not respond to PI therapy or relapse after prolonged PI have very dismal outcomes with median survival of less than one year. To date, several mechanisms of PI resistance have been reported, including mutations/amplification of proteasome catalytic subunits, dysregulations of unfolded protein response and autophagy, overexpression of MARCKS proteins or efflux transporters, increased formation of aggresomes, and others.<a onclick="showRef(event, 'ref38 ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref38 ref39 ref40 ref41">(38−41)</a> However, clinically relevant mechanisms of PI resistance remain to be uncovered, making it difficult to achieve an eventual goal of developing therapeutic options for patients refractory to current PI drugs.</div><div class="NLM_p">Several reports indicate that the proteasome remains indispensable to the survival of cancer cells despite their resistance to PI drugs. The proteasome plays fundamental roles in various cellular functions and to date there appears no pathway/machinery that can fully compensate for the loss of proteasome function. Several reports showed that Btz-resistant MM cells remain susceptible to the disruption of proteasome pathways.<a onclick="showRef(event, 'ref22 ref42 ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref22 ref42 ref43 ref44">(22,42−44)</a> For instance, an inhibitor targeting the noncatalytic α7 proteasome subunit was effective against bortezomib-resistant THP-1 cells harboring a mutated <i>PSMB5</i> gene encoding the catalytic β5 subunit.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> These <i>in vitro</i> results require further validation in clinical settings, but they support that proteasome inhibition may offer therapeutic gains even in patients with MM relapsed/refractory to currently used PIs in clinic.</div><div class="NLM_p last">In this study, we used two established cancer cell lines with <i>de novo</i> or acquired resistance to Cfz and identified a novel PI compound with promising efficacy against both cell lines. Among the tested compounds, we found that epoxyketones with previously underexplored P1′ substituents can overcome both <i>de novo</i> and to a lesser degree, acquired Cfz resistance in cell line models. Compared to the boronic acid–based PIs, peptide epoxyketones feature a much improved selectivity in their interactions with the proteasome by forming an 1,4-oxazepane adduct with the <i>N</i>-terminal catalytic threonine residue of the proteasome.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Recent extensive reviews of the literatures that describe the efficacy and toxicity profiles of carfilzomib-based regimens in clinic further supports the safety and tolerability of the peptide epoxyketone family.<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a> Peptide epoxyketones with an improved metabolic stability and an ability to bypass resistance mechanisms may offer a more promising route for further drug development efforts. Future studies will address the <i>in vivo</i> efficacy and metabolic stability of epoxyketones with previously underexplored P1′ substituents that can overcome both <i>de novo</i> and acquired Cfz resistance.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84426" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84426" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">By exploring the chemical space at the P1′ position of peptide epoxyketones, we identified novel PIs effective against cell line models of <i>de novo</i> and acquired resistance to Cfz as well as primary MM cells. Our lead compound closely mimics the FDA-approved Cfz except for the addition of a hydroxyl group at the P1′ position. Our lead peptide epoxyketone with an S1′-occupying component displayed an improved metabolic stability over Cfz. This could provide potentially important advantages in expanding the utility of PIs to the many solid cancers in need of improved therapeutics. Further investigations regarding the contribution of P1′ substituents to metabolic stability and activity against PI-resistant patient samples are ongoing.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15507" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15507" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> General</h3><div class="NLM_p">All chemical reagents starting materials and solvents were purchased from commercial vendors and used without further purification. TLC was performed on precoated plates and spots were detected by using UV or staining solution of phosphomolybdic acid hydrate (PMA) or iodine. Silica gel column chromatography was performed on 60 Å silica gel, 230–400 mesh (Merck). Proton and carbon NMR spectra were recorded on a Varian spectrometer at 400 MHz. Chemical shifts were reported in ppm units with tetramethylsilane as a reference standard. Multiplicities of NMR signals were reported using different abbreviations like singlet (s), doublet (d), triplet (t), quartet (q), and multiplet (m). Chemical shifts were reported in parts per million (ppm) and coupling constant (<i>J)</i> is reported in Hz. Mass spectra were recorded on an Agilent Technologies 6120 Quadrupole LC/MS. The mobile phases used were A, H<sub>2</sub>O containing 0.1% formic acid and B, acetonitrile (CH<sub>3</sub>CN) containing 0.1% formic acid. The linear gradient of B/A from 5:95 to 90:10 over 18 min and then 100:0 over 7 min was used in an Agilent Eclipse XBD-C18 column (5-μm particle size), 4.6 mm diameter ×150 mm with a flow rate of 0.4 mL/min. The purity of all final compound used in bioassay was determined in an Agilent Technologies 1200 series equipped with a UV detector set at 254 nm using same column, gradient and flow rate to be ≥95%. Melting points were determined on Thermo Scientific 1001D apparatus and were uncorrected.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> Synthesis</h4><div id="sec5_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i17" class="anchor-spacer"></div><h5 class="article-section__title" id="_i17"> General Procedure for Deprotection of Benzyl Group</h5><div class="NLM_p last">Benzyl ester was dissolved in methanol and 5 mol % Pd/C was added. The solution was stirred under hydrogen gas environment for 30 min. Deprotected carboxylic acid was filtered through Celite and solvent was concentrated. Deprotected carboxylic acid was used in the next step without further purification.</div></div><div id="sec5_1_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i18" class="anchor-spacer"></div><h5 class="article-section__title" id="_i18"> General Procedure for Deprotection of Boc Group</h5><div class="NLM_p last">To the solution of Boc-protected amine in dichloromethane (DCM), excess of TFA was added and the reaction solution was stirred at room temperature for 1 h. Solvent was evaporated under reduced pressure and the crude TFA salt of amine was used in next step without further purification.</div></div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> (S)-<i>tert</i>-Butyl 2-((<i>tert</i>-butyldiphenylsilyloxy)methyl)-6-methyl-3-oxohept-1-en-4-ylcarbamate (<b>1a</b>)</h4><div class="NLM_p">A solution of <i>n</i>-BuLi (25.46 mL, 40.76 mmol) in hexane was added dropwise to the stirred solution of dimethyl methylphosphonate (4.43 mL, 40.76 mmol) in THF at −78 °C. The reaction mixture was stirred at the same temperature for 2 h. A solution of <i>N</i>-(<i>tert</i>-butoxycarbonyl)-<span class="smallcaps smallerCapital">l</span>-leucine methyl ester (2.5 g, 10.19 mmol) in THF was then added to the reaction mixture, and the reaction solution was further stirred for 3 h at same temperature. Reaction temperature was gradually increased up to room temperature, and the reaction was quenched with the addition of water. The product was extracted with ethyl acetate three times, and the collected organic layer was dried over sodium sulfate. It was then filtered, concentrated under reduced pressure, and purified through flash column chromatography using 50% ethyl acetate in hexane to yield pure product ((S)-<i>tert</i>-butyl 1-(dimethoxyphosphoryl)-5-methyl-2-oxohexan-3-ylcarbamate) as a colorless sticky oil (1.88 g, 55% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.18 (d, <i>J</i> = 8.6 Hz, 1H), 4.40–4.26 (m, 1H), 3.79 (d, <i>J</i> = 4.5 Hz, 3H), 3.76 (d, <i>J</i> = 4.4 Hz, 3H), 3.32 (dd, <i>J</i> = 14.2, 22.6 Hz, 1H), 3.08 (dd, <i>J</i> = 14.2, 22.0 Hz, 1H), 1.76–1.61 (m, 2H), 1.43 (s, 10H), 0.99–0.86 (m, 6H).</div><div class="NLM_p">To the stirred solution of (S)-<i>tert</i>-butyl 1-(dimethoxyphosphoryl)-5-methyl-2-oxohexan-3-ylcarbamate (1.88 g, 5.57 mmol) and formaldehyde (1.35 mL, 16.71 mmol) in 30 mL of water, aq. solution of potassium carbonate (0.92 g, 6.68 mmol) was added dropwise at room temperature. Reaction mixture was further stirred for 4 h at the same temperature. The crude product was extracted with ethyl acetate three times, and the collected organic layer was dried over sodium sulfate. It was then filtered, concentrated under reduced pressure, and purified by flash column chromatography using 30% ethyl acetate in hexane to yield pure product ((S)-<i>tert</i>-butyl 2-(hydroxymethyl)-6-methyl-3-oxohept-1-en-4-ylcarbamate) as colorless oil (0.89 g, 59% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.22 (s, 1H), 6.17–6.06 (m, 1H), 5.03 (d, <i>J</i> = 12.6 Hz, 2H), 4.34 (t, <i>J</i> = 10.2 Hz, 2H), 1.73 (s, 1H), 1.42 (d, <i>J</i> = 3.4 Hz, 12H), 0.99 (d, <i>J</i> = 6.3 Hz, 3H), 0.90 (d, <i>J</i> = 6.5 Hz, 3H).</div><div class="NLM_p last">To the stirred solution of (S)-<i>tert</i>-butyl 2-(hydroxymethyl)-6-methyl-3-oxohept-1-en-4-ylcarbamate (0.9 g, 3.30 mmol) and imidazole (0.67 g, 9.92 mmol) in DCM at room temperature, TBDPS-Cl (2.53 mL, 9.92 mmol) was added dropwise, and the reaction solution was stirred at same temperature for 30 min. Solvent was removed under reduced pressure, and residue was purified by flash column chromatography using 5% ethyl acetate in hexane to yield pure product (<b>1a</b>) as colorless thick oil (1.2 g, 71% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.66–7.58 (m, 4H), 7.44–7.31 (m, 6H), 6.33 (s, 1H), 6.24 (s, 1H), 5.10–4.93 (m, 2H), 4.50–4.27 (m, 2H), 1.68 (t, <i>J</i> = 7.6 Hz, 1H), 1.24 (ddd, <i>J</i> = 4.5, 10.0, 14.0 Hz, 2H), 1.05 (d, <i>J</i> = 2.2 Hz, 9H), 0.97 (d, <i>J</i> = 6.5 Hz, 3H), 0.87 (d, <i>J</i> = 6.6 Hz, 3H).</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> (S)-<i>tert</i>-Butyl 2-(methoxymethyl)-6-methyl-3-oxohept-1-en-4-ylcarbamate (<b>1b</b>)</h4><div class="NLM_p last">To the solution of (S)-<i>tert</i>-butyl 2-(hydroxymethyl)-6-methyl-3-oxohept-1-en-4-ylcarbamate (100 mg, 0.36 mmol) and iodomethane (0.23 μL, 3.68 mmol) in acetonitrile, silver oxide (427 mg, 1.84 mmol) was added, and the reaction mixture was stirred at room temperature for 24 h. The solvent was removed under reduced pressure and residue was purified by flash column chromatography using 10% ethyl acetate in hexane. Pure product was collected as colorless sticky solid (54 mg, 51% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.23 (s, 1H), 6.09 (s, 1H), 5.09 (d, <i>J</i> = 9.0 Hz, 1H), 5.00 (td, <i>J</i> = 3.5, 9.5 Hz, 1H), 4.09 (t, <i>J</i> = 1.5 Hz, 2H), 3.36 (s, 3H), 1.80–1.62 (m, 1H), 1.39 (m, 11H), 0.97 (d, <i>J</i> = 6.5 Hz, 3H), 0.87 (d, <i>J</i> = 6.7 Hz, 3H).</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> <i>tert</i>-Butyl (S)-1-((S)-2-((<i>tert</i>-butyldiphenylsilyloxy)methyl)oxiran-2-yl)-4-methyl-1-oxopentan-2-ylcarbamate (<b>2a</b>) (General Procedure for Epoxidation)</h4><div class="NLM_p last">The mixture of <b>1a</b> (1.2 g, 2.35 mmol), benzonitrile (2.4 mL, 23.5 mmol) and hydrogen peroxide (3.99 mL, 58.75 mmol) in methanol was stirred at 0 °C, and DIEA (4.10 mL, 23.5 mmol) was added dropwise. The reaction mass was stirred at the same temperature for 3 h. Methanol was removed under reduced pressure, and the reaction mixture was extracted with ethyl acetate three times. The collected organic layer was dried under sodium sulfate, filtered, and concentrated. Crude product was purified by flash column chromatography using 10% ethyl acetate in hexane. Pure required product was collected as colorless sticky solid (500 mg, 41% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.68 (m, 4H), 7.46–7.36 (m, 6H), 5.08 (dd, <i>J</i> = 7.2, 23.4 Hz, 2H), 4.47 (d,<i>J</i> = 10.5 Hz, 1H), 3.49 (d, <i>J</i> = 11.5 Hz, 1H), 3.17 (d, <i>J</i> = 4.9 Hz, 1H), 2.98 (d, <i>J</i> = 4.9 Hz, 1H), 1.23–1.11 (m, 2H), 1.00 (d, <i>J</i> = 1.9 Hz, 10H), 0.93 (d, <i>J</i> = 5.6 Hz, 6H).</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> <i>tert</i>-Butyl (S)-1-((S)-2-(methoxymethyl)oxiran-2-yl)-4-methyl-1-oxopentan-2-ylcarbamate (<b>2b</b>)</h4><div class="NLM_p last">Compound <b>2b</b> was prepared using same general procedure for epoxidation as <b>2a</b> from (S)-<i>tert</i>-butyl 2-(methoxymethyl)-6-methyl-3-oxohept-1-en-4-ylcarbamate (<b>1b</b>) to yield colorless sticky solid (20 mg, 35% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.89 (dd, <i>J</i> = 7.2, 23.4 Hz, 2H), 4.53 (d, <i>J</i> = 10.5 Hz, 1H), 3.51 (d, <i>J</i> = 11.5 Hz, 1H), 3.15 (d, <i>J</i> = 4.9 Hz, 1H), 2.98 (d, <i>J</i> = 4.9 Hz, 1H), 1.85–1.63 (m, 1H), 1.39–1.28 (m, 11H), 0.99 (d, <i>J</i> = 6.5 Hz, 3H), 0.87 (d, <i>J</i> = 6.7 Hz, 3H).</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> (S)-Benzyl 2-heptanamidopropanoate (<b>3</b>) (General Procedure for Amide Coupling)</h4><div class="NLM_p last">To the stirred solution of alanine benzyl ester hydrochloride (1 g, 2.84 mmol) and heptanoic acid (0.44 mL, 3.13 mmol) in DCM, HBTU (2.15 g, 5.68 mmol), HOBt (0.77 g, 5.68 mmol), and DIEA (2.48 mL, 14.2 mmol) were added at room temperature, and the resulting reaction mixture was stirred at the same temperature overnight. Solvent was removed under reduced pressure, and residue was purified by flash column chromatography using 30% ethyl acetate in hexane. Pure product was collected as white sticky solid (0.68 g, 82%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.63–7.31 (m, 5H), 5.95 (s, 1H), 5.16 (t, <i>J</i> = 4.6 Hz, 2H), 4.72–4.56 (m, 1H), 2.18 (td, <i>J</i> = 2.8, 8.0 Hz, 2H), 1.59 (d, <i>J</i> = 9.0 Hz, 2H), 1.46–1.12 (m, 9H), 0.86 (t, <i>J</i> = 8.6 Hz, 3H).</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>N</i>-((S)-1-((S)-1-((S)-2-((<i>tert</i>-Butyldiphenylsilyloxy)methyl)oxiran-2-yl)-4-methyl-1-oxopentan-2-ylamino)-1-oxopropan-2-yl)heptanamide (<b>4</b>)</h4><div class="NLM_p last">Benzyl ester was deprotected from compound <b>3</b> using general procedure for benzyl deprotection reaction and Boc group was deprotected from intermediate <b>2a</b> using general procedure for Boc deprotection reaction. Thus, obtained free carboxylic acid and amines were coupled using general procedure for amide coupling reaction to yield intermediate <b>4</b> as colorless sticky solid (91%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.74–7.59 (m, 4H), 7.38 (dt, <i>J</i> = 6.7, 8.9 Hz, 6H), 6.71 (d, <i>J</i> = 7.5 Hz, 1H), 6.09 (d, <i>J</i> = 7.5 Hz, 1H), 4.65–4.52 (m, 2H), 4.48 (d, <i>J</i> = 11.4 Hz, 1H), 3.47 (d, <i>J</i> = 11.5 Hz, 1H), 3.20 (d, <i>J</i> = 5.1 Hz, 1H), 2.97 (d, <i>J</i> = 5.1 Hz, 1H), 2.25–2.07 (m, 2H), 1.82–1.50 (m, 4H), 1.42–1.16 (m, 10H), 0.99 (s, 9H), 0.95 (d, <i>J</i> = 6.3 Hz, 3H), 0.91 (d, <i>J</i> = 6.3 Hz, 3H), 0.89–0.81 (m, 3H).</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> <i>N</i>-((S)-1-((S)-1-((R)-2-(Hydroxymethyl)oxiran-2-yl)-4-methyl-1-oxopentan-2-ylamino)-1-oxopropan-2-yl)heptanamide (<b>5</b>) (General Procedure for TBDPS Deprotection)</h4><div class="NLM_p last">To the solution of compound <b>4</b> (71 mg, 0.12 mmmol) in DCM, TBAF (0.25 mL, 0.25 mmol) was added at room temperature, and the reaction mass was stirred at the same temperature for 30 min. Solvent was removed under reduced pressure, and the resulting residue was purified by flash column chromatography using 5% methanol in DCM to yield pure product as colorless sticky solid (30 mg, 70% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.97 (d, <i>J</i> = 7.4 Hz, 1H), 6.16 (d, <i>J</i> = 7.6 Hz, 1H), 4.65–4.44 (m, 2H), 4.19 (dd, <i>J</i> = 4.3, 12.7 Hz, 1H), 3.70 (dd, <i>J</i> = 4.7, 12.7 Hz, 1H), 3.31 (d, <i>J</i> = 5.0 Hz, 1H), 3.06 (d, <i>J</i> = 5.0 Hz, 1H), 2.54 (d, <i>J</i> = 6.6 Hz, 1H), 2.15 (dt, <i>J</i> = 4.3, 8.8 Hz, 2H), 1.96 (d, <i>J</i> = 4.6 Hz, 1H), 1.72–1.49 (m, 4H), 1.41–1.15 (m, 9H), 0.91 (t, <i>J</i> = 7.6 Hz, 5H), 0.87–0.80 (m, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 207.72, 173.14, 172.51, 62.02, 61.42, 51.01, 49.31, 48.28, 39.07, 36.56, 31.46, 28.86, 25.55, 25.13, 23.30, 22.43, 21.09, 17.97, 13.98; LCMS (ES+) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>35</sub>N<sub>2</sub>O<sub>5</sub> [M + H]<sup>+</sup> 371.2, found: 371.2.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (S)-Benzyl 2-((S)-4-methyl-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentan-emido)-3-phenylpropanoate (<b>6</b>)</h4><div class="NLM_p">Intermediate <b>6</b> was prepared in three steps starting from Boc-Leu-OH. Dipeptide (S)-benzyl 2-((S)-2-(<i>tert</i>-butoxycarbonylamino)-4-methylpentanamido)-3-phenylpropanoate was prepared using the general procedure for amide coupling reaction from Boc-Leu-OH and phenylalanine benzyl ester hydrochloride as white solid (81%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.34 (m, 3H), 7.30–7.22 (m, 2H), 7.19 (m, 3H), 7.00 (t, <i>J</i> = 4.3 Hz, 2H), 6.45 (d, <i>J</i> = 7.8 Hz, 1H), 5.19–5.05 (m, 2H), 4.91–4.83 (m, 1H), 4.77 (s, 1H), 3.10 (t, <i>J</i> = 6.7 Hz, 2H), 1.67–1.51 (m, 3H), 1.41 (s, 9H), 0.87 (dt, <i>J</i> = 4.0, 2.1 Hz, 6H).</div><div class="NLM_p">The Boc deprotected above prepared dipeptide was further coupled with Boc-<span class="smallcaps smallerCapital">l</span>-homophenylalanine using the general procedure for amide coupling reaction to prepare tripeptide (S)-benzyl 2-((S)-2-((S)-2-(<i>tert</i>-butoxycarbonylamino)-4-phenylbutanamido)-4-methylpentanamido)-3-phenylpropanoate as white solid (79%). White solid (79%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.33 (dd, <i>J</i> = 4.8, 1.8 Hz, 2H), 7.29–7.22 (m, 5H), 7.21–7.12 (m, 5H), 7.01–6.94 (m, 2H), 6.43 (d, <i>J</i> = 7.5 Hz, 1H), 6.37 (d, <i>J</i> = 8.0 Hz, 1H), 5.20–5.00 (m, 2H), 4.97–4.77 (m, 2H), 4.36 (td, <i>J</i> = 8.7, 4.9 Hz, 1H), 3.99 (d, <i>J</i> = 7.4 Hz, 1H), 3.07 (q, <i>J</i> = 7.9, 7.1 Hz, 2H), 2.62 (t, <i>J</i> = 7.9 Hz, 2H), 2.06 (dt, <i>J</i> = 14.2, 7.0 Hz, 1H), 1.85 (dd, <i>J</i> = 14.1, 7.6 Hz, 1H), 1.57 (s, 3H), 1.42 (s, 9H), 0.84 (t, <i>J</i> = 5.9 Hz, 6H).</div><div class="NLM_p last">Compound <b>6</b> was prepared from Boc deprotected tripeptide (S)-benzyl 2-((S)-2-((S)-2-(<i>tert</i>-butoxycarbonylamino)-4-phenylbutanamido)-4-methylpentanamido)-3-phenylpropanoate and morpholin-4-yl-acetic acid using the general procedure for amide coupling reaction. White solid (65%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.95 (s, 2H), 7.56 (d, <i>J</i> = 8.4 Hz, 1H), 7.34–7.27 (m, 2H), 7.26–7.18 (m, 3H), 7.17–7.08 (m, 5H), 6.97 (dd, <i>J</i> = 7.2, 2.3 Hz, 2H), 6.84 (d, <i>J</i> = 7.8 Hz, 1H), 6.66 (d, <i>J</i> = 7.7 Hz, 1H), 5.14–4.98 (m, 2H), 4.83 (dt, <i>J</i> = 7.6, 6.0 Hz, 1H), 4.44 (td, <i>J</i> = 8.1, 5.8 Hz, 1H), 4.35 (ddd, <i>J</i> = 9.0, 7.8, 5.3 Hz, 1H), 3.74–3.63 (m, 4H), 3.12–2.97 (m, 2H), 2.94 (d, <i>J</i> = 5.9 Hz, 2H), 2.57 (dq, <i>J</i> = 8.8, 3.1 Hz, 2H), 2.46 (q, <i>J</i> = 4.5 Hz, 4H), 2.17–2.03 (m, 1H), 1.97–1.84 (m, 1H), 1.62–1.39 (m, 3H), 0.81 (dd, <i>J</i> = 9.5, 6.1 Hz, 6H).</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> (S)-<i>N</i>-((S)-1-((S)-1-((S)-2-((<i>tert</i>-Butyldiphenylsilyloxy)methyl)oxiran-2-yl)-4-methyl-1-oxopentan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-4-methyl-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide (<b>7</b>)</h4><div class="NLM_p last">Compound <b>7</b> was prepared from benzyl deprotected <b>6</b> and Boc deprotected <b>2a</b> using the general procedure for amide coupling reaction. White solid (45%); melting point, 87–91 °C; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.69–7.66 (m, 4H), 7.47–7.34 (m, 6H), 7.29–7.09 (m, 9H), 7.09–6.98 (m, 1H), 4.69–4.50 (m, 3H), 4.41- 4.33 (m, 2H), 3.69 (m, 4H), 3.35 (d, <i>J</i> = 11.4 Hz, 1H), 3.18–3.04 (m, 2H), 3.04–2.97 (m, 2H), 2.96–2.83 (m, 2H), 2.62–2.42 (m, 6H), 2.01–1.86 (m, 2H), 1.72–1.72 (m, 2H), 1.57–1.44 (m, 3H), 1.34 (t, <i>J</i> = 10.5 Hz, 1H), 0.99 (d, <i>J</i> = 0.7 Hz, 9H), 0.94–0.78 (m, 12H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) δ 135.31, 135.24, 129.58, 129.57, 128.95, 128.08, 128.05, 127.91, 127.43, 127.41, 126.23, 125.66, 66.45, 63.45, 61.02, 53.88, 53.31, 52.55, 51.07, 48.20, 47.99, 47.84, 47.77, 47.56, 47.35, 47.13, 46.92, 40.47, 38.21, 37.40, 33.99, 31.66, 25.74, 24.88, 24.39, 22.49, 21.97, 20.56, 20.12; LCMS (ES+) <i>m</i>/<i>z</i> calcd for C<sub>56</sub>H<sub>76</sub>N<sub>5</sub>O<sub>8</sub>Si [M + H]<sup>+</sup> 974.5, found: 974.5. Purity: ≥ 98% and retention time is 14.21 min by HPLC analysis.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (S)-<i>N</i>-((S)-1-((S)-1-((S)-2-(Methoxymethyl)oxiran-2-yl)-4-methyl-1-oxopentan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-4-methyl-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide (<b>8</b>)</h4><div class="NLM_p last">Compound <b>8</b> was prepared from benzyl deprotected <b>6</b> and Boc deprotected <b>2b</b> using the general procedure for amide coupling reaction. White solid (48%); melting point, 129–133 °C; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.28–7.22 (m, 2H), 7.22–7.08 (m, 7H), 7.08–7.00 (m, 1H), 4.66–4.57 (m, 1H), 4.51 (dd, <i>J</i> = 2.8, 10.9 Hz, 1H), 4.37 (ddd, <i>J</i> = 5.8, 9.0, 22.4 Hz, 2H), 4.19 (ddd, <i>J</i> = 0.7, 11.3, 16.9 Hz, 1H), 3.70 (td, <i>J</i> = 2.1, 4.8, 5.3 Hz, 4H), 3.29 (ddd, <i>J</i> = 1.3, 2.2, 4.1 Hz, 3H), 3.26–3.11 (m, 2H), 3.09 (dt, <i>J</i> = 1.3, 5.3 Hz, 1H), 3.04–2.99 (m, 2H), 2.99–2.93 (m, 1H), 2.93–2.77 (m, 2H), 2.64–2.44 (m, 6H), 2.08–1.82 (m, 2H), 1.73–1.41 (m, 5H), 1.29 (ddd, <i>J</i> = 4.5, 10.8, 14.3 Hz, 1H), 0.95–0.70 (m, 12H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) δ 205.96, 172.59, 172.24, 171.83, 170.93, 141.03, 136.75, 128.93, 128.08, 128.05, 127.91, 126.24, 125.67, 71.00, 66.45, 61.28, 61.02, 58.46, 53.84, 53.32, 52.54, 51.76, 50.74, 48.20, 47.99, 47.78, 47.56, 47.35, 47.14, 46.93, 40.46, 37.89, 37.35, 34.02, 31.65, 24.76, 24.37, 22.37, 21.96, 20.56, 20.05.; LCMS (ES+) <i>m</i>/<i>z</i> calcd for C<sub>41</sub>H<sub>60</sub>N<sub>5</sub>O<sub>8</sub> [M + H]<sup>+</sup> 750.4, found: 750.4. Purity: ≥ 96% and retention time is 10.14 min by HPLC analysis.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (S)-<i>N</i>-((S)-1-((S)-1-((R)-2-(Hydroxymethyl)oxiran-2-yl)-4-methyl-1-oxopentan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-4-methyl-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide (<b>9</b>)</h4><div class="NLM_p last">Compound <b>9</b> was prepared from compound <b>7</b> using the general procedure for TBDPS deprotection reaction. White solid (64%); melting point, 118–122 °C; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.30–7.21 (m, 2H), 7.21–7.09 (m, 7H), 7.09–7.01 (m, 1H), 4.61 (dd, <i>J</i> = 5.4, 8.7 Hz, 1H), 4.52 (dd, <i>J</i> = 2.9, 11.0 Hz, 1H), 4.36 (ddd, <i>J</i> = 5.6, 8.8, 19.5 Hz, 2H), 4.26 (d, <i>J</i> = 12.6 Hz, 1H), 3.79–3.66 (m, 4H), 3.45 (d, <i>J</i> = 12.6 Hz, 1H), 3.14–3.05 (m, 2H), 3.00 (dd, <i>J</i> = 5.0, 10.1 Hz, 3H), 2.86 (dd, <i>J</i> = 8.7, 14.0 Hz, 1H), 2.63–2.42 (m, 6H), 2.06–1.83 (m, 2H), 1.72–1.42 (m, 5H), 1.29 (ddd, <i>J</i> = 3.9, 10.9, 14.5 Hz, 1H), 0.97–0.77 (m, 12H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) δ 206.57, 172.59, 172.26, 171.80, 170.95, 141.03, 136.74, 128.92, 128.07, 128.05, 127.90, 126.23, 125.66, 66.45, 62.40, 61.02, 60.28, 53.85, 53.31, 52.55, 51.76, 50.74, 48.19, 48.05, 47.98, 47.84, 47.76, 47.55, 47.34, 47.12, 46.91, 40.43, 37.82, 37.35, 33.98, 31.64, 24.76, 24.37, 22.36, 21.94, 20.53, 20.02; LCMS (ES+) <i>m</i>/<i>z</i> calcd for C<sub>40</sub>H<sub>58</sub>N<sub>5</sub>O<sub>8</sub> [M + H]<sup>+</sup> 736.4, found: 736.4. Purity: ≥ 95% and retention time is 13.18 min by HPLC analysis.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (S)-<i>N</i>-((S)-1-((S)-1-((S)-2-((Methoxymethoxy)methyl)oxiran-2-yl)-4-methyl-1-oxopentan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-4-methyl-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide (<b>10</b>)</h4><div class="NLM_p last">To the solution of compound <b>9</b> (25 mg, 0.033 mmol) in DCM, MOM-Cl (13 μL, 0.165 mmol) and DIEA (29 μL, 0.165 mmol) were added, and the reaction mixture was stirred at room temperature for 24 h. Solvent was removed under reduced pressure and residue was purified by flash column chromatography using 5% methanol in DCM to yield 16 mg (60%) white solid as pure compound. Melting point, 107–110 °C; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.29–7.20 (m, 2H), 7.20–7.09 (m, 7H), 7.09–6.99 (m, 1H), 4.64–4.58 (m, 1H), 4.58–4.55 (m, 2H), 4.51 (dd, <i>J</i> = 2.8, 10.9 Hz, 1H), 4.42–4.31 (m, 3H), 3.70 (td, <i>J</i> = 2.1, 4.4 Hz, 4H), 3.32 (d, <i>J</i> = 11.4 Hz, 1H), 3.29 (p, <i>J</i> = 1.6 Hz, 3H), 3.11 (dd, <i>J</i> = 5.2, 14.3 Hz, 2H), 3.00 (dd, <i>J</i> = 5.3, 7.7 Hz, 3H), 2.91–2.76 (m, 2H), 2.65–2.42 (m, 6H), 2.10–1.80 (m, 2H), 1.61–1.39 (m, 4H), 1.29 (ddd, <i>J</i> = 4.5, 10.9, 13.8 Hz, 2H), 0.97–0.75 (m, 12H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) δ 209.84, 176.54, 176.20, 175.78, 174.88, 144.97, 140.69, 132.87, 132.02, 131.99, 131.85, 130.18, 129.60, 100.10, 70.38, 69.96, 65.09, 64.95, 58.11, 57.77, 57.25, 56.48, 55.69, 54.64, 52.14, 51.97, 51.92, 51.78, 51.71, 51.50, 51.28, 51.07, 50.86, 44.38, 41.79, 41.29, 37.95, 35.59, 28.68, 28.31, 26.32, 25.90, 24.48, 23.98; LCMS (ES+) <i>m</i>/<i>z</i> calcd for C<sub>42</sub>H<sub>62</sub>N<sub>5</sub>O<sub>9</sub> [M + H]<sup>+</sup> 780.4, found: 780.4. Purity: ≥ 97% and retention time is 14.60 min by HPLC analysis.</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (S)-<i>N</i>-((S)-1-((S)-1-((S)-2-(((2-Methoxyethoxy)methoxy)methyl)oxiran-2-yl)-4-methyl-1-oxopentan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-4-methyl-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide (<b>11</b>)</h4><div class="NLM_p last">To the solution of compound <b>9</b> (25 mg, 0.033 mmol) in DCM, MEM-Cl (19 μL, 0.165 mmol) and DIEA (29 μL, 0.165 mmol) were added, and the reaction mass was stirred at room temperature for 24 h. Solvent was removed under reduced pressure and residue was purified by flash column chromatography using 5% methanol in DCM to yield 18 mg (64%) white solid as pure compound. Melting point, 85–88 °C; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.28–7.20 (m, 2H), 7.20–7.10 (m, 7H), 7.08–7.00 (m, 1H), 4.68–4.59 (m, 3H), 4.51 (dd, <i>J</i> = 2.8, 10.9 Hz, 1H), 4.42–4.30 (m, 3H), 3.70 (td, <i>J</i> = 2.1, 4.7 Hz, 4H), 3.66–3.57 (m, 2H), 3.57–3.49 (m, 2H), 3.37 (dd, <i>J</i> = 0.7, 11.4 Hz, 1H), 3.33 (dd, <i>J</i> = 0.8, 3.7 Hz, 1H), 3.29 (ddt, <i>J</i> = 1.3, 2.3, 3.3 Hz, 2H), 3.17–3.05 (m, 2H), 3.05–2.95 (m, 3H), 2.86 (dd, <i>J</i> = 8.7, 14.0 Hz, 1H), 2.64–2.43 (m, 6H), 2.06–1.94 (m, 1H), 1.94–1.83 (m, 1H), 1.72–1.63 (m, 1H), 1.60–1.42 (m, 4H), 1.34–1.23 (m, 2H), 0.95–0.77 (m, 12H). <sup>13</sup>C NMR (101 CD<sub>3</sub>OD) δ 205.91, 172.59, 172.24, 171.82, 170.93, 141.04, 136.74, 128.93, 128.08, 128.06, 127.91, 126.24, 125.67, 95.20, 71.44, 66.52, 66.45, 66.07, 61.13, 61.03, 57.62, 53.83, 53.32, 52.54, 51.76, 50.69, 40.46, 37.91, 37.36, 34.02, 31.66, 24.75, 24.38, 22.38, 21.97, 20.56, 20.08; LCMS (ES+) <i>m</i>/<i>z</i> calcd for C<sub>44</sub>H<sub>66</sub>N<sub>5</sub>O<sub>10</sub> [M + H]<sup>+</sup> 824.4, found: 824.4. Purity: ≥ 95% and retention time is 12.66 min by HPLC analysis.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> ((S)-2-((4S,7S,10S,13S)-10-Benzyl-7-isobutyl-15-methyl-1-morpholino-2,5,8,11-tetraoxo-4-phenethyl-3,6,9,12-tetraazahexadecanecarbonyl)oxiran-2-yl)methylmethanesulfonate (<b>12</b>)</h4><div class="NLM_p last">A mixture of compound <b>9</b> (25 mg, 0.033 mmol), methanesulfonyl chloride (13 μL, 0.165 mmol), and DIEA (29 μL, 0.165 mmol) in DCM was stirred at room temperature for 24 h. Solvent was removed under reduced pressure and residue was purified by flash column chromatography using 5% methanol in DCM to yield 20 mg (64%) pure compound as white solid. Melting point, 87–90 °C; <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.25 (dd, <i>J</i> = 6.6, 8.5 Hz, 2H), 7.21–7.11 (m, 7H), 7.11–7.01 (m, 1H), 5.04 (d, <i>J</i> = 11.4 Hz, 1H), 4.61 (dd, <i>J</i> = 5.4, 8.8 Hz, 1H), 4.47 (dd, <i>J</i> = 3.0, 10.8 Hz, 1H), 4.36 (ddd, <i>J</i> = 5.5, 8.8, 21.9 Hz, 2H), 4.03 (d, <i>J</i> = 11.6 Hz, 1H), 3.70 (td, <i>J</i> = 2.1, 4.5 Hz, 4H), 3.15–3.05 (m, 5H), 3.02 (d, <i>J</i> = 4.9 Hz, 2H), 2.86 (dd, <i>J</i> = 8.8, 14.0 Hz, 1H), 2.65–2.45 (m, 6H), 2.06–1.95 (m, 1H), 1.95–1.84 (m, 1H), 1.68 (dd, <i>J</i> = 3.6, 6.7 Hz, 1H), 1.62–1.40 (m, 4H), 1.39–1.22 (m, 1H), 0.96–0.81 (m, 12H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD) δ 208.65, 176.56, 176.24, 175.85, 174.88, 144.97, 140.64, 132.86, 132.02, 132.01, 131.87, 130.21, 129.62, 72.69, 70.38, 64.94, 63.58, 57.75, 57.25, 56.52, 55.72, 54.25, 52.77, 52.14, 51.93, 51.71, 51.50, 51.29, 51.07, 50.86, 44.34, 41.77, 41.25, 39.76, 37.94, 35.60, 28.66, 28.31, 26.24, 25.90, 24.47, 23.97; LCMS (ES+) <i>m</i>/<i>z</i> calcd for C<sub>41</sub>H<sub>60</sub>N<sub>5</sub>O<sub>10</sub>S [M + H]<sup>+</sup> 814.4, found: 814.4. Purity: ≥ 96% and retention time is 14.24 min by HPLC analysis.</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Biological Assay</h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Enzyme Kinetics Assays</h4><div class="NLM_p last">Purified human 20S immunoproteasome (Boston Biochem) or RPMI 8226 cell lysates were diluted in 20S proteasome assay buffer (20 mM Tris-HCl, 0.5 mM EDTA, 0.035% SDS, pH 8.0) and incubated with various concentrations of each inhibitor for 1 h in a 96-well plate. The fluorogenic substrates Suc-Leu-Leu-Val-Tyr-AMC (Bachem) or Ac-Pro-Ala-Leu-AMC (Boston Biochem) were used at the final substrate concentration of 100 μM to measure the remaining levels of chymotrypsin-like activity or LMP2-specific catalytic activity, respectively. Fluorescence signals from the release of free AMC (7-amino-4-methylcoumarin) were monitored every minute for 1 h via a SpectraMax M5 microplate reader (Molecular Devices) using excitation and emission wavelengths of 360 and 460 nm, respectively. The initial hydrolysis rates (slopes) for individual wells were calculated via linear regression and normalized to the values from vehicle-treated control wells. Nonlinear regression analysis was performed using GraphPad Prism 7 to calculate an IC<sub>50</sub> value for each compound in inhibiting proteasomal CT-L or LMP2 activity.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Cell Culture</h4><div class="NLM_p last">Human cancer cell lines H23, H727, and RPMI8226 were obtained from the ATCC (American Type Culture Collection) and maintained in the ATCC recommended media, RPMI1640 supplemented with 10% fetal bovine serum (Gibco, and Atlanta Biologicals). RPMI8226 cells with acquired resistance to Cfz were established by adapting them in the presence of stepwise increasing concentrations of Cfz up to 80 nM over a period of approximately 6 months. Cfz-resistant cells were maintained in 80 nM Cfz and then grown in the absence of Cfz for approximately 1 week prior to the experiments.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Isolation of Primary MM Cells</h4><div class="NLM_p last">Bone marrow (BM) aspirates were obtained from patients after approval by the UC Cancer Institute Institutional Review Board followed by positive selection with miltenyi CD138 microbeads developed for the isolation of plasma cells. Immunophenotyping by flow cytometry was performed to confirm the purity and quantity of selected CD138<sup>+</sup> plasma cells.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Cell Viability Assay</h4><div id="sec5_2_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> Established Cancer Cell Lines</h5><div class="NLM_p last">H23 cells or H727 cells were plated at 5000 or 10 000 cells per well, respectively. RPMI8226 cells and Cfz-resistant RPMI8226 sublines growing in suspension were plated at 10 000 cells per well. Twenty-four hours after plating, media containing the test compounds were added to each well to deliver the intended final concentration. After 72 h, cell viability was determined using the assay protocol recommended by the manufacturer (CellTiter 96 Aqueous One Solution Cell Proliferation assay, Promega). The resulting signals were measured using a SpectraMax M5 microplate spectrophotometer (Molecular Devices). Nonlinear regression analysis was performed using GraphPad Prism 7 to calculate an IC<sub>50</sub> value for each compound to incur cell death.</div></div><div id="sec5_2_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> Primary MM Cells</h5><div class="NLM_p last">Purified primary MM cells were plated on 96-well plates at a density of 20 000 cells per well in IMDM media (Gibco) supplemented with 10% FBS. After cells were treated with test compounds for 48 h, the percentage of viable cells was determined using the CellTiter Glo Luminescent Cell Viability Assay (Promega) and a Veritas microplate luminometer (Promega).</div></div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Immunoblotting</h4><div class="NLM_p last">Cell lysates were prepared using ice-cold RIPA lysis buffer (50 mM Tris–Cl, 150 mM NaCl, 1% NP-40, 1% Triton X-100) supplemented with 1% protease inhibitor cocktail (Sigma–Aldrich). After centrifugation at 14 000<i>g</i> at 4 °C for 20 min, the resulting supernatant was collected and subject to the total protein assay using Protein Assay Dye Reagent Concentrate (Bio-Rad). Proteins were resolved by 7.5% SDS-PAGE and transferred onto PVDF membranes (Bio-Rad) via semidry transfer. After blocking in 5% nonfat dry milk, membranes were incubated with primary antibodies (anti-P-gp (Abcam) or anti-β-actin (Enzo)) at 4 °C overnight. Membranes were washed and incubated with appropriate peroxidase-conjugated secondary antibodies for 1 h at room temperature. Proteins were visualized on Kodak BioMax XAR Films (Sigma-Aldrich) using ECL.</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>In Vitro</i> Metabolic Stability of Cfz–OH</h4><div class="NLM_p">To assess whether Cfz–OH has indeed an improved metabolic stability over Cfz, we compared the rate by which Cfz–OH or Cfz disappears in the presence of rat liver homogenates, as previously reported.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Briefly, the liver was obtained from male Sprague–Dawley rats (8 week-old, Nara Biotech Co. Ltd., Seoul, Korea) using the protocol approved by the Seoul National University Institutional Animal Care and Use Committee (approval No. SNU-160512–5–1). The harvested liver was washed with phosphate-buffered saline (PBS, pH 7.4) and homogenized using five-fold excess volume of PBS per gram of tissue. After preincubation at 37 °C, an aliquot of liver homogenates was spiked with the stock solution of Cfz or Cfz–OH to achieve the final concentration of 1 μM (total volume of 400 μL, <i>n</i> = 3). At the predesignated time (0, 5, 10, and 20 min), an aliquot (40 μL) was collected and mixed with four-fold excess volume of ice-cold acetonitrile containing chlorpropamide (an internal standard, IS, 0.5 μM). After vortexing and centrifugation, the drug levels in the resulting supernatant were analyzed via HPLC interfaced with mass spectrometry (LC–MS/MS).</div><div class="NLM_p last">The analytical conditions for Cfz were reported previously.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Cfz–OH was quantified using the slightly modified analytical conditions via LC–MS/MS (1260 infinity HPLC system interfaced with 6430 Triple Quad LC–MS system, Agilent Technologies, Palo Alto, CA) in a positive ion mode. The chromatic separation was performed using a Poroshell 120 EC-C18 column (4.6 × 50 mm<sup>2</sup>, 2.7 μm, Agilent Technologies, Palo Alto, CA) and an isocratic mobile phase composed of acetonitrile and water (75:25, v/v) at a flow rate of 0.3 mL/min. The retention time of Cfz–OH was 1.7 min, and the gas temperature was set at 300 °C. The source-dependent parameters, the fragment voltage, collision energy, and cell accelerator voltage were set as follows: 170, 75, and 1 V for Cfz–OH and 90 V, 30 and 7 V for chlorpropamide (IS). Quantification was performed in the selected reaction monitoring (SRM) mode using the following transitions: <i>m</i>/<i>z</i> 736.2 > 99.9 for Cfz–OH and <i>m</i>/<i>z</i> 276.9 > 110.8 for chlorpropamide (IS). The calibration samples were prepared in the range of 1 to 200 nM and the signals showed linearity with the <i>r</i><sup>2</sup> value greater than 0.98. The data were processed using the MassHunter Workstation Software Quantitative Analysis (vB.05.00; Agilent Technologies).</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42"><a href="/doi/suppl/10.1021/acs.jmedchem.8b01943" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60077" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60077" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b01943" class="ext-link">10.1021/acs.jmedchem.8b01943</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Cell viability data of H727 and H23 cells for carfilzomib; effect of reversin-121 on carfilzomib sensitivity in RPMI 8226 with acquired carfilzomib resistance; <sup>1</sup>H NMR, <sup>13</sup>C NMR spectra; LC–MS profiles and molecular formula strings of <b>5</b> and <b>7</b>–<b>12</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01943/suppl_file/jm8b01943_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular docking models in PDB format (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01943/suppl_file/jm8b01943_si_002.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Compound data (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01943/suppl_file/jm8b01943_si_003.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01943/suppl_file/jm8b01943_si_001.pdf">jm8b01943_si_001.pdf (3.1 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01943/suppl_file/jm8b01943_si_002.pdf">jm8b01943_si_002.pdf (636.58 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01943/suppl_file/jm8b01943_si_003.csv">jm8b01943_si_003.csv (1.12 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b01943" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47561" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47561" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kyung Bo Kim</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, University of
Kentucky, Lexington, Kentucky 40536, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4744-2466" title="Orcid link">http://orcid.org/0000-0003-4744-2466</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4d262f2624207f0d38263463282938"><span class="__cf_email__" data-cfemail="5f343d3436326d1f2a3426713a3b2a">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Min Jae Lee</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, University of
Kentucky, Lexington, Kentucky 40536, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deepak Bhattarai</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, University of
Kentucky, Lexington, Kentucky 40536, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jisu Yoo</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zach Miller</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, University of
Kentucky, Lexington, Kentucky 40536, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ji Eun Park</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sukyeong Lee</span> - <span class="hlFld-Affiliation affiliation">Verna
and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wooin Lee</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James J. Driscoll</span> - <span class="hlFld-Affiliation affiliation">Department
of Internal Medicine, Division of Hematology
and Oncology and University of Cincinnati Cancer Institute, Cincinnati, Ohio 45267, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>M.J.L. and D.B. contributed equally to this work. K.B.K., W.L., J.J.D., S.L., and M.J.L. conceived the study, designed the experiments, and wrote the paper. D.B., M.J.L., Z.M., J.E.P., and J.Y. conducted experiments and acquired and analyzed the data. All authors discussed the results and conclusions and reviewed the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i44">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38663" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38663" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We would like to thank the National Institutes of Health (R01 CA188354 to K.B.K. and R01 GM111084 to S.L.), the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (No. 1520250 to W.L.), and Creative-Pioneering Researchers Program through Seoul National University (to W.L.) for financially supporting this work.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">proteasome inhibitor</p></td></tr><tr><td class="NLM_term">Btz</td><td class="NLM_def"><p class="first last">bortezomib</p></td></tr><tr><td class="NLM_term">Cfz</td><td class="NLM_def"><p class="first last">carfilzomib</p></td></tr><tr><td class="NLM_term">Ixz</td><td class="NLM_def"><p class="first last">ixazomib</p></td></tr><tr><td class="NLM_term">UPS</td><td class="NLM_def"><p class="first last">ubiquitin-proteasome system</p></td></tr><tr><td class="NLM_term">CT-L</td><td class="NLM_def"><p class="first last">chymotrypsin-like</p></td></tr><tr><td class="NLM_term">MM</td><td class="NLM_def"><p class="first last">multiple myeloma</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">P-glycoprotein transporter</p></td></tr><tr><td class="NLM_term">mAb</td><td class="NLM_def"><p class="first last">monoclonal antibody</p></td></tr><tr><td class="NLM_term">IFN-γ</td><td class="NLM_def"><p class="first last">interferon-gamma</p></td></tr><tr><td class="NLM_term">TBDMS</td><td class="NLM_def"><p class="first last"><i>t</i>-butyldimethylsilyl</p></td></tr><tr><td class="NLM_term">TBDPS</td><td class="NLM_def"><p class="first last"><i>t</i>-butyldiphenylsilyl</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">mEH</td><td class="NLM_def"><p class="first last">microsomal epoxide hydrolase</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i46">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21653" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21653" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 50 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergsagel, P. L.</span></span> <span> </span><span class="NLM_article-title">Where we were, where we are, where we are going: progress in multiple myeloma</span>. <i>Am. Soc. Clin Oncol Educ Book</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.14694/EdBook_AM.2014.34.199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.14694%2FEdBook_AM.2014.34.199" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=199-203&author=P.+L.+Bergsagel&title=Where+we+were%2C+where+we+are%2C+where+we+are+going%3A+progress+in+multiple+myeloma&doi=10.14694%2FEdBook_AM.2014.34.199"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.14694%2FEdBook_AM.2014.34.199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14694%252FEdBook_AM.2014.34.199%26sid%3Dliteratum%253Aachs%26aulast%3DBergsagel%26aufirst%3DP.%2BL.%26atitle%3DWhere%2520we%2520were%252C%2520where%2520we%2520are%252C%2520where%2520we%2520are%2520going%253A%2520progress%2520in%2520multiple%2520myeloma%26jtitle%3DAm.%2520Soc.%2520Clin%2520Oncol%2520Educ%2520Book%26date%3D2014%26volume%3D34%26spage%3D199%26epage%3D203%26doi%3D10.14694%2FEdBook_AM.2014.34.199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lonial, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palumbo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San-Miguel, J.</span></span> <span> </span><span class="NLM_article-title">Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">526</span>– <span class="NLM_lpage">535</span>, <span class="refDoi"> DOI: 10.1038/leu.2015.223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1038%2Fleu.2015.223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=26265184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1OnsbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=526-535&author=S.+Lonialauthor=B.+Durieauthor=A.+Palumboauthor=J.+San-Miguel&title=Monoclonal+antibodies+in+the+treatment+of+multiple+myeloma%3A+current+status+and+future+perspectives&doi=10.1038%2Fleu.2015.223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives</span></div><div class="casAuthors">Lonial, S.; Durie, B.; Palumbo, A.; San-Miguel, J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">526-535</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The treatment landscape for patients with multiple myeloma (MM) is constantly evolving.  Over the past decade, the introduction of novel agents such as proteasome inhibitors and immunomodulatory drugs has led to notable changes in therapeutic strategy, and improvements in survival, yet MM remains incurable in the vast majority of cases.  More recently, a targeted approach to MM treatment has emerged, using monoclonal antibodies (mAbs) to target antigens expressed on the surface of MM cells.  MAbs tested to date kill MM cells via the host's immune system and/or by promoting apoptosis, and appear to have generally improved tolerability compared with currently available treatments.  Due to their distinct mode of action, mAbs are promising both for patients who have exhausted current regimens, and as part of first-line treatments in newly diagnosed patients.  This review examines the recent developments in mAb-based therapy for MM, primarily focused on those agents in ongoing clin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2QiypmVuBwLVg90H21EOLACvtfcHk0liQD0B4iBtFUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1OnsbvO&md5=649a630bbb026c68efe821f0f7ab01e4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.223%26sid%3Dliteratum%253Aachs%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DDurie%26aufirst%3DB.%26aulast%3DPalumbo%26aufirst%3DA.%26aulast%3DSan-Miguel%26aufirst%3DJ.%26atitle%3DMonoclonal%2520antibodies%2520in%2520the%2520treatment%2520of%2520multiple%2520myeloma%253A%2520current%2520status%2520and%2520future%2520perspectives%26jtitle%3DLeukemia%26date%3D2016%26volume%3D30%26spage%3D526%26epage%3D535%26doi%3D10.1038%2Fleu.2015.223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. L.</span></span> <span> </span><span class="NLM_article-title">Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0283-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1186%2Fs13045-016-0283-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=27363983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVGktr7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=51-58&author=L.+Sanchezauthor=Y.+Wangauthor=D.+S.+Siegelauthor=M.+L.+Wang&title=Daratumumab%3A+a+first-in-class+CD38+monoclonal+antibody+for+the+treatment+of+multiple+myeloma&doi=10.1186%2Fs13045-016-0283-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma</span></div><div class="casAuthors">Sanchez, Larysa; Wang, Yucai; Siegel, David S.; Wang, Michael L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51/1-51/8</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells.  Preclin. studies have shown that daratumumab induces MM cell death through several mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis.  Given the encouraging efficacy and acceptable safety profile of daratumumab demonstrated in clin. trials, daratumumab has emerged as a novel treatment option for myeloma and became the first monoclonal antibody approved by the FDA for the treatment of MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_qCAS_SP2S7Vg90H21EOLACvtfcHk0lgwNmgLkWtqOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVGktr7J&md5=d95152cd0036adfd4a0dec28293bed6b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0283-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0283-0%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSiegel%26aufirst%3DD.%2BS.%26aulast%3DWang%26aufirst%3DM.%2BL.%26atitle%3DDaratumumab%253A%2520a%2520first-in-class%2520CD38%2520monoclonal%2520antibody%2520for%2520the%2520treatment%2520of%2520multiple%2520myeloma%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D51%26epage%3D58%26doi%3D10.1186%2Fs13045-016-0283-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">San-Miguel, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hungria, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beksac, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimopoulos, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elghandour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jedrzejczak, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunther, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakorn, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siritanaratkul, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlossman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonial, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einsele, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sopala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bengoudifa, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binlich, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span> <span> </span><span class="NLM_article-title">Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial</span>. <i>Lancet Haematol</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e506</span>– <span class="NLM_lpage">e515</span>, <span class="refDoi"> DOI: 10.1016/S2352-3026(16)30147-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2FS2352-3026%2816%2930147-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=27751707" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&pages=e506-e515&author=J.+F.+San-Miguelauthor=V.+T.+Hungriaauthor=S.+S.+Yoonauthor=M.+Beksacauthor=M.+A.+Dimopoulosauthor=A.+Elghandourauthor=W.+W.+Jedrzejczakauthor=A.+Guntherauthor=T.+N.+Nakornauthor=N.+Siritanaratkulauthor=R.+L.+Schlossmanauthor=J.+Houauthor=P.+Moreauauthor=S.+Lonialauthor=J.+H.+Leeauthor=H.+Einseleauthor=M.+Sopalaauthor=B.+R.+Bengoudifaauthor=F.+Binlichauthor=P.+G.+Richardson&title=Overall+survival+of+patients+with+relapsed+multiple+myeloma+treated+with+panobinostat+or+placebo+plus+bortezomib+and+dexamethasone+%28the+PANORAMA+1+trial%29%3A+a+randomised%2C+placebo-controlled%2C+phase+3+trial&doi=10.1016%2FS2352-3026%2816%2930147-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS2352-3026%2816%2930147-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2352-3026%252816%252930147-8%26sid%3Dliteratum%253Aachs%26aulast%3DSan-Miguel%26aufirst%3DJ.%2BF.%26aulast%3DHungria%26aufirst%3DV.%2BT.%26aulast%3DYoon%26aufirst%3DS.%2BS.%26aulast%3DBeksac%26aufirst%3DM.%26aulast%3DDimopoulos%26aufirst%3DM.%2BA.%26aulast%3DElghandour%26aufirst%3DA.%26aulast%3DJedrzejczak%26aufirst%3DW.%2BW.%26aulast%3DGunther%26aufirst%3DA.%26aulast%3DNakorn%26aufirst%3DT.%2BN.%26aulast%3DSiritanaratkul%26aufirst%3DN.%26aulast%3DSchlossman%26aufirst%3DR.%2BL.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DMoreau%26aufirst%3DP.%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DEinsele%26aufirst%3DH.%26aulast%3DSopala%26aufirst%3DM.%26aulast%3DBengoudifa%26aufirst%3DB.%2BR.%26aulast%3DBinlich%26aufirst%3DF.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26atitle%3DOverall%2520survival%2520of%2520patients%2520with%2520relapsed%2520multiple%2520myeloma%2520treated%2520with%2520panobinostat%2520or%2520placebo%2520plus%2520bortezomib%2520and%2520dexamethasone%2520%2528the%2520PANORAMA%25201%2520trial%2529%253A%2520a%2520randomised%252C%2520placebo-controlled%252C%2520phase%25203%2520trial%26jtitle%3DLancet%2520Haematol%26date%3D2016%26volume%3D3%26spage%3De506%26epage%3De515%26doi%3D10.1016%2FS2352-3026%2816%2930147-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanahan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">Hallmarks of cancer: the next generation</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">646</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2011.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2Fj.cell.2011.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=21376230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2011&pages=646-674&author=D.+Hanahanauthor=R.+A.+Weinberg&title=Hallmarks+of+cancer%3A+the+next+generation&doi=10.1016%2Fj.cell.2011.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of cancer: the next generation</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">646-674</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The hallmarks of cancer comprise six biol. capabilities acquired during the multistep development of human tumors.  The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease.  They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.  Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions.  Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metab. and evading immune destruction.  In addn. to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment.".  Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTcpqXALcb6LVg90H21EOLACvtfcHk0lgTSTONltD5AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D&md5=b36f160c417a712e83cb83c577f0018e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DHallmarks%2520of%2520cancer%253A%2520the%2520next%2520generation%26jtitle%3DCell%26date%3D2011%26volume%3D144%26spage%3D646%26epage%3D674%26doi%3D10.1016%2Fj.cell.2011.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solimini, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elledge, S. J.</span></span> <span> </span><span class="NLM_article-title">Principles of cancer therapy: oncogene and non-oncogene addiction</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">823</span>– <span class="NLM_lpage">837</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.02.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2Fj.cell.2009.02.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=19269363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltFSnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2009&pages=823-837&author=J.+Luoauthor=N.+L.+Soliminiauthor=S.+J.+Elledge&title=Principles+of+cancer+therapy%3A+oncogene+and+non-oncogene+addiction&doi=10.1016%2Fj.cell.2009.02.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Principles of cancer therapy: oncogene and non-oncogene addiction</span></div><div class="casAuthors">Luo, Ji; Solimini, Nicole L.; Elledge, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">823-837</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Cancer is a complex collection of distinct genetic diseases united by common hallmarks.  Here, we expand upon the classic hallmarks to include the stress phenotypes of tumorigenesis.  We describe a conceptual framework of how oncogene and non-oncogene addictions contribute to these hallmarks and how they can be exploited through stress sensitization and stress overload to selectively kill cancer cells.  In particular, we present evidence for a large class of non-oncogenes that are essential for cancer cell survival and present attractive drug targets.  Finally, we discuss the path ahead to therapeutic discovery and provide theor. considerations for combining orthogonal cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrH3NH_D9W6LVg90H21EOLACvtfcHk0lgTSTONltD5AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltFSnsLw%253D&md5=dfbc7a874dcad44f8af947083dab8c33</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.02.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.02.024%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DSolimini%26aufirst%3DN.%2BL.%26aulast%3DElledge%26aufirst%3DS.%2BJ.%26atitle%3DPrinciples%2520of%2520cancer%2520therapy%253A%2520oncogene%2520and%2520non-oncogene%2520addiction%26jtitle%3DCell%26date%3D2009%26volume%3D136%26spage%3D823%26epage%3D837%26doi%3D10.1016%2Fj.cell.2009.02.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Moigne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djakovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss von
Soly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madriaga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kampmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aftab, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakes, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shawver, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wustrow, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span> <span> </span><span class="NLM_article-title">Targeting the AAA ATPase p97 as an approach to treat cancer through disruption of protein homeostasis</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">653</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2Fj.ccell.2015.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=26555175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVSksr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=653-665&author=D.+J.+Andersonauthor=R.+Le+Moigneauthor=S.+Djakovicauthor=B.+Kumarauthor=J.+Riceauthor=S.+Wongauthor=J.+Wangauthor=B.+Yaoauthor=E.+Valleauthor=S.+Kiss+von%0ASolyauthor=A.+Madriagaauthor=F.+Sorianoauthor=M.+K.+Menonauthor=Z.+Y.+Wuauthor=M.+Kampmannauthor=Y.+Chenauthor=J.+S.+Weissmanauthor=B.+T.+Aftabauthor=F.+M.+Yakesauthor=L.+Shawverauthor=H.+J.+Zhouauthor=D.+Wustrowauthor=M.+Rolfe&title=Targeting+the+AAA+ATPase+p97+as+an+approach+to+treat+cancer+through+disruption+of+protein+homeostasis&doi=10.1016%2Fj.ccell.2015.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis</span></div><div class="casAuthors">Anderson, Daniel J.; Le Moigne, Ronan; Djakovic, Stevan; Kumar, Brajesh; Rice, Julie; Wong, Steve; Wang, Jinhai; Yao, Bing; Valle, Eduardo; Kiss von Soly, Szerenke; Madriaga, Antonett; Soriano, Ferdie; Menon, Mary-Kamala; Wu, Zhi Yong; Kampmann, Martin; Chen, Yuwen; Weissman, Jonathan S.; Aftab, Blake T.; Yakes, F. Michael; Shawver, Laura; Zhou, Han-Jie; Wustrow, David; Rolfe, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">653-665</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">P97 is a AAA-ATPase with multiple cellular functions, one of which is crit. regulation of protein homeostasis pathways.  We describe the characterization of CB-5083, a potent, selective, and orally bioavailable inhibitor of p97.  Treatment of tumor cells with CB-5083 leads to accumulation of poly-ubiquitinated proteins, retention of endoplasmic reticulum-assocd. degrdn. (ERAD) substrates, and generation of irresolvable proteotoxic stress, leading to activation of the apoptotic arm of the unfolded protein response.  In xenograft models, CB-5083 causes modulation of key p97-related pathways, induces apoptosis, and has antitumor activity in a broad range of both hematol. and solid tumor models.  Mol. determinants of CB-5083 activity include expression of genes in the ERAD pathway, providing a potential strategy for patient selection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7c4WXhvOlYLVg90H21EOLACvtfcHk0lix1JGujdI0dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVSksr%252FN&md5=662df92598397deba1586e8993f2bb7a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DLe%2BMoigne%26aufirst%3DR.%26aulast%3DDjakovic%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DB.%26aulast%3DRice%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DB.%26aulast%3DValle%26aufirst%3DE.%26aulast%3DKiss%2Bvon%2BSoly%26aufirst%3DS.%26aulast%3DMadriaga%26aufirst%3DA.%26aulast%3DSoriano%26aufirst%3DF.%26aulast%3DMenon%26aufirst%3DM.%2BK.%26aulast%3DWu%26aufirst%3DZ.%2BY.%26aulast%3DKampmann%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWeissman%26aufirst%3DJ.%2BS.%26aulast%3DAftab%26aufirst%3DB.%2BT.%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DShawver%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DH.%2BJ.%26aulast%3DWustrow%26aufirst%3DD.%26aulast%3DRolfe%26aufirst%3DM.%26atitle%3DTargeting%2520the%2520AAA%2520ATPase%2520p97%2520as%2520an%2520approach%2520to%2520treat%2520cancer%2520through%2520disruption%2520of%2520protein%2520homeostasis%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D28%26spage%3D653%26epage%3D665%26doi%3D10.1016%2Fj.ccell.2015.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arcy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">706</span>– <span class="NLM_lpage">716</span>, <span class="refDoi"> DOI: 10.1182/blood-2013-05-500033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1182%2Fblood-2013-05-500033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=24319254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVGqtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2014&pages=706-716&author=Z.+Tianauthor=P.+D%E2%80%99Arcyauthor=X.+Wangauthor=A.+Rayauthor=Y.+T.+Taiauthor=Y.+Huauthor=R.+D.+Carrascoauthor=P.+Richardsonauthor=S.+Linderauthor=D.+Chauhanauthor=K.+C.+Anderson&title=A+novel+small+molecule+inhibitor+of+deubiquitylating+enzyme+USP14+and+UCHL5+induces+apoptosis+in+multiple+myeloma+and+overcomes+bortezomib+resistance&doi=10.1182%2Fblood-2013-05-500033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance</span></div><div class="casAuthors">Tian, Ze; D'Arcy, Padraig; Wang, Xin; Ray, Arghya; Tai, Yu-Tzu; Hu, Yiguo; Carrasco, Ruben D.; Richardson, Paul; Linder, Stig; Chauhan, Dharminder; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">706-716</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Proteasome inhibitors have demonstrated that targeting protein degrdn. is effective therapy in multiple myeloma (MM).  Here we show that deubiquitylating enzymes (DUBs) USP14 and UCHL5 are more highly expressed in MM cells than in normal plasma cells.  USP14 and UCHL5 short interfering RNA knockdown decreases MM cell viability.  A novel 19S regulatory particle inhibitor b-AP15 selectively blocks deubiquitylating activity of USP14 and UCHL5 without inhibiting proteasome activity.  B-AP15 decreases viability in MM cell lines and patient MM cells, inhibits proliferation of MM cells even in the presence of bone marrow stroma cells, and overcomes bortezomib resistance.  Anti-MM activity of b-AP15 is assocd. with growth arrest via downregulation of CDC25C, CDC2, and cyclin B1 as well as induction of caspase-dependent apoptosis and activation of unfolded protein response.  In vivo studies using distinct human MM xenograft models show that b-AP15 is well tolerated, inhibits tumor growth, and prolongs survival.  Combining b-AP15 with suberoylanilide hydroxamic acid, lenalidomide, or dexamethasone induces synergistic anti-MM activity.  Our preclin. data showing efficacy of b-AP15 in MM disease models validates targeting DUBs in the ubiquitin proteasomal cascade to overcome proteasome inhibitor resistance and provides the framework for clin. evaluation of USP14/UCHL5 inhibitors to improve patient outcome in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8aTcAtVqIcbVg90H21EOLACvtfcHk0lix1JGujdI0dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVGqtLc%253D&md5=abf0d4ca5dadf6f7bf0cd1de3798702f</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-05-500033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-05-500033%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DZ.%26aulast%3DD%25E2%2580%2599Arcy%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DTai%26aufirst%3DY.%2BT.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DCarrasco%26aufirst%3DR.%2BD.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DLinder%26aufirst%3DS.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DA%2520novel%2520small%2520molecule%2520inhibitor%2520of%2520deubiquitylating%2520enzyme%2520USP14%2520and%2520UCHL5%2520induces%2520apoptosis%2520in%2520multiple%2520myeloma%2520and%2520overcomes%2520bortezomib%2520resistance%26jtitle%3DBlood%26date%3D2014%26volume%3D123%26spage%3D706%26epage%3D716%26doi%3D10.1182%2Fblood-2013-05-500033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Selvaraju, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazurkiewicz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullbo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arcy, P.</span></span> <span> </span><span class="NLM_article-title">Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21–22</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/j.drup.2015.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2Fj.drup.2015.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=26183292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A280%3ADC%252BC28%252Fjsl2rug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21%E2%80%9322&publication_year=2015&pages=20-29&author=K.+Selvarajuauthor=M.+Mazurkiewiczauthor=X.+Wangauthor=J.+Gullboauthor=S.+Linderauthor=P.+D%E2%80%99Arcy&title=Inhibition+of+proteasome+deubiquitinase+activity%3A+a+strategy+to+overcome+resistance+to+conventional+proteasome+inhibitors%3F&doi=10.1016%2Fj.drup.2015.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?</span></div><div class="casAuthors">Selvaraju Karthik; Wang Xin; Mazurkiewicz Magdalena; Gullbo Joachim; Linder Stig; D'Arcy Padraig</div><div class="citationInfo"><span class="NLM_cas:title">Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21-22</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although more traditionally associated with degradation and maintenance of protein homeostasis, the ubiquitin-proteasome system (UPS) has emerged as a critical component in the regulation of cancer cell growth and survival.  The development of inhibitors that block the proteolytic activities of the proteasome have highlighted its suitability as a bona fide anti-cancer drug target.  However, key determinants including the development of drug resistance and dose-limiting toxicity call for the identification of alternative components of the UPS for novel drug targeting.  Recently the deubiquitinases (DUBs), a diverse family of enzymes that catalyze ubiquitin removal, have attracted significant interest as targets for the development of next generation UPS inhibitors.  In particular, pharmacological inhibition of the proteasomal cysteine DUBs (i.e., USP14 and UCHL5) has been shown to be particularly cytotoxic to cancer cells and inhibit tumour growth in several in vivo models.  In the current review we focus on the modes of action of proteasome DUB inhibitors and discus the potential of DUB inhibitors to circumvent acquired drug resistance and provide a therapeutic option for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRZaGfvi-WByzslzEEsg76ufW6udTcc2eYwmpNoT9mwV7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252Fjsl2rug%253D%253D&md5=3429b630445039d5891d777124fc4f7a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2015.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2015.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DSelvaraju%26aufirst%3DK.%26aulast%3DMazurkiewicz%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGullbo%26aufirst%3DJ.%26aulast%3DLinder%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Arcy%26aufirst%3DP.%26atitle%3DInhibition%2520of%2520proteasome%2520deubiquitinase%2520activity%253A%2520a%2520strategy%2520to%2520overcome%2520resistance%2520to%2520conventional%2520proteasome%2520inhibitors%253F%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2015%26volume%3D21%25E2%2580%259322%26spage%3D20%26epage%3D29%26doi%3D10.1016%2Fj.drup.2015.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulcinniti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodrasov, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kingsbury, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minvielle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">358</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2012.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2Fj.ccr.2012.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=22975377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlCju77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=345-358&author=D.+Chauhanauthor=Z.+Tianauthor=B.+Nicholsonauthor=K.+G.+Kumarauthor=B.+Zhouauthor=R.+Carrascoauthor=J.+L.+McDermottauthor=C.+A.+Leachauthor=M.+Fulcinnitiauthor=M.+P.+Kodrasovauthor=J.+Weinstockauthor=W.+D.+Kingsburyauthor=T.+Hideshimaauthor=P.+K.+Shahauthor=S.+Minvielleauthor=M.+Altunauthor=B.+M.+Kesslerauthor=R.+Orlowskiauthor=P.+Richardsonauthor=N.+Munshiauthor=K.+C.+Anderson&title=A+small+molecule+inhibitor+of+ubiquitin-specific+protease-7+induces+apoptosis+in+multiple+myeloma+cells+and+overcomes+bortezomib+resistance&doi=10.1016%2Fj.ccr.2012.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance</span></div><div class="casAuthors">Chauhan, Dharminder; Tian, Ze; Nicholson, Benjamin; Kumar, K. G. Suresh; Zhou, Bin; Carrasco, Ruben; McDermott, Jeffrey L.; Leach, Craig A.; Fulcinniti, Mariaterresa; Kodrasov, Matthew P.; Weinstock, Joseph; Kingsbury, William D.; Hideshima, Teru; Shah, Parantu K.; Minvielle, Stephane; Altun, Mikael; Kessler, Benedikt M.; Orlowski, Robert; Richardson, Paul; Munshi, Nikhil; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">345-358</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Bortezomib therapy has proven successful for the treatment of relapsed/refractory, relapsed, and newly diagnosed multiple myeloma (MM); however, dose-limiting toxicities and the development of resistance limit its long-term utility.  Here, we show that P5091 is an inhibitor of deubiquitylating enzyme USP7, which induces apoptosis in MM cells resistant to conventional and bortezomib therapies.  Biochem. and genetic studies show that blockade of HDM2 and p21 abrogates P5091-induced cytotoxicity.  In animal tumor model studies, P5091 is well tolerated, inhibits tumor growth, and prolongs survival.  Combining P5091 with lenalidomide, HDAC inhibitor SAHA, or dexamethasone triggers synergistic anti-MM activity.  Our preclin. study therefore supports clin. evaluation of USP7 inhibitor, alone or in combination, as a potential MM therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVKqojA-HcmLVg90H21EOLACvtfcHk0lgg_2RW9E-TPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlCju77F&md5=9c70da62de17591850c1e8195d5f97f7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2012.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2012.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DTian%26aufirst%3DZ.%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DKumar%26aufirst%3DK.%2BG.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DCarrasco%26aufirst%3DR.%26aulast%3DMcDermott%26aufirst%3DJ.%2BL.%26aulast%3DLeach%26aufirst%3DC.%2BA.%26aulast%3DFulcinniti%26aufirst%3DM.%26aulast%3DKodrasov%26aufirst%3DM.%2BP.%26aulast%3DWeinstock%26aufirst%3DJ.%26aulast%3DKingsbury%26aufirst%3DW.%2BD.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DShah%26aufirst%3DP.%2BK.%26aulast%3DMinvielle%26aufirst%3DS.%26aulast%3DAltun%26aufirst%3DM.%26aulast%3DKessler%26aufirst%3DB.%2BM.%26aulast%3DOrlowski%26aufirst%3DR.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DMunshi%26aufirst%3DN.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DA%2520small%2520molecule%2520inhibitor%2520of%2520ubiquitin-specific%2520protease-7%2520induces%2520apoptosis%2520in%2520multiple%2520myeloma%2520cells%2520and%2520overcomes%2520bortezomib%2520resistance%26jtitle%3DCancer%2520Cell%26date%3D2012%26volume%3D22%26spage%3D345%26epage%3D358%26doi%3D10.1016%2Fj.ccr.2012.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuiatse, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjorklund, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, R. Z.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the MDM2 E3 ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e103015</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0103015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1371%2Fjournal.pone.0103015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=25181509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yrt7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=D.+Guauthor=S.+Wangauthor=I.+Kuiatseauthor=H.+Wangauthor=J.+Heauthor=Y.+Daiauthor=R.+J.+Jonesauthor=C.+C.+Bjorklundauthor=J.+Yangauthor=S.+Grantauthor=R.+Z.+Orlowski&title=Inhibition+of+the+MDM2+E3+ligase+induces+apoptosis+and+autophagy+in+wild-type+and+mutant+p53+models+of+multiple+myeloma%2C+and+acts+synergistically+with+ABT-737&doi=10.1371%2Fjournal.pone.0103015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the MDM2 E3 ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737</span></div><div class="casAuthors">Gu, Dongmin; Wang, Shuhong; Kuiatse, Isere; Wang, Hua; He, Jin; Dai, Yun; Jones, Richard J.; Bjorklund, Chad C.; Yang, Jing; Grant, Steven; Orlowski, Robert Z.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e103015/1-e103015/12, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Intracellular proteolytic pathways have been validated as rational targets in multiple myeloma with the approval of two proteasome inhibitors in this disease, and with the finding that immunomodulatory agents work through an E3 ubiquitin ligase contg. Cereblon.  Another E3 ligase that could be a rational target is the murine double minute (MDM) 2 protein, which plays a role in p53 turnover.  A novel inhibitor of this complex, MI-63, was found to induce apoptosis in p53 wild-type myeloma models in assocn. with activation of a p53-mediated cell death program.  MI-63 overcame adhesion-mediated drug resistance, showed anti-tumor activity in vivo, enhanced the activity of bortezomib and lenalidomide, and also overcame lenalidomide resistance.  In mutant p53 models, inhibition of MDM2 with MI-63 also activated apoptosis, albeit at higher concns., and this was assocd. with activation of autophagy.  When MI-63 was combined with the BH3 mimetic ABT-737, enhanced activity was seen in both wild-type and mutant p53 models.  Finally, this regimen showed efficacy against primary plasma cells from patients with newly diagnosed and relapsed/refractory myeloma.  These findings support the translation of novel MDM2 inhibitors both alone, and in combination with other novel agents, to the clinic for patients with multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokKNSMvmPF2bVg90H21EOLACvtfcHk0lgAm8zkP2aEgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yrt7jP&md5=d29157fc2b710290b3f7cb6d9c2b6f78</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0103015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0103015%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DKuiatse%26aufirst%3DI.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DJones%26aufirst%3DR.%2BJ.%26aulast%3DBjorklund%26aufirst%3DC.%2BC.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DGrant%26aufirst%3DS.%26aulast%3DOrlowski%26aufirst%3DR.%2BZ.%26atitle%3DInhibition%2520of%2520the%2520MDM2%2520E3%2520ligase%2520induces%2520apoptosis%2520and%2520autophagy%2520in%2520wild-type%2520and%2520mutant%2520p53%2520models%2520of%2520multiple%2520myeloma%252C%2520and%2520acts%2520synergistically%2520with%2520ABT-737%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0103015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masszi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzasko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahlis, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pour, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandhu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganly, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoppa, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gimsing, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palumbo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garderet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Touzeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buadi, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laubach, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Bacco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Velde, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Group, T.-M. S.</span></span> <span> </span><span class="NLM_article-title">Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">1621</span>– <span class="NLM_lpage">1634</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1516282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1056%2FNEJMoa1516282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=27119237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOltLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=1621-1634&author=P.+Moreauauthor=T.+Massziauthor=N.+Grzaskoauthor=N.+J.+Bahlisauthor=M.+Hanssonauthor=L.+Pourauthor=I.+Sandhuauthor=P.+Ganlyauthor=B.+W.+Bakerauthor=S.+R.+Jacksonauthor=A.+M.+Stoppaauthor=D.+R.+Simpsonauthor=P.+Gimsingauthor=A.+Palumboauthor=L.+Garderetauthor=M.+Cavoauthor=S.+Kumarauthor=C.+Touzeauauthor=F.+K.+Buadiauthor=J.+P.+Laubachauthor=D.+T.+Bergauthor=J.+Linauthor=A.+Di+Baccoauthor=A.+M.+Huiauthor=H.+van+de+Veldeauthor=P.+G.+Richardsonauthor=T.-M.+S.+Group&title=Oral+ixazomib%2C+lenalidomide%2C+and+dexamethasone+for+multiple+myeloma&doi=10.1056%2FNEJMoa1516282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma</span></div><div class="casAuthors">Moreau, P.; Masszi, T.; Grzasko, N.; Bahlis, N. J.; Hansson, M.; Pour, L.; Sandhu, I.; Ganly, P.; Baker, B. W.; Jackson, S. R.; Stoppa, A.-M.; Simpson, D. R.; Gimsing, P.; Palumbo, A.; Garderet, L.; Cavo, M.; Kumar, S.; Touzeau, C.; Buadi, F. K.; Laubach, J. P.; Berg, D. T.; Lin, J.; Di Bacco, A.; Hui, A.-M.; van de Velde, H.; Richardson, P. G.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1621-1634</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Ixazomib is an oral proteasome inhibitor that is currently being studied for the treatment of multiple myeloma.  In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 722 patients who had relapsed, refractory, or relapsed and refractory multiple myeloma to receive ixazomib plus lenalidomide-dexamethasone (ixazomib group) or placebo plus lenalidomide-dexamethasone (placebo group).  The primary end point was progression-free survival.  Progression-free survival was significantly longer in the ixazomib group than in the placebo group at a median follow-up of 14.7 mo (median progression-free survival, 20.6 mo vs. 14.7 mo; hazard ratio for disease progression or death in the ixazomib group, 0.74; P = 0.01); a benefit with respect to progression-free survival was obsd. with the ixazomib regimen, as compared with the placebo regimen, in all prespecified patient subgroups, including in patients with high-risk cytogenetic abnormalities.  The overall rates of response were 78% in the ixazomib group and 72% in the placebo group, and the corresponding rates of complete response plus very good partial response were 48% and 39%.  The median time to response was 1.1 mo in the ixazomib group and 1.9 mo in the placebo group and the corresponding median duration of response was 20.5 mo and 15.0 mo.  At a median follow-up of approx. 23 mo, the median overall survival has not been reached in either study group, and follow-up is ongoing.  The rates of serious adverse events were similar in the two study groups (47% in the ixazomib group and 49% in the placebo group), as were the rates of death during the study period (4% and 6%, resp.); adverse events of at least grade 3 severity occurred in 74% and 69% of the patients, resp.  Thrombocytopenia of grade 3 and grade 4 severity occurred more frequently in the ixazomib group (12% and 7% of the patients, resp.) than in the placebo group (5% and 4% of the patients, resp.).  Rash occurred more frequently in the ixazomib group than in the placebo group (36% vs. 23% of the patients), as did gastrointestinal adverse events, which were predominantly low grade.  The incidence of peripheral neuropathy was 27% in the ixazomib group and 22% in the placebo group (grade 3 events occurred in 2% of the patients in each study group).  Patient-reported quality of life was similar in the two study groups.  The addn. of ixazomib to a regimen of lenalidomide and dexamethasone was assocd. with significantly longer progression-free survival; the addnl. toxic effects with this all-oral regimen were limited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe5omTDIjGVLVg90H21EOLACvtfcHk0lgAm8zkP2aEgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOltLjN&md5=b71bd9b8d3afd6c02e1c541abdb44c0e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1516282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1516282%26sid%3Dliteratum%253Aachs%26aulast%3DMoreau%26aufirst%3DP.%26aulast%3DMasszi%26aufirst%3DT.%26aulast%3DGrzasko%26aufirst%3DN.%26aulast%3DBahlis%26aufirst%3DN.%2BJ.%26aulast%3DHansson%26aufirst%3DM.%26aulast%3DPour%26aufirst%3DL.%26aulast%3DSandhu%26aufirst%3DI.%26aulast%3DGanly%26aufirst%3DP.%26aulast%3DBaker%26aufirst%3DB.%2BW.%26aulast%3DJackson%26aufirst%3DS.%2BR.%26aulast%3DStoppa%26aufirst%3DA.%2BM.%26aulast%3DSimpson%26aufirst%3DD.%2BR.%26aulast%3DGimsing%26aufirst%3DP.%26aulast%3DPalumbo%26aufirst%3DA.%26aulast%3DGarderet%26aufirst%3DL.%26aulast%3DCavo%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DTouzeau%26aufirst%3DC.%26aulast%3DBuadi%26aufirst%3DF.%2BK.%26aulast%3DLaubach%26aufirst%3DJ.%2BP.%26aulast%3DBerg%26aufirst%3DD.%2BT.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DDi%2BBacco%26aufirst%3DA.%26aulast%3DHui%26aufirst%3DA.%2BM.%26aulast%3Dvan%2Bde%2BVelde%26aufirst%3DH.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DGroup%26aufirst%3DT.-M.%2BS.%26atitle%3DOral%2520ixazomib%252C%2520lenalidomide%252C%2520and%2520dexamethasone%2520for%2520multiple%2520myeloma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D1621%26epage%3D1634%26doi%3D10.1056%2FNEJMoa1516282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gallerani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucchetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marangon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noberasco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delmonte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Braud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsoni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cereda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Incalci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sessa, C.</span></span> <span> </span><span class="NLM_article-title">A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">290</span>– <span class="NLM_lpage">296</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2012.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2Fj.ejca.2012.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=23058787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSnsbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=290-296&author=E.+Galleraniauthor=M.+Zucchettiauthor=D.+Brunelliauthor=E.+Marangonauthor=C.+Noberascoauthor=D.+Hessauthor=A.+Delmonteauthor=G.+Martinelliauthor=S.+Bohmauthor=C.+Driessenauthor=F.+De+Braudauthor=S.+Marsoniauthor=R.+Ceredaauthor=F.+Salaauthor=M.+D%E2%80%99Incalciauthor=C.+Sessa&title=A+first+in+human+phase+I+study+of+the+proteasome+inhibitor+CEP-18770+in+patients+with+advanced+solid+tumours+and+multiple+myeloma&doi=10.1016%2Fj.ejca.2012.09.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma</span></div><div class="casAuthors">Gallerani, Elisa; Zucchetti, Massimo; Brunelli, Dario; Marangon, Elena; Noberasco, Cristina; Hess, Dagmar; Delmonte, Angelo; Martinelli, Giovanni; Bohm, Steffen; Driessen, Christopher; De Braud, Filippo; Marsoni, Silvia; Cereda, Roberta; Sala, Federica; D'Incalci, Maurizio; Sessa, Cristiana</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">290-296</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The safety, pharmacokinetics (PK) and pharmacodynamics of CEP-18770, a new peptide boronic acid proteasome inhibitor, have been investigated after i.v. administration on days 1, 4, 8 and 11 of every 21 d cycle in patients with solid tumors and multiple myeloma (MM).Thirty-eight patients were treated with CEP-18770 at escalating doses from 0.1 to 1.8 mg/m2 where 2 out of 5 patients showed dose limiting toxicities.  The max. tolerated/recommended dose (MTD/RD) of 1.5 mg/m2 was tested in 12 addnl. patients.  Skin rash was dose-limiting and occurred in 53% of patients; other frequent toxicities were asthenia (29%), stomatitis (21%) and pyrexia (16%).  No significant peripheral neuropathy was obsd.  PK in plasma was linear with a half-life of the elimination phase of 62.0 ± 43.5 h.  Proteasome inhibition in peripheral blood mononuclear cells was dose related in MM patients; it was of 45.4 ± 11.5% at the RD.CEP-18770 showed a favorable safety profile with lack of neurotoxicity and linear plasma PK.  The definition of the optimal biol. dose and schedule of treatment is actively pursued because of the high incidence of skin toxicity of the twice a week schedule.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI8KtW1FW2LrVg90H21EOLACvtfcHk0lgf-VNvGI9myQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSnsbvK&md5=29f393ac09aebfb7c0a4758fc9436af7</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2012.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2012.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DGallerani%26aufirst%3DE.%26aulast%3DZucchetti%26aufirst%3DM.%26aulast%3DBrunelli%26aufirst%3DD.%26aulast%3DMarangon%26aufirst%3DE.%26aulast%3DNoberasco%26aufirst%3DC.%26aulast%3DHess%26aufirst%3DD.%26aulast%3DDelmonte%26aufirst%3DA.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DBohm%26aufirst%3DS.%26aulast%3DDriessen%26aufirst%3DC.%26aulast%3DDe%2BBraud%26aufirst%3DF.%26aulast%3DMarsoni%26aufirst%3DS.%26aulast%3DCereda%26aufirst%3DR.%26aulast%3DSala%26aufirst%3DF.%26aulast%3DD%25E2%2580%2599Incalci%26aufirst%3DM.%26aulast%3DSessa%26aufirst%3DC.%26atitle%3DA%2520first%2520in%2520human%2520phase%2520I%2520study%2520of%2520the%2520proteasome%2520inhibitor%2520CEP-18770%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%2520and%2520multiple%2520myeloma%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2013%26volume%3D49%26spage%3D290%26epage%3D296%26doi%3D10.1016%2Fj.ejca.2012.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendelson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillenwater, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arastu-Kapur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span> <span> </span><span class="NLM_article-title">A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">216</span>– <span class="NLM_lpage">224</span>, <span class="refDoi"> DOI: 10.1007/s10637-016-0327-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1007%2Fs10637-016-0327-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=26924128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC28XjslCrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=216-224&author=J.+R.+Infanteauthor=D.+S.+Mendelsonauthor=H.+A.+Burrisauthor=J.+C.+Bendellauthor=A.+W.+Tolcherauthor=M.+S.+Gordonauthor=H.+H.+Gillenwaterauthor=S.+Arastu-Kapurauthor=H.+L.+Wongauthor=K.+P.+Papadopoulos&title=A+first-in-human+dose-escalation+study+of+the+oral+proteasome+inhibitor+oprozomib+in+patients+with+advanced+solid+tumors&doi=10.1007%2Fs10637-016-0327-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors</span></div><div class="casAuthors">Infante, Jeffrey R.; Mendelson, David S.; Burris, Howard A., III; Bendell, Johanna C.; Tolcher, Anthony W.; Gordon, Michael S.; Gillenwater, Heidi H.; Arastu-Kapur, Shirin; Wong, Hansen L.; Papadopoulos, Kyriakos P.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">216-224</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">To det. the dose-limiting toxicities (DLTs), max. tolerated dose (MTD), safety, and pharmacokinetic and pharmacodynamic profiles of the tripeptide epoxyketone proteasome inhibitor oprozomib in patients with advanced refractory or recurrent solid tumors.  Patients received escalating once daily (QD) or split doses of oprozomib on days 1-5 of 14-day cycles (C).  The split-dose arm was implemented and compared in fasted (C1) and fed (C2) states.  Pharmacokinetic samples were collected during C1 and C2.  Proteasome inhibition was evaluated in red blood cells and peripheral blood mononuclear cells.  Forty-four patients (QD, n = 25; split dose, n = 19) were enrolled.  The most common primary tumor types were non-small cell lung cancer (18 %) and colorectal cancer (16%).  In the 180-mg QD cohort, two patients experienced DLTs: grade 3 vomiting and dehydration; grade 3 hypophosphatemia (n = 1 each).  In the split-dose group, three DLTs were obsd. 180-mg cohort: grade 3 hypophosphatemia; 210-mg cohort: grade 5 gastrointestinal hemorrhage and grade 3 hallucinations (n = 1 each).  In the QD and split-dose groups, the MTD was 150 and 180 mg, resp.  Common adverse events (all grades) included nausea (91%), vomiting (86%), and diarrhea (61%).  Peak concns. and total exposure of oprozomib generally increased with the increasing dose.  Oprozomib induced dose-dependent proteasome inhibition.  Best response was stable disease.  While generally low-grade, clin. relevant gastrointestinal toxicities occurred frequently with this oprozomib formulation.  Despite dose-dependent increases in pharmacokinetics and pharmacodynamics, single-agent oprozomib had minimal antitumor activity in this patient population with advanced solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW2c034hrkubVg90H21EOLACvtfcHk0lg1EYCqgajW3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjslCrtr0%253D&md5=e54838bb160c0886d08c5d0b8cb81a6a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs10637-016-0327-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-016-0327-x%26sid%3Dliteratum%253Aachs%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DMendelson%26aufirst%3DD.%2BS.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DGordon%26aufirst%3DM.%2BS.%26aulast%3DGillenwater%26aufirst%3DH.%2BH.%26aulast%3DArastu-Kapur%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DH.%2BL.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26atitle%3DA%2520first-in-human%2520dose-escalation%2520study%2520of%2520the%2520oral%2520proteasome%2520inhibitor%2520oprozomib%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2016%26volume%3D34%26spage%3D216%26epage%3D224%26doi%3D10.1007%2Fs10637-016-0327-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmeister, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanan-Khan, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laubach, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubowiak, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trikha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052–101 Part 1</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">2693</span>– <span class="NLM_lpage">2700</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-12-686378</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1182%2Fblood-2015-12-686378" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=27009059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1ent7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=2693-2700&author=P.+G.+Richardsonauthor=T.+M.+Zimmermanauthor=C.+C.+Hofmeisterauthor=M.+Talpazauthor=A.+A.+Chanan-Khanauthor=J.+L.+Kaufmanauthor=J.+P.+Laubachauthor=D.+Chauhanauthor=A.+J.+Jakubowiakauthor=S.+Reichauthor=M.+Trikhaauthor=K.+C.+Anderson&title=Phase+1+study+of+marizomib+in+relapsed+or+relapsed+and+refractory+multiple+myeloma%3A+NPI-0052%E2%80%93101+Part+1&doi=10.1182%2Fblood-2015-12-686378"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1</span></div><div class="casAuthors">Richardson, Paul G.; Zimmerman, Todd M.; Hofmeister, Craig C.; Talpaz, Moshe; Chanan-Khan, Asher A.; Kaufman, Jonathan L.; Laubach, Jacob P.; Chauhan, Dharminder; Jakubowiak, Andrzej J.; Reich, Steven; Trikha, Mohit; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2693-2700</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Marizomib (MRZ) is a novel, irreversible proteasome inhibitor in clin. development for the treatment of relapsed or relapsed and refractory multiple myeloma (RRMM).  MRZ inhibits the 3 proteolytic activities of the 20S proteasome with specificity distinct from bortezomib and carfilzomib.  StudyNPI-0052-101 Part 1 enrolled relapsed or RRMMpatients into an open-label, dose-escalation design to det. the max. tolerated dose and recommended phase 2 dose (RP2D) of MRZ administered i.v. on 2 different schedules: scheduleA (0.025-0.7mg/m2 once weekly on days 1, 8, and 15 of 4-wk cycles) and schedule B (0.15-0.6 mg/m2 twice weekly on days 1, 4, 8, and 11 of 3-wk cycles; concomitant dexamethasone was allowed with schedule B).  Patients had received an av. of 4.9 and 7.3 prior treatment regimens (schedules A and B, resp.).  MRZ schedule A was administered to 32 patients, and theRP2D was established as 0.7mg/m2 infused over 10 min.  ScheduleBwas administered to 36 patients, and theRP2Dwas detd. to be 0.5 mg/m2 infused over 2 h.  The most common (>20% of patients) related adverse events were fatigue, headache, nausea, diarrhea, dizziness, and vomiting.Six patients achieved clin. benefit responses (defined as minimal response or better), including 5 partial responses (1 patient on schedule A and 4 on schedule B; 3 of these 4 patients received concomitant dexamethasone).  MRZ was generallywell tolerated, and results suggest activity in previously treated RRMMpatients.  Combination studies using pomalidomide and dexamethasone are now underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPAcz9tcgETLVg90H21EOLACvtfcHk0lg1EYCqgajW3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1ent7jE&md5=883effc65e2ed7cbc2a3e870737b4afe</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-12-686378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-12-686378%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DZimmerman%26aufirst%3DT.%2BM.%26aulast%3DHofmeister%26aufirst%3DC.%2BC.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DChanan-Khan%26aufirst%3DA.%2BA.%26aulast%3DKaufman%26aufirst%3DJ.%2BL.%26aulast%3DLaubach%26aufirst%3DJ.%2BP.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DJakubowiak%26aufirst%3DA.%2BJ.%26aulast%3DReich%26aufirst%3DS.%26aulast%3DTrikha%26aufirst%3DM.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DPhase%25201%2520study%2520of%2520marizomib%2520in%2520relapsed%2520or%2520relapsed%2520and%2520refractory%2520multiple%2520myeloma%253A%2520NPI-0052%25E2%2580%2593101%2520Part%25201%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26spage%3D2693%26epage%3D2700%26doi%3D10.1182%2Fblood-2015-12-686378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span> <span> </span><span class="NLM_article-title">New investigational drugs with single-agent activity in multiple myeloma</span>. <i>Blood Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e451</span> <span class="refDoi"> DOI: 10.1038/bcj.2016.53</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1038%2Fbcj.2016.53" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=27471867" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&author=A.+M.+Rajanauthor=S.+Kumar&title=New+investigational+drugs+with+single-agent+activity+in+multiple+myeloma&doi=10.1038%2Fbcj.2016.53"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2016.53&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2016.53%26sid%3Dliteratum%253Aachs%26aulast%3DRajan%26aufirst%3DA.%2BM.%26aulast%3DKumar%26aufirst%3DS.%26atitle%3DNew%2520investigational%2520drugs%2520with%2520single-agent%2520activity%2520in%2520multiple%2520myeloma%26jtitle%3DBlood%2520Cancer%2520J.%26date%3D2016%26volume%3D6%26doi%3D10.1038%2Fbcj.2016.53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vogl, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vij, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikhael, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delforge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparetto, C.</span></span> <span> </span><span class="NLM_article-title">Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma</span>. <i>Leuk. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1080/10428194.2016.1263842</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1080%2F10428194.2016.1263842" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2017&pages=1-11&author=D.+T.+Voglauthor=T.+G.+Martinauthor=R.+Vijauthor=P.+Hariauthor=J.+R.+Mikhaelauthor=D.+Siegelauthor=K.+L.+Wuauthor=M.+Delforgeauthor=C.+Gasparetto&title=Phase+I%2FII+study+of+the+novel+proteasome+inhibitor+delanzomib+%28CEP-18770%29+for+relapsed+and+refractory+multiple+myeloma&doi=10.1080%2F10428194.2016.1263842"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1080%2F10428194.2016.1263842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428194.2016.1263842%26sid%3Dliteratum%253Aachs%26aulast%3DVogl%26aufirst%3DD.%2BT.%26aulast%3DMartin%26aufirst%3DT.%2BG.%26aulast%3DVij%26aufirst%3DR.%26aulast%3DHari%26aufirst%3DP.%26aulast%3DMikhael%26aufirst%3DJ.%2BR.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DK.%2BL.%26aulast%3DDelforge%26aufirst%3DM.%26aulast%3DGasparetto%26aufirst%3DC.%26atitle%3DPhase%2520I%252FII%2520study%2520of%2520the%2520novel%2520proteasome%2520inhibitor%2520delanzomib%2520%2528CEP-18770%2529%2520for%2520relapsed%2520and%2520refractory%2520multiple%2520myeloma%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2017%26volume%3D58%26spage%3D1%26epage%3D11%26doi%3D10.1080%2F10428194.2016.1263842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harshbarger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diedrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human 20S proteasome in complex with carfilzomib</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">418</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1016/j.str.2014.11.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2Fj.str.2014.11.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=25599644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2msbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=418-424&author=W.+Harshbargerauthor=C.+Millerauthor=C.+Diedrichauthor=J.+Sacchettini&title=Crystal+structure+of+the+human+20S+proteasome+in+complex+with+carfilzomib&doi=10.1016%2Fj.str.2014.11.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Human 20S Proteasome in Complex with Carfilzomib</span></div><div class="casAuthors">Harshbarger, Wayne; Miller, Chase; Diedrich, Chandler; Sacchettini, James</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">418-424</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Proteasome inhibition is highly effective as a treatment for multiple myeloma, and recently carfilzomib was granted US FDA approval for the treatment of relapsed and refractory multiple myeloma.  Here, we report the X-ray crystal structure of the human constitutive 20S proteasome with and without carfilzomib bound at 2.9 and 2.6 Å, resp.  Our data indicate that the S3 and S4 binding pockets play a pivotal role in carfilzomib's selectivity for chymotrypsin-like sites.  Structural comparison with the mouse immunoproteasome crystal structure reveals amino acid substitutions that explain carfilzomib's slight preference for chymotrypsin-like subunits of constitutive proteasomes.  In addn., comparison of the human proteasome:carfilzomib complex with the mouse proteasome:PR-957 complex reveals new details that explain why PR-957 is selective for immunoproteasomes.  Together, the data presented here support the design of inhibitors for either constitutive or immunoproteasomes, with implications for the treatment of cancers as well as autoimmune and neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQfIgWQjhexbVg90H21EOLACvtfcHk0liMWs8P2A-gSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2msbg%253D&md5=0249966770dad6c25b7844fb1cea59b1</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2014.11.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2014.11.017%26sid%3Dliteratum%253Aachs%26aulast%3DHarshbarger%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DC.%26aulast%3DDiedrich%26aufirst%3DC.%26aulast%3DSacchettini%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%252020S%2520proteasome%2520in%2520complex%2520with%2520carfilzomib%26jtitle%3DStructure%26date%3D2015%26volume%3D23%26spage%3D418%26epage%3D424%26doi%3D10.1016%2Fj.str.2014.11.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crotchett, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slaughter, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMartino, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogol, E. P.</span></span> <span> </span><span class="NLM_article-title">Formation of proteasome-PA700 complexes directly correlates with activation of peptidase activity</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">12927</span>– <span class="NLM_lpage">12932</span>, <span class="refDoi"> DOI: 10.1021/bi981482i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi981482i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADyaK1cXlsFSkt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=12927-12932&author=G.+M.+Adamsauthor=B.+Crotchettauthor=C.+A.+Slaughterauthor=G.+N.+DeMartinoauthor=E.+P.+Gogol&title=Formation+of+proteasome-PA700+complexes+directly+correlates+with+activation+of+peptidase+activity&doi=10.1021%2Fbi981482i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Formation of Proteasome-PA700 Complexes Directly Correlates with Activation of Peptidase Activity</span></div><div class="casAuthors">Adams, George M.; Crotchett, Brad; Slaughter, Clive A.; DeMartino, George N.; Gogol, Edward P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">12927-12932</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The proteolytic activity of the eukaryotic 20S proteasome is stimulated by a multisubunit activator, PA700, which forms both 1:1 and 2:1 complexes with the proteasome.  Formation of the complexes is enhanced by an addnl. protein assembly called modulator, which also stimulates the enzymic activity of the proteasome only in the presence of PA700.  Here we show that the binding of PA700 to the proteasome is cooperative, as is the activation of the proteasome's intrinsic peptidase activity.  Modulator increases the extent of complex formation and peptidase activation, while preserving the cooperative kinetics.  Furthermore, the increase in activity is not linear with the no. of PA700 assemblies bound to the proteasome, but rather with the no. of proteasome-PA700 complexes, regardless of the PA700:proteasome stoichiometry.  Hence the stimulation of peptidase activity is fully (or almost fully) effected by the binding of a single PA700 to the 20S proteasome.  The stimulation of peptidase by modulator is explained entirely by the increased no. of proteasome-PA700 complexes formed in its presence, rather than by any substantial direct stimulation of catalysis.  These observations are consistent with a model in which PA700, either alone or assisted by modulator, promotes conformational changes in the proteasome that activate the catalytic sites and/or facilitate access of peptide substrates to these sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMxmr_oOyVTrVg90H21EOLACvtfcHk0liMWs8P2A-gSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlsFSkt7k%253D&md5=b94171e60e10e409a51e74c4a85dc23d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fbi981482i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi981482i%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DG.%2BM.%26aulast%3DCrotchett%26aufirst%3DB.%26aulast%3DSlaughter%26aufirst%3DC.%2BA.%26aulast%3DDeMartino%26aufirst%3DG.%2BN.%26aulast%3DGogol%26aufirst%3DE.%2BP.%26atitle%3DFormation%2520of%2520proteasome-PA700%2520complexes%2520directly%2520correlates%2520with%2520activation%2520of%2520peptidase%2520activity%26jtitle%3DBiochemistry%26date%3D1998%26volume%3D37%26spage%3D12927%26epage%3D12932%26doi%3D10.1021%2Fbi981482i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Micale, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarbaci, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troiano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zappala, M.</span></span> <span> </span><span class="NLM_article-title">Peptide-based proteasome inhibitors in anticancer drug design</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1001</span>– <span class="NLM_lpage">1069</span>, <span class="refDoi"> DOI: 10.1002/med.21312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1002%2Fmed.21312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=24585725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1KisrjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=1001-1069&author=N.+Micaleauthor=K.+Scarbaciauthor=V.+Troianoauthor=R.+Ettariauthor=S.+Grassoauthor=M.+Zappala&title=Peptide-based+proteasome+inhibitors+in+anticancer+drug+design&doi=10.1002%2Fmed.21312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide-Based Proteasome Inhibitors in Anticancer Drug Design</span></div><div class="casAuthors">Micale, Nicola; Scarbaci, Kety; Troiano, Valeria; Ettari, Roberta; Grasso, Silvana; Zappala, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1001-1069</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The identification of the key role of the eukaryotic 26S proteasome in regulated intracellular proteolysis and its importance as a target in many pathol. conditions wherein the proteasomal activity is defective (e.g., malignancies, autoimmune diseases, neurodegenerative diseases, etc.) prompted several research groups to the development of specific inhibitors of this multicatalytic complex with the aim of obtaining valid drug candidates.  In regard to the anticancer therapy, the peptide boronate bortezomib (Velcade) represents the first mol. approved by FDA for the treatment of multiple myeloma in 2003 and mantle cell lymphoma in 2006.  Since then, a plethora of mols. targeting the proteasome have been identified as potential anticancer agents and a few of them reached clin. trials or are already in the market (i.e., carfilzomib; Kyprolis).  In most cases, the design of new proteasome inhibitors (PIs) takes into account a proven peptide or pseudopeptide motif as a base structure and places other chem. entities throughout the peptide skeleton in such a way to create an efficacious network of interactions within the catalytic sites.  The purpose of this review is to provide an in-depth look at the current state of the research in the field of peptide-based PIs, specifically those ones that might find an application as anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvlA1JIUEG-rVg90H21EOLACvtfcHk0lhW9lNrDEHjxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1KisrjI&md5=872c775a6c36b1c4d26e39e4a5237ae7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fmed.21312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21312%26sid%3Dliteratum%253Aachs%26aulast%3DMicale%26aufirst%3DN.%26aulast%3DScarbaci%26aufirst%3DK.%26aulast%3DTroiano%26aufirst%3DV.%26aulast%3DEttari%26aufirst%3DR.%26aulast%3DGrasso%26aufirst%3DS.%26aulast%3DZappala%26aufirst%3DM.%26atitle%3DPeptide-based%2520proteasome%2520inhibitors%2520in%2520anticancer%2520drug%2520design%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2014%26volume%3D34%26spage%3D1001%26epage%3D1069%26doi%3D10.1002%2Fmed.21312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattarai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span> <span> </span><span class="NLM_article-title">H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4089</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-40635-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1038%2Fs41598-019-40635-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=30858500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A280%3ADC%252BB3cbivVGktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=4089&author=M.+J.+Leeauthor=Z.+Millerauthor=J.+E.+Parkauthor=D.+Bhattaraiauthor=W.+Leeauthor=K.+B.+Kim&title=H727+cells+are+inherently+resistant+to+the+proteasome+inhibitor+carfilzomib%2C+yet+require+proteasome+activity+for+cell+survival+and+growth&doi=10.1038%2Fs41598-019-40635-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth</span></div><div class="casAuthors">Lee Min Jae; Miller Zachary; Bhattarai Deepak; Kim Kyung Bo; Park Ji Eun; Lee Wooin</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4089</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The second-in-class proteasome inhibitor (PI) carfilzomib (Kyprolis, Cfz) has contributed to a substantial advancement in multiple myeloma treatment by improving patient survival and quality of life.  A considerable portion of patients however display intrinsic resistance to Cfz.  Our mechanistic understanding of intrinsic Cfz resistance is limited due to a lack of suitable cell-based models.  We report that H727 human bronchial carcinoid cells are inherently resistant to Cfz, yet susceptible to other PIs and inhibitors targeting upstream components of the ubiquitin-proteasome system (UPS).  These results indicate that H727 cells remain dependent on the UPS for cell survival and growth despite harboring intrinsic resistance to Cfz.  Alterations in the composition of proteasome catalytic subunits via interferon-γ treatment or siRNA knockdown results in sensitization of H727 cells to Cfz.  We postulate that a potential link may exist between the composition of proteasome catalytic subunits and the cellular response to Cfz.  Overall, H727 cells may serve as a useful cell-based model for de novo Cfz resistance and our results suggest previously unexplored mechanisms of de novo PI resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHLlRY4-lmF3T4ugvCDgnZfW6udTcc2eYRrRLCjGxN_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbivVGktw%253D%253D&md5=2eac99d394dd7fa2e1fe2922cd32b87f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-40635-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-40635-1%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.%2BJ.%26aulast%3DMiller%26aufirst%3DZ.%26aulast%3DPark%26aufirst%3DJ.%2BE.%26aulast%3DBhattarai%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DK.%2BB.%26atitle%3DH727%2520cells%2520are%2520inherently%2520resistant%2520to%2520the%2520proteasome%2520inhibitor%2520carfilzomib%252C%2520yet%2520require%2520proteasome%2520activity%2520for%2520cell%2520survival%2520and%2520growth%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26spage%3D4089%26doi%3D10.1038%2Fs41598-019-40635-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cyrus, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span> <span> </span><span class="NLM_article-title">Towards immunoproteasome-specific inhibitors: an improved synthesis of dihydroeponemycin</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2005</i></span>,  <span class="NLM_fpage">4829</span>– <span class="NLM_lpage">4834</span>, <span class="refDoi"> DOI: 10.1002/ejoc.200500437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1002%2Fejoc.200500437" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2005&publication_year=2005&pages=4829-4834&author=A.+Hoauthor=K.+Cyrusauthor=K.+B.+Kim&title=Towards+immunoproteasome-specific+inhibitors%3A+an+improved+synthesis+of+dihydroeponemycin&doi=10.1002%2Fejoc.200500437"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fejoc.200500437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.200500437%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DA.%26aulast%3DCyrus%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DK.%2BB.%26atitle%3DTowards%2520immunoproteasome-specific%2520inhibitors%253A%2520an%2520improved%2520synthesis%2520of%2520dihydroeponemycin%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2005%26volume%3D2005%26spage%3D4829%26epage%3D4834%26doi%3D10.1002%2Fejoc.200500437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span> <span> </span><span class="NLM_article-title">Efficacy of carfilzomib in the treatment of relapsed and (or) refractory multiple myeloma: a meta-analysis of data from clinical trials</span>. <i>Discov Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">199</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=27875670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A280%3ADC%252BC2snpt1Gruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=189-199&author=R.+Chenauthor=B.+Chenauthor=X.+Zhangauthor=C.+Gao&title=Efficacy+of+carfilzomib+in+the+treatment+of+relapsed+and+%28or%29+refractory+multiple+myeloma%3A+a+meta-analysis+of+data+from+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of carfilzomib in the treatment of relapsed and (or) refractory multiple myeloma: a meta-analysis of data from clinical trials</span></div><div class="casAuthors">Chen Runzhe; Chen Baoan; Zhang Xiaoping; Gao Chong</div><div class="citationInfo"><span class="NLM_cas:title">Discovery medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">121</span>),
    <span class="NLM_cas:pages">189-199</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Recently, carfilzomib has become a promising therapeutic approach for relapsed and (or) refractory multiple myeloma (RRMM), but no study has summarized the overall effect of carfilzomib in RRMM.  To explore the role of carfilzomib, we performed a meta-analysis of all known prospective clinical trials to assess the efficacy of carfilzomib in patients with RRMM.  METHODS AND MATERIALS:  A systematic review of publications was performed on December 15, 2015.  Eight studies including 1,446 patients were identified.  Meta-analyses were carried out to calculate the overall response rate (ORR), complete response rate (CRR), and clinical benefit rate (CBR) of carfilzomib for RRMM.  RESULTS:  In patients with RRMM, ORR was 0.44, CRR was 0.13, and CBR was 0.54.  High heterogeneity between studies was observed, and funnel plots were symmetrical, negating publication bias.  Carfilzomib was generally well tolerated by patients reported in the studies though some manageable adverse effects occurred.  CONCLUSION:  Our analysis revealed a promising benefit of carfilzomib in the treatment of RRMM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQIx2Jf5i2yFyCEBeYuoi7AfW6udTcc2ebxyAHsaWZurbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snpt1Gruw%253D%253D&md5=72f2e237d747625c19bc4588dc95a5b5</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DC.%26atitle%3DEfficacy%2520of%2520carfilzomib%2520in%2520the%2520treatment%2520of%2520relapsed%2520and%2520%2528or%2529%2520refractory%2520multiple%2520myeloma%253A%2520a%2520meta-analysis%2520of%2520data%2520from%2520clinical%2520trials%26jtitle%3DDiscov%2520Med.%26date%3D2016%26volume%3D22%26spage%3D189%26epage%3D199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hawley, T.
S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riz, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakabayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depalma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawley, R. G.</span></span> <span> </span><span class="NLM_article-title">Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1</span>. <i>Am. J. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1002/ajh.23387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1002%2Fajh.23387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=23475625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC3sXks1GhsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2013&pages=265-272&author=T.%0AS.+Hawleyauthor=I.+Rizauthor=W.+Yangauthor=Y.+Wakabayashiauthor=L.+Depalmaauthor=Y.+T.+Changauthor=W.+Pengauthor=J.+Zhuauthor=R.+G.+Hawley&title=Identification+of+an+ABCB1+%28P-glycoprotein%29-positive+carfilzomib-resistant+myeloma+subpopulation+by+the+pluripotent+stem+cell+fluorescent+dye+CDy1&doi=10.1002%2Fajh.23387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1</span></div><div class="casAuthors">Hawley, Teresa S.; Riz, Irene; Yang, Wenjing; Wakabayashi, Yoshiyuki; DePalma, Louis; Chang, Young-Tae; Peng, Weiqun; Zhu, Jun; Hawley, Robert G.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hematology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">265-272</span>CODEN:
                <span class="NLM_cas:coden">AJHEDD</span>;
        ISSN:<span class="NLM_cas:issn">0361-8609</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Multiple myeloma (MM) is characterized by the malignant expansion of differentiated plasma cells.  Although many chemotherapeutic agents display cytotoxic activity toward MM cells, patients inevitably succumb to their disease because the tumor cells become resistant to the anticancer drugs.  The cancer stem cell hypothesis postulates that a small subpopulation of chemotherapy-resistant cancer cells is responsible for propagation of the tumor.  Herein we report that efflux of the pluripotent stem cell dye CDy1 identifies a subpopulation in MM cell lines characterized by increased expression of P-glycoprotein, a member of the ABC (ATP-binding cassette) superfamily of transporters encoded by ABCB1.  We also demonstrate that ABCB1-overexpressing MM cells are resistant to the second-generation proteasome inhibitor carfilzomib that recently received accelerated approval for the treatment of therapy-refractive MM by the U.S. Food and Drug Administration.  Moreover, increased resistance to carfilzomib in sensitive MM cells following drug selection was assocd. with upregulation of ABCB1 cell-surface expression which correlated with increased transporter activity as measured by CDy1 efflux.  We further show that chemosensitization of MM cells to carfilzomib could be achieved in vitro by cotreatment with vismodegib, a hedgehog pathway antagonist which is currently in MM clin. trials.  CDy1 efflux may therefore be a useful assay to det. whether high expression of ABCB1 is predictive of poor clin. responses in MM patients treated with carfilzomib.  Our data also suggest that inclusion of vismodegib might be a potential strategy to reverse ABCB1-mediated drug resistance should it occur.  Am. J. Hematol. 88:265-272, 2013. © 2013 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-sWqm6QARJbVg90H21EOLACvtfcHk0ljaj-8HibzqTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXks1GhsbY%253D&md5=34dbd19b95a258bbbbe123dce1102b58</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fajh.23387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajh.23387%26sid%3Dliteratum%253Aachs%26aulast%3DHawley%26aufirst%3DT.%2BS.%26aulast%3DRiz%26aufirst%3DI.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DWakabayashi%26aufirst%3DY.%26aulast%3DDepalma%26aufirst%3DL.%26aulast%3DChang%26aufirst%3DY.%2BT.%26aulast%3DPeng%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DHawley%26aufirst%3DR.%2BG.%26atitle%3DIdentification%2520of%2520an%2520ABCB1%2520%2528P-glycoprotein%2529-positive%2520carfilzomib-resistant%2520myeloma%2520subpopulation%2520by%2520the%2520pluripotent%2520stem%2520cell%2520fluorescent%2520dye%2520CDy1%26jtitle%3DAm.%2520J.%2520Hematol.%26date%3D2013%26volume%3D88%26spage%3D265%26epage%3D272%26doi%3D10.1002%2Fajh.23387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span> <span> </span><span class="NLM_article-title">Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2197</span>– <span class="NLM_lpage">2205</span>, <span class="refDoi"> DOI: 10.1021/mp300044b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp300044b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC38XptFCju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=2197-2205&author=L.+Aoauthor=Y.+Wuauthor=D.+Kimauthor=E.+R.+Jangauthor=K.+Kimauthor=D.+M.+Leeauthor=K.+B.+Kimauthor=W.+Lee&title=Development+of+peptide-based+reversing+agents+for+p-glycoprotein-mediated+resistance+to+carfilzomib&doi=10.1021%2Fmp300044b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Peptide-Based Reversing Agents for P-Glycoprotein-Mediated Resistance to Carfilzomib</span></div><div class="casAuthors">Ao, Lin; Wu, Ying; Kim, Donghern; Jang, Eun Ryoung; Kim, Kyunghwa; Lee, Do-min; Kim, Kyung Bo; Lee, Wooin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2197-2205</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Carfilzomib is a novel class of peptidyl epoxyketone proteasome inhibitor and has demonstrated promising activity in multiple clin. trials to treat patients with multiple myeloma and other types of cancers.  Here, we investigated mol. mechanisms underlying acquired resistance to carfilzomib and a potential strategy to restore cellular sensitivity to carfilzomib.  H23 and DLD-1 cells (human lung and colon adenocarcinoma cell lines) with acquired resistance to carfilzomib displayed marked cross-resistance to YU-101, a closely related proteasome inhibitor, and paclitaxel, a known substrate of Pgp.  However, carfilzomib-resistant cells remained sensitive to bortezomib, a clin. used dipeptide with boronic acid pharmacophore.  In accordance with these observations, carfilzomib-resistant H23 and DLD-1 cells showed marked upregulation of P-glycoprotein (Pgp) as compared to their parental controls, and coincubation with verapamil, a Pgp inhibitor, led to an almost complete restoration of cellular sensitivity to carfilzomib.  These results indicate that Pgp upregulation plays a major role in the development of carfilzomib resistance in these cell lines.  In developing a potential strategy to overcome carfilzomib resistance, we as a proof of concept prepd. a small library of peptide analogs derived from the peptide backbone of carfilzomib and screened these mols. for their activity to restore carfilzomib sensitivity when cotreated with carfilzomib.  We found that compds. as small as dipeptides are sufficient in restoring carfilzomib sensitivity.  Taken together, we found that Pgp upregulation plays a major role in the development of resistance to carfilzomib in lung and colon adenocarcinoma cell lines and that small peptide analogs lacking the pharmacophore can be used as agents to reverse acquired carfilzomib resistance.  Our findings may provide important information in developing a potential strategy to overcome drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrslgMOfDD53rVg90H21EOLACvtfcHk0ljaj-8HibzqTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptFCju7c%253D&md5=ba90f3b18f9e4cc80cf1fc72d523fb5c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fmp300044b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp300044b%26sid%3Dliteratum%253Aachs%26aulast%3DAo%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DJang%26aufirst%3DE.%2BR.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DD.%2BM.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DLee%26aufirst%3DW.%26atitle%3DDevelopment%2520of%2520peptide-based%2520reversing%2520agents%2520for%2520p-glycoprotein-mediated%2520resistance%2520to%2520carfilzomib%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26spage%3D2197%26epage%3D2205%26doi%3D10.1021%2Fmp300044b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gutman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boise, L. H.</span></span> <span> </span><span class="NLM_article-title">Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2181</span>– <span class="NLM_lpage">2183</span>, <span class="refDoi"> DOI: 10.1038/leu.2009.123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1038%2Fleu.2009.123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=19516276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A280%3ADC%252BD1MjltVyntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=2181-2183&author=D.+Gutmanauthor=A.+A.+Moralesauthor=L.+H.+Boise&title=Acquisition+of+a+multidrug-resistant+phenotype+with+a+proteasome+inhibitor+in+multiple+myeloma&doi=10.1038%2Fleu.2009.123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma</span></div><div class="casAuthors">Gutman D; Morales A A; Boise L H</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2181-3</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT1aBKLYf2evEBuFdjgVNKSfW6udTcc2ebxyAHsaWZurbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MjltVyntg%253D%253D&md5=7ae86eb631925aa5cc65b409072142bf</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fleu.2009.123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2009.123%26sid%3Dliteratum%253Aachs%26aulast%3DGutman%26aufirst%3DD.%26aulast%3DMorales%26aufirst%3DA.%2BA.%26aulast%3DBoise%26aufirst%3DL.%2BH.%26atitle%3DAcquisition%2520of%2520a%2520multidrug-resistant%2520phenotype%2520with%2520a%2520proteasome%2520inhibitor%2520in%2520multiple%2520myeloma%26jtitle%3DLeukemia%26date%3D2009%26volume%3D23%26spage%3D2181%26epage%3D2183%26doi%3D10.1038%2Fleu.2009.123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vij, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubowiak, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonial, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukreti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahlis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanan-Khan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buadi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reu, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somlo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zonder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmauer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wear, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, R. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagannath, S.</span></span> <span> </span><span class="NLM_article-title">A phase 2 study of single-agent carfilzomib (PX-171–003-A1) in patients with relapsed and refractory multiple myeloma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">2817</span>– <span class="NLM_lpage">2825</span>, <span class="refDoi"> DOI: 10.1182/blood-2012-05-425934</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1182%2Fblood-2012-05-425934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=22833546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFaksLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2012&pages=2817-2825&author=D.+S.+Siegelauthor=T.+Martinauthor=M.+Wangauthor=R.+Vijauthor=A.+J.+Jakubowiakauthor=S.+Lonialauthor=S.+Trudelauthor=V.+Kukretiauthor=N.+Bahlisauthor=M.+Alsinaauthor=A.+Chanan-Khanauthor=F.+Buadiauthor=F.+J.+Reuauthor=G.+Somloauthor=J.+Zonderauthor=K.+Songauthor=A.+K.+Stewartauthor=E.+Stadtmauerauthor=L.+Kunkelauthor=S.+Wearauthor=A.+F.+Wongauthor=R.+Z.+Orlowskiauthor=S.+Jagannath&title=A+phase+2+study+of+single-agent+carfilzomib+%28PX-171%E2%80%93003-A1%29+in+patients+with+relapsed+and+refractory+multiple+myeloma&doi=10.1182%2Fblood-2012-05-425934"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma</span></div><div class="casAuthors">Siegel, David S.; Martin, Thomas; Wang, Michael; Vij, Ravi; Jakubowiak, Andrzej J.; Lonial, Sagar; Trudel, Suzanne; Kukreti, Vishal; Bahlis, Nizar; Alsina, Melissa; Chanan-Khan, Asher; Buadi, Francis; Reu, Frederic J.; Somlo, George; Zonder, Jeffrey; Song, Kevin; Stewart, A. Keith; Stadtmauer, Edward; Kunkel, Lori; Wear, Sandra; Wong, Alvin F.; Orlowski, Robert Z.; Jagannath, Sundar</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2817-2825</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Carfilzomib is a next-generation, selective proteasome inhibitor being evaluated for the treatment of relapsed and refractory multiple myeloma.  In this open-label, single-arm phase 2 study (PX-171-003-A1), patients received single-agent carfilzomib 20 mg/m2 i.v. twice weekly for 3 of 4 wk in cycle 1, then 27 mg/m2 for ≤ 12 cycles.  The primary endpoint was overall response rate (≥ partial response).  Secondary endpoints included clin. benefit response rate (≥ minimal response), duration of response, progression-free survival, overall survival, and safety.  A total of 266 patients were evaluable for safety, 257 for efficacy; 95% were refractory to their last therapy; 80% were refractory or intolerant to both bortezomib and lenalidomide.  Patients had median of 5 prior lines of therapy, including bortezomib, lenalidomide, and thalidomide.  Overall response rate was 23.7% with median duration of response of 7.8 mo.  Median overall survival was 15.6 mo.  Adverse events (AEs) were manageable without cumulative toxicities.  Common AEs were fatigue (49%), anemia (46%), nausea (45%), and thrombocytopenia (39%).  Thirty-three patients (12.4%) experienced peripheral neuropathy, primarily grades 1 or 2.  Thirty-three patients (12.4%) withdrew because of an AE.  Durable responses and an acceptable tolerability profile in this heavily pretreated population demonstrate the potential of carfilzomib to offer meaningful clin. benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptn9sXStS-8LVg90H21EOLACvtfcHk0lgfJQmrjJMJVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFaksLbM&md5=f96b01b750ff27ea4097c5aba4453bcb</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1182%2Fblood-2012-05-425934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2012-05-425934%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DD.%2BS.%26aulast%3DMartin%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DVij%26aufirst%3DR.%26aulast%3DJakubowiak%26aufirst%3DA.%2BJ.%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DTrudel%26aufirst%3DS.%26aulast%3DKukreti%26aufirst%3DV.%26aulast%3DBahlis%26aufirst%3DN.%26aulast%3DAlsina%26aufirst%3DM.%26aulast%3DChanan-Khan%26aufirst%3DA.%26aulast%3DBuadi%26aufirst%3DF.%26aulast%3DReu%26aufirst%3DF.%2BJ.%26aulast%3DSomlo%26aufirst%3DG.%26aulast%3DZonder%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DStewart%26aufirst%3DA.%2BK.%26aulast%3DStadtmauer%26aufirst%3DE.%26aulast%3DKunkel%26aufirst%3DL.%26aulast%3DWear%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DA.%2BF.%26aulast%3DOrlowski%26aufirst%3DR.%2BZ.%26aulast%3DJagannath%26aufirst%3DS.%26atitle%3DA%2520phase%25202%2520study%2520of%2520single-agent%2520carfilzomib%2520%2528PX-171%25E2%2580%2593003-A1%2529%2520in%2520patients%2520with%2520relapsed%2520and%2520refractory%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2012%26volume%3D120%26spage%3D2817%26epage%3D2825%26doi%3D10.1182%2Fblood-2012-05-425934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargagna-Mohan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span> <span> </span><span class="NLM_article-title">LMP2-specific inhibitors: Novel chemical genetic tools for proteasome biology</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2007.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2Fj.chembiol.2007.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=17462577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkslaitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=419-430&author=Y.+K.+Hoauthor=P.+Bargagna-Mohanauthor=R.+Mohanauthor=K.+B.+Kim&title=LMP2-specific+inhibitors%3A+Novel+chemical+genetic+tools+for+proteasome+biology&doi=10.1016%2Fj.chembiol.2007.03.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">LMP2-Specific Inhibitors: Chemical Genetic Tools for Proteasome Biology</span></div><div class="casAuthors">Ho, Yik Khuan; Bargagna-Mohan, Paola; Wehenkel, Marie; Mohan, Royce; Kim, Kyung-Bo</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">419-430</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The immunoproteasome, having been linked to neurodegenerative diseases and hematol. cancers, has been shown to play an important role in MHC class I antigen presentation.  However, its other pathophysiol. functions are still not very well understood.  This can be attributed mainly to a lack of appropriate mol. probes that can selectively modulate the immunoproteasome catalytic subunits.  Herein, the authors report the development of mol. probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome.  The authors show that these compds. irreversibly modify the LMP2 subunit with high specificity.  Importantly, LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of malignant tumors that highly express LMP2.  Thus, the development of the immunoproteasome catalytic subunit LMP2-specific inhibitors may not only hold great potential as a therapeutic agent for certain diseases but can also provide a valuable chem. genetic probe to investigate immunoproteasome biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDvEUufIJ3K7Vg90H21EOLACvtfcHk0lgfJQmrjJMJVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkslaitbY%253D&md5=d12fa5065f6bdd4aee8ad12491a1c072</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2007.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2007.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DY.%2BK.%26aulast%3DBargagna-Mohan%26aufirst%3DP.%26aulast%3DMohan%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DK.%2BB.%26atitle%3DLMP2-specific%2520inhibitors%253A%2520Novel%2520chemical%2520genetic%2520tools%2520for%2520proteasome%2520biology%26jtitle%3DChem.%2520Biol.%26date%3D2007%26volume%3D14%26spage%3D419%26epage%3D430%26doi%3D10.1016%2Fj.chembiol.2007.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Bruin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Rooden, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Ayed, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisselev, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Stelt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Marel, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of beta1i or beta5i specific inhibitors of human immunoproteasomes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">6197</span>– <span class="NLM_lpage">6209</span>, <span class="refDoi"> DOI: 10.1021/jm500716s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500716s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6197-6209&author=G.+de%0ABruinauthor=E.+M.+Huberauthor=B.+T.+Xinauthor=E.+J.+van+Roodenauthor=K.+Al-Ayedauthor=K.+B.+Kimauthor=A.+F.+Kisselevauthor=C.+Driessenauthor=M.+van+der+Steltauthor=G.+A.+van+der+Marelauthor=M.+Grollauthor=H.+S.+Overkleeft&title=Structure-based+design+of+beta1i+or+beta5i+specific+inhibitors+of+human+immunoproteasomes&doi=10.1021%2Fjm500716s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm500716s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500716s%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BBruin%26aufirst%3DG.%26aulast%3DHuber%26aufirst%3DE.%2BM.%26aulast%3DXin%26aufirst%3DB.%2BT.%26aulast%3Dvan%2BRooden%26aufirst%3DE.%2BJ.%26aulast%3DAl-Ayed%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DKisselev%26aufirst%3DA.%2BF.%26aulast%3DDriessen%26aufirst%3DC.%26aulast%3Dvan%2Bder%2BStelt%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BMarel%26aufirst%3DG.%2BA.%26aulast%3DGroll%26aufirst%3DM.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26atitle%3DStructure-based%2520design%2520of%2520beta1i%2520or%2520beta5i%2520specific%2520inhibitors%2520of%2520human%2520immunoproteasomes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6197%26epage%3D6209%26doi%3D10.1021%2Fjm500716s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huber, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinemeyer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groettrup, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span> <span> </span><span class="NLM_article-title">Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">738</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2011.12.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2Fj.cell.2011.12.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=22341445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtV2qsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2012&pages=727-738&author=E.+M.+Huberauthor=M.+Baslerauthor=R.+Schwabauthor=W.+Heinemeyerauthor=C.+J.+Kirkauthor=M.+Groettrupauthor=M.+Groll&title=Immuno-+and+constitutive+proteasome+crystal+structures+reveal+differences+in+substrate+and+inhibitor+specificity&doi=10.1016%2Fj.cell.2011.12.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity</span></div><div class="casAuthors">Huber, Eva M.; Basler, Michael; Schwab, Ricarda; Heinemeyer, Wolfgang; Kirk, Christopher J.; Groettrup, Marcus; Groll, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">727-738</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Constitutive proteasomes and immunoproteasomes shape the peptide repertoire presented by major histocompatibility complex class I (MHC-I) mols. by harboring different sets of catalytically active subunits.  Here, we present the crystal structures of constitutive proteasomes and immunoproteasomes from mouse in the presence and absence of the epoxyketone inhibitor PR-957 (ONX 0914) at 2.9 Å resoln.  Based on our X-ray data, we propose a unique catalytic feature for the immunoproteasome subunit β5i/LMP7.  Comparison of ligand-free and ligand-bound proteasomes reveals conformational changes in the S1 pocket of β5c/X but not β5i, thereby explaining the selectivity of PR-957 for β5i.  Time-resolved structures of yeast proteasome:PR-957 complexes indicate that ligand docking to the active site occurs only via the reactive head group and the P1 side chain.  Together, our results support structure-guided design of inhibitory lead structures selective for immunoproteasomes that are linked to cytokine prodn. and diseases like cancer and autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2OWN02GZMFbVg90H21EOLACvtfcHk0lgPOQTxuddQCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtV2qsL8%253D&md5=ee9f24ec6a0720808e4baf27bf87fcad</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.12.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.12.030%26sid%3Dliteratum%253Aachs%26aulast%3DHuber%26aufirst%3DE.%2BM.%26aulast%3DBasler%26aufirst%3DM.%26aulast%3DSchwab%26aufirst%3DR.%26aulast%3DHeinemeyer%26aufirst%3DW.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DGroettrup%26aufirst%3DM.%26aulast%3DGroll%26aufirst%3DM.%26atitle%3DImmuno-%2520and%2520constitutive%2520proteasome%2520crystal%2520structures%2520reveal%2520differences%2520in%2520substrate%2520and%2520inhibitor%2520specificity%26jtitle%3DCell%26date%3D2012%26volume%3D148%26spage%3D727%26epage%3D738%26doi%3D10.1016%2Fj.cell.2011.12.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul Hameed, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehenkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzyka, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, C. G.</span></span> <span> </span><span class="NLM_article-title">Molecular basis of the selectivity of the immunoproteasome catalytic subunit LMP2-specific inhibitor revealed by molecular modeling and dynamics simulations</span>. <i>J. Phys. Chem. B</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">12333</span>– <span class="NLM_lpage">12339</span>, <span class="refDoi"> DOI: 10.1021/jp1058098</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp1058098" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2010&pages=12333-12339&author=B.+Leiauthor=M.+D.+Abdul+Hameedauthor=A.+Hamzaauthor=M.+Wehenkelauthor=J.+L.+Muzykaauthor=X.+J.+Yaoauthor=K.+B.+Kimauthor=C.+G.+Zhan&title=Molecular+basis+of+the+selectivity+of+the+immunoproteasome+catalytic+subunit+LMP2-specific+inhibitor+revealed+by+molecular+modeling+and+dynamics+simulations&doi=10.1021%2Fjp1058098"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjp1058098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp1058098%26sid%3Dliteratum%253Aachs%26aulast%3DLei%26aufirst%3DB.%26aulast%3DAbdul%2BHameed%26aufirst%3DM.%2BD.%26aulast%3DHamza%26aufirst%3DA.%26aulast%3DWehenkel%26aufirst%3DM.%26aulast%3DMuzyka%26aufirst%3DJ.%2BL.%26aulast%3DYao%26aufirst%3DX.%2BJ.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DZhan%26aufirst%3DC.%2BG.%26atitle%3DMolecular%2520basis%2520of%2520the%2520selectivity%2520of%2520the%2520immunoproteasome%2520catalytic%2520subunit%2520LMP2-specific%2520inhibitor%2520revealed%2520by%2520molecular%2520modeling%2520and%2520dynamics%2520simulations%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D2010%26volume%3D114%26spage%3D12333%26epage%3D12339%26doi%3D10.1021%2Fjp1058098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bomba, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">230</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.047662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1124%2Fdmd.112.047662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=23118326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1Ontg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=230-237&author=Z.+Wangauthor=J.+Yangauthor=C.+Kirkauthor=Y.+Fangauthor=M.+Alsinaauthor=A.+Badrosauthor=K.+Papadopoulosauthor=A.+Wongauthor=T.+Wooauthor=D.+Bombaauthor=J.+Liauthor=J.+R.+Infante&title=Clinical+pharmacokinetics%2C+metabolism%2C+and+drug-drug+interaction+of+carfilzomib&doi=10.1124%2Fdmd.112.047662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib</span></div><div class="casAuthors">Wang, Zhengping; Yang, Jinfu; Kirk, Christopher; Fang, Ying; Alsina, Melissa; Badros, Ashraf; Papadopoulos, Kyriakos; Wong, Alvin; Woo, Tina; Bomba, Darrin; Li, Jin; Infante, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">230-237</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM).  Here we summarize the clin. pharmacokinetics (PK), metab., and drug-drug interaction (DDI) profile of carfilzomib.  The PK of carfilzomib, infused over 2-10 min, was evaluated in patients with solid tumors or MM.  Metabolites of carfilzomib were characterized in patient plasma and urine samples.  In vitro drug metab. and DDI studies were conducted in human liver microsomes and hepatocytes.  A clin. DDI study was conducted in patients with solid tumors to evaluate the effect of carfilzomib on CYP3A activity.  Plasma concns. of carfilzomib declined rapidly and in a biphasic manner after i.v. administration.  The systemic half-life was short and the systemic clearance rate was higher than hepatic blood flow.  Carfilzomib was cleared largely extrahepatically via peptidase cleavage and epoxide hydrolysis.  Cytochrome P 450-mediated metab. played a minor role, suggesting that coadministration of P 450 inhibitors or inducers is unlikely to change its PK profile.  Carfilzomib showed direct and time-dependent inhibition of CYP3A in human liver microsome prepns. and exposure to carfilzomib resulted in redns. in CYP3A and 1A2 gene expression in cultured human hepatocytes.  However, administration of carfilzomib did not affect the PK of midazolam in patients with solid tumors, and there were no safety signals indicative of potential drug interactions.  We conclude that the rapid systemic clearance and short half-life of carfilzomib limit clin. significant DDI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBFQz6vn1lHbVg90H21EOLACvtfcHk0lgPOQTxuddQCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1Ontg%253D%253D&md5=f3f74eb39c59681aadf7a10b3af45510</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.047662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.047662%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DKirk%26aufirst%3DC.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DAlsina%26aufirst%3DM.%26aulast%3DBadros%26aufirst%3DA.%26aulast%3DPapadopoulos%26aufirst%3DK.%26aulast%3DWong%26aufirst%3DA.%26aulast%3DWoo%26aufirst%3DT.%26aulast%3DBomba%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26atitle%3DClinical%2520pharmacokinetics%252C%2520metabolism%252C%2520and%2520drug-drug%2520interaction%2520of%2520carfilzomib%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2013%26volume%3D41%26spage%3D230%26epage%3D237%26doi%3D10.1124%2Fdmd.112.047662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausville, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutler, R. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span> <span> </span><span class="NLM_article-title">A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">861</span>– <span class="NLM_lpage">868</span>, <span class="refDoi"> DOI: 10.1007/s00280-013-2267-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1007%2Fs00280-013-2267-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=23975329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlOrtrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2013&pages=861-868&author=K.+P.+Papadopoulosauthor=H.+A.+Burrisauthor=M.+Gordonauthor=P.+Leeauthor=E.+A.+Sausvilleauthor=P.+J.+Rosenauthor=A.+Patnaikauthor=R.+E.+Cutlerauthor=Z.+Wangauthor=S.+Leeauthor=S.+F.+Jonesauthor=J.+R.+Infante&title=A+phase+I%2FII+study+of+carfilzomib+2%E2%80%9310-min+infusion+in+patients+with+advanced+solid+tumors&doi=10.1007%2Fs00280-013-2267-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors</span></div><div class="casAuthors">Papadopoulos, Kyriakos P.; Burris, Howard A.; Gordon, Michael; Lee, Peter; Sausville, Edward A.; Rosen, Peter J.; Patnaik, Amita; Cutler, Richard E., Jr.; Wang, Zhengping; Lee, Susan; Jones, Suzanne F.; Infante, Jeffery R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">861-868</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Tolerability, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of carfilzomib, a selective proteasome inhibitor, administered twice weekly by 2-10-min i.v. (IV) infusion on days 1, 2, 8, 9, 15, and 16 in 28-day cycles, were assessed in patients with advanced solid tumors in this phase I/II study.  Methods: Adult patients with solid tumors progressing after ≥1 prior therapies were enrolled.  The dose was 20 mg/m2 in week 1 of cycle 1 and 20, 27, or 36 mg/m2 thereafter.  The max. tolerated dose or protocol-defined max. planned dose (MPD) identified during dose escalation was administered to an expansion cohort and to patients with small cell lung, non-small cell lung, ovarian, and renal cancer in phase II tumor-specific cohorts.  Results: Fourteen patients received carfilzomib during dose escalation.  The single dose-limiting toxicity at 20/36 mg/m2 was grade 3 fatigue, establishing the MPD as the expansion and phase II dose.  Sixty-five addnl. patients received carfilzomib at the MPD.  Adverse events included fatigue, nausea, anorexia, and dyspnea.  Carfilzomib PK was dose proportional with a half-life <1 h.  All doses resulted in at least 80 % proteasome inhibition in blood.  Partial responses occurred in two patients in phase I, with 21.5 % stable disease after four cycles in evaluable patients in the expansion and phase II cohorts.  Conclusion: Carfilzomib 20/36 mg/m2 was well tolerated when administered twice weekly by 2-10-min IV infusion.  At this dose and infusion rate, carfilzomib inhibited the proteasome in blood but demonstrated limited antitumor activity in patients with advanced solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw4kZY9JrtI7Vg90H21EOLACvtfcHk0ljGVyIG7hS-og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlOrtrvN&md5=bebfbc6be14861a4d25f9402dfea67b8</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1007%2Fs00280-013-2267-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-013-2267-x%26sid%3Dliteratum%253Aachs%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DGordon%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DP.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DRosen%26aufirst%3DP.%2BJ.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DCutler%26aufirst%3DR.%2BE.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DS.%2BF.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26atitle%3DA%2520phase%2520I%252FII%2520study%2520of%2520carfilzomib%25202%25E2%2580%259310-min%2520infusion%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2013%26volume%3D72%26spage%3D861%26epage%3D868%26doi%3D10.1007%2Fs00280-013-2267-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teague, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">In vitro metabolism of oprozomib, an oral proteasome inhibitor: role of epoxide hydrolases and cytochrome P450s</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">712</span>– <span class="NLM_lpage">720</span>, <span class="refDoi"> DOI: 10.1124/dmd.117.075226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1124%2Fdmd.117.075226" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=712-720&author=Z.+Wangauthor=Y.+Fangauthor=J.+Teagueauthor=H.+Wongauthor=C.+Morisseauauthor=B.+D.+Hammockauthor=D.+A.+Rockauthor=Z.+Wang&title=In+vitro+metabolism+of+oprozomib%2C+an+oral+proteasome+inhibitor%3A+role+of+epoxide+hydrolases+and+cytochrome+P450s&doi=10.1124%2Fdmd.117.075226"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1124%2Fdmd.117.075226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.117.075226%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DTeague%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DRock%26aufirst%3DD.%2BA.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DIn%2520vitro%2520metabolism%2520of%2520oprozomib%252C%2520an%2520oral%2520proteasome%2520inhibitor%253A%2520role%2520of%2520epoxide%2520hydrolases%2520and%2520cytochrome%2520P450s%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2017%26volume%3D45%26spage%3D712%26epage%3D720%26doi%3D10.1124%2Fdmd.117.075226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saenz-Mendez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Kempner, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ventura, O. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, M.</span></span> <span> </span><span class="NLM_article-title">Structural insights into human microsomal epoxide hydrolase by combined homology modeling, molecular dynamics simulations, and molecular docking calculations</span>. <i>Proteins: Struct., Funct., Genet.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">720</span>– <span class="NLM_lpage">730</span>, <span class="refDoi"> DOI: 10.1002/prot.25251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1002%2Fprot.25251" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2017&pages=720-730&author=P.+Saenz-Mendezauthor=A.+Katzauthor=M.+L.+Perez-Kempnerauthor=O.+N.+Venturaauthor=M.+Vazquez&title=Structural+insights+into+human+microsomal+epoxide+hydrolase+by+combined+homology+modeling%2C+molecular+dynamics+simulations%2C+and+molecular+docking+calculations&doi=10.1002%2Fprot.25251"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fprot.25251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.25251%26sid%3Dliteratum%253Aachs%26aulast%3DSaenz-Mendez%26aufirst%3DP.%26aulast%3DKatz%26aufirst%3DA.%26aulast%3DPerez-Kempner%26aufirst%3DM.%2BL.%26aulast%3DVentura%26aufirst%3DO.%2BN.%26aulast%3DVazquez%26aufirst%3DM.%26atitle%3DStructural%2520insights%2520into%2520human%2520microsomal%2520epoxide%2520hydrolase%2520by%2520combined%2520homology%2520modeling%252C%2520molecular%2520dynamics%2520simulations%252C%2520and%2520molecular%2520docking%2520calculations%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D2017%26volume%3D85%26spage%3D720%26epage%3D730%26doi%3D10.1002%2Fprot.25251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1789</span>– <span class="NLM_lpage">1808</span>, <span class="refDoi"> DOI: 10.1021/jm201468j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201468j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ajtrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1789-1808&author=H.+C.+Shenauthor=B.+D.+Hammock&title=Discovery+of+inhibitors+of+soluble+epoxide+hydrolase%3A+a+target+with+multiple+potential+therapeutic+indications&doi=10.1021%2Fjm201468j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Inhibitors of Soluble Epoxide Hydrolase: A Target with Multiple Potential Therapeutic Indications</span></div><div class="casAuthors">Shen, Hong C.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1789-1808</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The inhibition of sol. epoxide hydrolase (sEH) by small mols. has been shown to increase the levels of fatty acid epoxides such as epoxyeicosatrienoic acids (EETs), and decrease the levels of the corresponding fatty acid diols including dihydroxyeicosatrienoic acids (DHETs).  Due to numerous beneficial effects of EETs, the elevation of their levels, as a result of sEH inhibition, may eventually lead to new therapeutic approaches for multiple diseases.  Specifically, it has been shown, largely in rodent models, that sEH inhibitors can be used to treat heart failure, hypertension, diabetes, stroke, dyslipidemia, inflammatory and neuropathic pain, immunol. disorders, eye diseases, neurol. diseases, and other indications.  Medicinal chem. strategies, key biol. data of benchmark compds., and possible paths for sEH inhibitors to reach the clinic will be reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBjFZ7QGkOVbVg90H21EOLACvtfcHk0ljGVyIG7hS-og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ajtrzK&md5=1a2ba726f26b7e207df467f67685cf2d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm201468j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201468j%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DH.%2BC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520inhibitors%2520of%2520soluble%2520epoxide%2520hydrolase%253A%2520a%2520target%2520with%2520multiple%2520potential%2520therapeutic%2520indications%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1789%26epage%3D1808%26doi%3D10.1021%2Fjm201468j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hosagrahara, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettie, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omiecinski, C. J.</span></span> <span> </span><span class="NLM_article-title">Functional analysis of human microsomal epoxide hydrolase genetic variants</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1016/j.cbi.2004.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2Fj.cbi.2004.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=15535985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVKnsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2004&pages=149-159&author=V.+P.+Hosagraharaauthor=A.+E.+Rettieauthor=C.+Hassettauthor=C.+J.+Omiecinski&title=Functional+analysis+of+human+microsomal+epoxide+hydrolase+genetic+variants&doi=10.1016%2Fj.cbi.2004.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Functional analysis of human microsomal epoxide hydrolase genetic variants</span></div><div class="casAuthors">Hosagrahara, Vinayak P.; Rettie, Allan E.; Hassett, Christopher; Omiecinski, Curtis J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">149-159</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Human microsomal epoxide hydrolase (EPHX1) is active in the metab. of many potentially carcinogenic or otherwise genotoxic epoxides, such as those derived from the oxidn. of polyarom. hydrocarbons.  EPHX1 is polymorphic and encodes allelic variation at least two amino acid positions, Y113H and H139R.  In a no. of recent mol. epidemiol. investigations, EPHX1 polymorphism has been suggested as a susceptibility factor for several human diseases.  To better evaluate the functional contribution of EPHX1 genetic polymorphism, we characterized the enzymic properties assocd. with each of the resp. variant proteins.  Enzymic profiles were evaluated with cis-stilbene oxide (cSO) and benzo[a]pyrene-4,5-epoxide (BaPO), two prototypical substrates for the hydrolase.  In one series of expts., activities of recombinant EPHX1 proteins were analyzed subsequent to their expression using the pFastbac baculovirus vector in Spodoptera frugiperda-9 (Sf9) insect cells, and purifn. by column chromatog.  In parallel studies, EPHX1 activities were evaluated with human liver microsomes derived from individuals of known EPHX1 genotype.  Using the purified protein prepns., rates of cSO and BaPO hydrolysis for the ref. protein, Y113/H139, were approx. 2-fold greater than those measured with the other EPHX1 allelic variants.  However, when activities were analyzed using human liver microsomal fractions, no major differences were evident in the reaction rates generated among prepns. representing the different EPHX1 alleles.  Collectively, these results suggest that the structural differences encoded by the Y113H and H139R variant alleles exert only modest impact on EPHX1-specific enzymic activities in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO9BXOsS5nNbVg90H21EOLACvtfcHk0liWQM4PeNpDQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVKnsLk%253D&md5=6e945c146c9c6ad5e6681012d2b4edd8</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2004.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2004.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DHosagrahara%26aufirst%3DV.%2BP.%26aulast%3DRettie%26aufirst%3DA.%2BE.%26aulast%3DHassett%26aufirst%3DC.%26aulast%3DOmiecinski%26aufirst%3DC.%2BJ.%26atitle%3DFunctional%2520analysis%2520of%2520human%2520microsomal%2520epoxide%2520hydrolase%2520genetic%2520variants%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2004%26volume%3D150%26spage%3D149%26epage%3D159%26doi%3D10.1016%2Fj.cbi.2004.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verbrugge, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assaraf, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niewerth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Meerloo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cloos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Veer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffer, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderl, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zweegman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dijkmans, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lems, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheper, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Gruijl, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, G.</span></span> <span> </span><span class="NLM_article-title">Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors</span>. <i>Exp. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1186/2162-3619-2-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1186%2F2162-3619-2-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=23305345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivFGktLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=2-13&author=S.+E.+Verbruggeauthor=M.+Alauthor=Y.+G.+Assarafauthor=D.+Niewerthauthor=J.+van+Meerlooauthor=J.+Cloosauthor=M.+van+der+Veerauthor=G.+L.+Schefferauthor=G.+J.+Petersauthor=E.+T.+Chanauthor=J.+L.+Anderlauthor=C.+J.+Kirkauthor=S.+Zweegmanauthor=B.+A.+Dijkmansauthor=W.+F.+Lemsauthor=R.+J.+Scheperauthor=T.+D.+de+Gruijlauthor=G.+Jansen&title=Overcoming+bortezomib+resistance+in+human+B+cells+by+anti-CD20%2Frituximab-mediated+complement-dependent+cytotoxicity+and+epoxyketone-based+irreversible+proteasome+inhibitors&doi=10.1186%2F2162-3619-2-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors</span></div><div class="casAuthors">Verbrugge, Sue Ellen; Al, Marjon; Assaraf, Yehuda G.; Niewerth, Denise; van Meerloo, Johan; Cloos, Jacqueline; van der Veer, Michael; Scheffer, George L.; Peters, Godefridus J.; Chan, Elena T.; Andrerl, Janet L.; Kirk, Christopher J.; Zweegman, Sonja; Dijkmans, Ben A. C.; Lems, Willem F.; Scheper, Rik J.; de Gruijl, Tanja D.; Jansen, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Hematology & Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2</span>CODEN:
                <span class="NLM_cas:coden">EHOXAU</span>;
        ISSN:<span class="NLM_cas:issn">2162-3619</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: In clin. and exptl. settings, antibody-based anti-CD20/rituximab and small mol. proteasome inhibitor (PI) bortezomib (BTZ) treatment proved effective modalities for B cell depletion in lymphoproliferative disorders as well as autoimmune diseases.  However, the chronic nature of these diseases requires either prolonged or re-treatment, often with acquired resistance as a consequence.  Methods: Here we studied the mol. basis of acquired resistance to BTZ in JY human B lymphoblastic cells following prolonged exposure to this drug and examd. possibilities to overcome resistance by next generation PIs and anti-CD20/rituximab-mediated complement-dependent cytotoxicity (CDC).  Results: Characterization of BTZ-resistant JY/BTZ cells compared to parental JY/WT cells revealed the following features: (a) 10-12 fold resistance to BTZ assocd. with the acquisition of a mutation in the PSMB5 gene (encoding the constitutive β5 proteasome subunit) introducing an amino acid substitution (Met45Ile) in the BTZ-binding pocket, (b) a significant 2-4 fold increase in the mRNA and protein levels of the constitutive β5 proteasome subunit along with unaltered immunoproteasome expression, (c) full sensitivity to the irreversible epoxyketone-based PIs carfilzomib and (to a lesser extent) the immunoproteasome inhibitor ONX 0914.  Finally, in assocn. with impaired ubiquitination and attenuated breakdown of CD20, JY/BTZ cells harbored a net 3-fold increase in CD20 cell surface expression, which was functionally implicated in conferring a significantly increased anti-CD20/rituximab-mediated CDC.  Conclusions: These results demonstrate that acquired resistance to BTZ in B cells can be overcome by next generation PIs and by anti-CD20/rituximab-induced CDC, thereby paving the way for salvage therapy in BTZ-resistant disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9mBdftcNY5LVg90H21EOLACvtfcHk0liWQM4PeNpDQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivFGktLs%253D&md5=acf3434db935d0a06c6704aa21da4c21</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1186%2F2162-3619-2-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2162-3619-2-2%26sid%3Dliteratum%253Aachs%26aulast%3DVerbrugge%26aufirst%3DS.%2BE.%26aulast%3DAl%26aufirst%3DM.%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26aulast%3DNiewerth%26aufirst%3DD.%26aulast%3Dvan%2BMeerloo%26aufirst%3DJ.%26aulast%3DCloos%26aufirst%3DJ.%26aulast%3Dvan%2Bder%2BVeer%26aufirst%3DM.%26aulast%3DScheffer%26aufirst%3DG.%2BL.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26aulast%3DChan%26aufirst%3DE.%2BT.%26aulast%3DAnderl%26aufirst%3DJ.%2BL.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DZweegman%26aufirst%3DS.%26aulast%3DDijkmans%26aufirst%3DB.%2BA.%26aulast%3DLems%26aufirst%3DW.%2BF.%26aulast%3DScheper%26aufirst%3DR.%2BJ.%26aulast%3Dde%2BGruijl%26aufirst%3DT.%2BD.%26aulast%3DJansen%26aufirst%3DG.%26atitle%3DOvercoming%2520bortezomib%2520resistance%2520in%2520human%2520B%2520cells%2520by%2520anti-CD20%252Frituximab-mediated%2520complement-dependent%2520cytotoxicity%2520and%2520epoxyketone-based%2520irreversible%2520proteasome%2520inhibitors%26jtitle%3DExp.%2520Hematol.%2520Oncol.%26date%3D2013%26volume%3D2%26spage%3D2%26epage%3D13%26doi%3D10.1186%2F2162-3619-2-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verbrugge, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assaraf, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dijkmans, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffer, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Uyl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oerlemans, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Heijden, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Gruijl, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheper, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, G.</span></span> <span> </span><span class="NLM_article-title">Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">174</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.187542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1124%2Fjpet.111.187542" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=22235146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVagtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2012&pages=174-182&author=S.+E.+Verbruggeauthor=Y.+G.+Assarafauthor=B.+A.+Dijkmansauthor=G.+L.+Schefferauthor=M.+Alauthor=D.+den+Uylauthor=R.+Oerlemansauthor=E.+T.+Chanauthor=C.+J.+Kirkauthor=G.+J.+Petersauthor=J.+W.+van+der+Heijdenauthor=T.+D.+de+Gruijlauthor=R.+J.+Scheperauthor=G.+Jansen&title=Inactivating+PSMB5+mutations+and+P-glycoprotein+%28multidrug+resistance-associated+protein%2FATP-binding+cassette+B1%29+mediate+resistance+to+proteasome+inhibitors%3A+ex+vivo+efficacy+of+%28immuno%29proteasome+inhibitors+in+mononuclear+blood+cells+from+patients+with+rheumatoid+arthritis&doi=10.1124%2Fjpet.111.187542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis</span></div><div class="casAuthors">Verbrugge, Sue Ellen; Assaraf, Yehuda G.; Dijkmans, Ben A. C.; Scheffer, George L.; Al, Marjon; den Uyl, Debby; Oerlemans, Ruud; Chan, Elena T.; Kirk, Christopher J.; Peters, Godefridus J.; van der Heijden, Joost W.; de Gruijl, Tanja D.; Scheper, Rik J.; Jansen, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">174-182</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bortezomib (BTZ), a registered proteasome inhibitor (PI) for multiple myeloma, has also been proposed as a potential antirheumatic agent.  Its reported side effects, however, make it unappealing for long-term administration, and resistance may also develop.  To overcome this, second-generation PIs became available.  Here, we investigated whether a novel class of peptide epoxyketone-based PIs, including carfilzomib, N-((S)-3-methoxy-1-(((S)-3-methoxy-1-(((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)-2-methylthiazole-5-carboxamide (ONX0912), and (S)-3-(4-methoxyphenyl)-N-((S)-1-((S)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide (ONX0914), might escape two established BTZ-resistance mechanisms: (1) mutations in the proteasome β5 subunit (PSMB5) targeted by these PIs, and (2) drug efflux mediated by ATP-binding cassette transporters.  THP1 myeloid sublines with acquired resistance to BTZ (54- to 235-fold) caused by mutations in the PSMB5 gene displayed marked cross-resistance but less pronounced cross-resistance to carfilzomib (9- to 32-fold), ONX0912 (39- to 62-fold), and ONX0914 (27- to 97-fold).  As for ATP-binding cassette transporter-mediated efflux, lymphoid CEM/VLB cells with P-glycoprotein (Pgp)/multidrug resistance 1 overexpression exhibited substantial resistance to carfilzomib (114-fold), ONX0912 (23-fold), and ONX0914 (162-fold), whereas less resistance to BTZ (4.5-fold) was obsd.  Consistently, β5 subunit-assocd. chymotrypsin-like proteasome activity was significantly less inhibited in these CEM/VLB cells.  Ex vivo anal. of peripheral blood mononuclear cells from therapy-naive patients with rheumatoid arthritis revealed that, although basal Pgp levels were low, P-glycoprotein expression compromised the inhibitory effect of carfilzomib and ONX0914.  However, the use of P121 (reversin 121), a Pgp transport inhibitor, restored parental cell inhibitory levels in both CEM/VLB cells and peripheral blood mononuclear cells.  These results indicate that the pharmacol. activity of these PIs may be hindered by drug resistance mechanisms involving PSMBS mutations and PI extrusion via Pgp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLjyDKKBsD_7Vg90H21EOLACvtfcHk0liWQM4PeNpDQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVagtr8%253D&md5=5b87626879dfdca4f1003e35833af2e0</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.187542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.187542%26sid%3Dliteratum%253Aachs%26aulast%3DVerbrugge%26aufirst%3DS.%2BE.%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26aulast%3DDijkmans%26aufirst%3DB.%2BA.%26aulast%3DScheffer%26aufirst%3DG.%2BL.%26aulast%3DAl%26aufirst%3DM.%26aulast%3Dden%2BUyl%26aufirst%3DD.%26aulast%3DOerlemans%26aufirst%3DR.%26aulast%3DChan%26aufirst%3DE.%2BT.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26aulast%3Dvan%2Bder%2BHeijden%26aufirst%3DJ.%2BW.%26aulast%3Dde%2BGruijl%26aufirst%3DT.%2BD.%26aulast%3DScheper%26aufirst%3DR.%2BJ.%26aulast%3DJansen%26aufirst%3DG.%26atitle%3DInactivating%2520PSMB5%2520mutations%2520and%2520P-glycoprotein%2520%2528multidrug%2520resistance-associated%2520protein%252FATP-binding%2520cassette%2520B1%2529%2520mediate%2520resistance%2520to%2520proteasome%2520inhibitors%253A%2520ex%2520vivo%2520efficacy%2520of%2520%2528immuno%2529proteasome%2520inhibitors%2520in%2520mononuclear%2520blood%2520cells%2520from%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D174%26epage%3D182%26doi%3D10.1124%2Fjpet.111.187542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung-Hagesteijn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdmann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reece, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiedemann, R. E.</span></span> <span> </span><span class="NLM_article-title">Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">304</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2013.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2Fj.ccr.2013.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=24029229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVahsb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=289-304&author=C.+Leung-Hagesteijnauthor=N.+Erdmannauthor=G.+Cheungauthor=J.+J.+Keatsauthor=A.+K.+Stewartauthor=D.+E.+Reeceauthor=K.+C.+Chungauthor=R.+E.+Tiedemann&title=Xbp1s-negative+tumor+B+cells+and+pre-plasmablasts+mediate+therapeutic+proteasome+inhibitor+resistance+in+multiple+myeloma&doi=10.1016%2Fj.ccr.2013.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma</span></div><div class="casAuthors">Leung-Hagesteijn, Chungyee; Erdmann, Natalie; Cheung, Grace; Keats, Jonathan J.; Stewart, A. Keith; Reece, Donna E.; Chung, Kim Chan; Tiedemann, Rodger E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">289-304</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Proteasome inhibitor (PI) resistance mechanisms in multiple myeloma (MM) remain controversial.  We report the existence of a progenitor organization in primary MM that recapitulates maturation stages between B cells and plasma cells and that contributes to clin. PI resistance.  Xbp1s- tumor B cells and pre-plasmablasts survive therapeutic PI, preventing cure, while maturation arrest of MM before the plasmablast stage enables progressive disease on PI treatment.  Mechanistically, suppression of Xbp1s in MM is shown to induce bortezomib resistance via de-commitment to plasma cell maturation and Ig prodn., diminishing endoplasmic reticulum (ER) front-loading and cytotoxic susceptibility to PI-induced inhibition of ER-assocd. degrdn.  These results reveal the tumor progenitor structure in MM and highlight its role in therapeutic failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_GJzGqektqrVg90H21EOLACvtfcHk0lggoo8NFkM-MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVahsb%252FK&md5=8a493f4178b5a53a257e991b3d02e742</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2013.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2013.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DLeung-Hagesteijn%26aufirst%3DC.%26aulast%3DErdmann%26aufirst%3DN.%26aulast%3DCheung%26aufirst%3DG.%26aulast%3DKeats%26aufirst%3DJ.%2BJ.%26aulast%3DStewart%26aufirst%3DA.%2BK.%26aulast%3DReece%26aufirst%3DD.%2BE.%26aulast%3DChung%26aufirst%3DK.%2BC.%26aulast%3DTiedemann%26aufirst%3DR.%2BE.%26atitle%3DXbp1s-negative%2520tumor%2520B%2520cells%2520and%2520pre-plasmablasts%2520mediate%2520therapeutic%2520proteasome%2520inhibitor%2520resistance%2520in%2520multiple%2520myeloma%26jtitle%3DCancer%2520Cell%26date%3D2013%26volume%3D24%26spage%3D289%26epage%3D304%26doi%3D10.1016%2Fj.ccr.2013.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niewerth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assaraf, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zweegman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaspers, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cloos, J.</span></span> <span> </span><span class="NLM_article-title">Molecular basis of resistance to proteasome inhibitors in hematological malignancies</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">18</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1016/j.drup.2014.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2Fj.drup.2014.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=25670156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A280%3ADC%252BC2MrksFOrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2015&pages=18-35&author=D.+Niewerthauthor=G.+Jansenauthor=Y.+G.+Assarafauthor=S.+Zweegmanauthor=G.+J.+Kaspersauthor=J.+Cloos&title=Molecular+basis+of+resistance+to+proteasome+inhibitors+in+hematological+malignancies&doi=10.1016%2Fj.drup.2014.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis of resistance to proteasome inhibitors in hematological malignancies</span></div><div class="casAuthors">Niewerth Denise; Kaspers Gertjan J L; Jansen Gerrit; Assaraf Yehuda G; Zweegman Sonja; Cloos Jacqueline</div><div class="citationInfo"><span class="NLM_cas:title">Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18-35</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Over the past decade, the proteasome inhibitor bortezomib (Velcade) has not only gained a cornerstone position in the treatment of hematological malignancies, particularly multiple myeloma and mantle cell lymphoma, but also in experimental therapeutics of acute leukemia.  However, the therapeutic efficacy of bortezomib is hampered by the emergence of acquired resistance, for which multifactorial mechanisms have been identified.  This review summarizes the current status of the molecular mechanisms underlying resistance to proteasome inhibitors that emerged in preclinical therapeutic studies, and discusses these findings in the clinical perspective of novel therapeutic modalities of hematological malignancies.  The specific topics that will be addressed in the current review include the recently established mechanisms of resistance to proteasome inhibitors: the role of constitutive and immunoproteasomes, mutations in proteasome subunits, unfolded protein response, XBP1 and MARCKS proteins, multidrug efflux transporters, aggresomes and autophagy, as well as the impact of pro-survival signaling pathways and bone marrow microenvironment.  The growing knowledge of the determinants that confer bortezomib resistance and/or toxicity has provided the basis for the rational development of second generation proteasome inhibitors, some of which were recently approved or that are undergoing clinical evaluation as novel strategies to overcome bortezomib resistance as well as to enhance clinical therapeutic efficacy along with minimal side effects.  Collectively, these combined approaches should enhance therapeutic efficacy and outcome in patients with hematological malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsj6vKDkCfumyYR5VtavbzfW6udTcc2eaYJWFKOX1WGrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MrksFOrsA%253D%253D&md5=f015e1bdf6c2b1ac7247beac331c02eb</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2014.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2014.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DNiewerth%26aufirst%3DD.%26aulast%3DJansen%26aufirst%3DG.%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26aulast%3DZweegman%26aufirst%3DS.%26aulast%3DKaspers%26aufirst%3DG.%2BJ.%26aulast%3DCloos%26aufirst%3DJ.%26atitle%3DMolecular%2520basis%2520of%2520resistance%2520to%2520proteasome%2520inhibitors%2520in%2520hematological%2520malignancies%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2015%26volume%3D18%26spage%3D18%26epage%3D35%26doi%3D10.1016%2Fj.drup.2014.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunsucker, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voorhees, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, R. Z.</span></span> <span> </span><span class="NLM_article-title">Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">4667</span>– <span class="NLM_lpage">4676</span>, <span class="refDoi"> DOI: 10.1182/blood-2008-07-171637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1182%2Fblood-2008-07-171637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=19050304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvVyqurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=4667-4676&author=D.+J.+Kuhnauthor=S.+A.+Hunsuckerauthor=Q.+Chenauthor=P.+M.+Voorheesauthor=M.+Orlowskiauthor=R.+Z.+Orlowski&title=Targeted+inhibition+of+the+immunoproteasome+is+a+potent+strategy+against+models+of+multiple+myeloma+that+overcomes+resistance+to+conventional+drugs+and+nonspecific+proteasome+inhibitors&doi=10.1182%2Fblood-2008-07-171637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors</span></div><div class="casAuthors">Kuhn, Deborah J.; Hunsucker, Sally A.; Chen, Qing; Voorhees, Peter M.; Orlowski, Marian; Orlowski, Robert Z.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4667-4676</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Proteasome inhibition is a validated strategy for therapy of multiple myeloma, but this disease remains challenging as relapses are common, and often assocd. with increasing chemoresistance.  Moreover, nonspecific proteasome inhibitors such as bortezomib can induce peripheral neuropathy and other toxicities that may compromise the ability to deliver therapy at full doses, thereby decreasing efficacy.  One novel approach may be to target the immunoproteasome, a proteasomal variant found predominantly in cells of hematopoietic origin that differs from the constitutive proteasome found in most other cell types.  Using purified prepns. of constitutive and immunoproteasomes, we screened a rationally designed series of peptidyl-aldehydes and identified several with relative specificity for the immunoproteasome.  The most potent immunoproteasome-specific inhibitor, IPSI-001, preferentially targeted the β1i subunit of the immunoproteasome in vitro and in cellulo in a dose-dependent manner.  This agent induced accumulation of ubiquitin-protein conjugates, proapoptotic proteins, and activated caspase-mediated apoptosis.  IPSI-001 potently inhibited proliferation in myeloma patient samples and other hematol. malignancies.  Importantly, IPSI-001 was able to overcome conventional and novel drug resistance, including resistance to bortezomib.  These findings provide a rationale for the translation of IPSIs to the clinic, where they may provide antimyeloma activity with greater specificity and less toxicity than current inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyFUysXTzcsrVg90H21EOLACvtfcHk0ljL2zkpRV51qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvVyqurk%253D&md5=6753f40ae6057eeadbbde2f6650828fc</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-07-171637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-07-171637%26sid%3Dliteratum%253Aachs%26aulast%3DKuhn%26aufirst%3DD.%2BJ.%26aulast%3DHunsucker%26aufirst%3DS.%2BA.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DVoorhees%26aufirst%3DP.%2BM.%26aulast%3DOrlowski%26aufirst%3DM.%26aulast%3DOrlowski%26aufirst%3DR.%2BZ.%26atitle%3DTargeted%2520inhibition%2520of%2520the%2520immunoproteasome%2520is%2520a%2520potent%2520strategy%2520against%2520models%2520of%2520multiple%2520myeloma%2520that%2520overcomes%2520resistance%2520to%2520conventional%2520drugs%2520and%2520nonspecific%2520proteasome%2520inhibitors%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D4667%26epage%3D4676%26doi%3D10.1182%2Fblood-2008-07-171637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruckrich, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kammer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovaa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessen, C.</span></span> <span> </span><span class="NLM_article-title">Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1038/sj.leu.2404414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1038%2Fsj.leu.2404414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=17024115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlSqurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=84-92&author=M.+Krausauthor=T.+Ruckrichauthor=M.+Reichauthor=J.+Gogelauthor=A.+Beckauthor=W.+Kammerauthor=C.+R.+Berkersauthor=D.+Burgauthor=H.+Overkleeftauthor=H.+Ovaaauthor=C.+Driessen&title=Activity+patterns+of+proteasome+subunits+reflect+bortezomib+sensitivity+of+hematologic+malignancies+and+are+variable+in+primary+human+leukemia+cells&doi=10.1038%2Fsj.leu.2404414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells</span></div><div class="casAuthors">Kraus, M.; Rueckrich, T.; Reich, M.; Gogel, J.; Beck, A.; Kammer, W.; Berkers, C. R.; Burg, D.; Overkleeft, H.; Ovaa, H.; Driessen, C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-92</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Proteasomal proteolysis relies on the activity of six catalytically active proteasomal subunits (β1, β2, β5, β1i, β2i and β5i).  Applying a functional proteomics approach, we used a recently developed activity-based, cell-permeable proteasome-specific probe that for the first time allows differential visualization of individual active proteasomal subunits in intact primary cells.  In primary leukemia samples, we obsd. remarkable variability in the amts. of active β1/1i-, β2/2i- and β5/5i-type of subunits, contrasting with their const. protein expression.  Bortezomib inhibited β5- and β1-type, but to a lesser extend β2-type of subunits in live primary cells in vitro and in vivo.  When we adapted the bortezomib-sensitive human acute myeloid leukemia cell line HL-60 to bortezomib 40 nM (HL-60a), proteasomal activity profiling revealed an upregulation of active subunits, and residual β1/β5-type of activity could be visualized in the presence of bortezomib 20 nM, in contrast to control cells.  In a panel of cell lines from hematol. malignancies, the ratio between β2-type and (β1+β5)-type of active proteasomal polypeptides mirrored different degrees of bortezomib sensitivity.  We thus conclude that the proteasomal activity profile varies in primary leukemia cells, and that the pattern of proteasomal subunit activity influences the sensitivity of hematol. malignancies toward bortezomib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhSfjpxWwrmrVg90H21EOLACvtfcHk0ljL2zkpRV51qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlSqurzL&md5=a7e3c1e5930d38f7359836967ee8c066</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2404414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2404414%26sid%3Dliteratum%253Aachs%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DRuckrich%26aufirst%3DT.%26aulast%3DReich%26aufirst%3DM.%26aulast%3DGogel%26aufirst%3DJ.%26aulast%3DBeck%26aufirst%3DA.%26aulast%3DKammer%26aufirst%3DW.%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3DBurg%26aufirst%3DD.%26aulast%3DOverkleeft%26aufirst%3DH.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DDriessen%26aufirst%3DC.%26atitle%3DActivity%2520patterns%2520of%2520proteasome%2520subunits%2520reflect%2520bortezomib%2520sensitivity%2520of%2520hematologic%2520malignancies%2520and%2520are%2520variable%2520in%2520primary%2520human%2520leukemia%2520cells%26jtitle%3DLeukemia%26date%3D2007%26volume%3D21%26spage%3D84%26epage%3D92%26doi%3D10.1038%2Fsj.leu.2404414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geurink, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weyburne, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirabella, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silzle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shabaneh, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Linden, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bruin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haile, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Rooden, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appenzeller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisselev, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessen, C.</span></span> <span> </span><span class="NLM_article-title">The novel beta2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">1350</span>– <span class="NLM_lpage">1360</span>, <span class="refDoi"> DOI: 10.3324/haematol.2014.109421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.3324%2Fhaematol.2014.109421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=26069288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVKitrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2015&pages=1350-1360&author=M.+Krausauthor=J.+Baderauthor=P.+P.+Geurinkauthor=E.+S.+Weyburneauthor=A.+C.+Mirabellaauthor=T.+Silzleauthor=T.+B.+Shabanehauthor=W.+A.+van+der+Lindenauthor=G.+de+Bruinauthor=S.+R.+Haileauthor=E.+van+Roodenauthor=C.+Appenzellerauthor=N.+Liauthor=A.+F.+Kisselevauthor=H.+Overkleeftauthor=C.+Driessen&title=The+novel+beta2-selective+proteasome+inhibitor+LU-102+synergizes+with+bortezomib+and+carfilzomib+to+overcome+proteasome+inhibitor+resistance+of+myeloma+cells&doi=10.3324%2Fhaematol.2014.109421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells</span></div><div class="casAuthors">Kraus, Marianne; Bader, Juergen; Geurink, Paul P.; Weyburne, Emily S.; Mirabella, Anne C.; Silzle, Tobias; Shabaneh, Tamer B.; van der Linden, Wouter A.; de Bruin, Gerjan; Haile, Sarah R.; van Rooden, Eva; Appenzeller, Christina; Li, Nan; Kisselev, Alexei F.; Overkleeft, Herman; Driessen, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1350-1360</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">1592-8721</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">Proteasome inhibitor resistance is a challenge for myeloma therapy.  Bortezomib targets the β5 and β1 activity, but not the β2 activity of the proteasome.  Bortezomib-resistant myeloma cells down-regulate the activation status of the unfolded protein response, and up-regulate β2 proteasome activity.  To improve proteasome inhibition in bortezomib-resistant myeloma and to achieve more efficient UPR activation, we have developed LU-102, a selective inhibitor of the β2 proteasome activity.  LU-102 inhibited the β2 activity in intact myeloma cells at low micromolar concns. without relevant co-inhibition of β1 and β5 proteasome subunits.  In protea-some inhibitor-resistant myeloma cells, significantly more potent proteasome inhibition was achieved by bortezomib or carfilzomib in combination with LU-102, compared to bortezomib/carfilzomib alone, resulting in highly synergistic cytotoxic activity of the drug combination via endoplasmatic reticulum stress-induced apoptosis.  Combining bortezomib/carfilzomib with LU-102 significantly prolonged proteasome inhibition and increased activation of the unfolded protein response and IRE1-α activity.  IRE1-α has recently been shown to control myeloma cell differentiation and bortezomib sensitivity (Leung-Hagesteijn, Cancer Cell 24:3, 289-304).  Thus, β2-selective proteasome inhibition by LU-102 in combination with bortezomib or carfilzomib re-sults in synergistic proteasome inhibition, activation of the unfolded protein response, and cytotoxicity, and overcomes bortezomib/carfilzomib resistance in myeloma cells in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhWaSEQ0aXHbVg90H21EOLACvtfcHk0ljL2zkpRV51qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVKitrjE&md5=7895da9ac823a56178903ca149c8d39f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2014.109421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2014.109421%26sid%3Dliteratum%253Aachs%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DBader%26aufirst%3DJ.%26aulast%3DGeurink%26aufirst%3DP.%2BP.%26aulast%3DWeyburne%26aufirst%3DE.%2BS.%26aulast%3DMirabella%26aufirst%3DA.%2BC.%26aulast%3DSilzle%26aufirst%3DT.%26aulast%3DShabaneh%26aufirst%3DT.%2BB.%26aulast%3Dvan%2Bder%2BLinden%26aufirst%3DW.%2BA.%26aulast%3Dde%2BBruin%26aufirst%3DG.%26aulast%3DHaile%26aufirst%3DS.%2BR.%26aulast%3Dvan%2BRooden%26aufirst%3DE.%26aulast%3DAppenzeller%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DKisselev%26aufirst%3DA.%2BF.%26aulast%3DOverkleeft%26aufirst%3DH.%26aulast%3DDriessen%26aufirst%3DC.%26atitle%3DThe%2520novel%2520beta2-selective%2520proteasome%2520inhibitor%2520LU-102%2520synergizes%2520with%2520bortezomib%2520and%2520carfilzomib%2520to%2520overcome%2520proteasome%2520inhibitor%2520resistance%2520of%2520myeloma%2520cells%26jtitle%3DHaematologica%26date%3D2015%26volume%3D100%26spage%3D1350%26epage%3D1360%26doi%3D10.3324%2Fhaematol.2014.109421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprangers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franke, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbrugge, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adomat, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Religa, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cloos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guns, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batey, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A. D.</span></span> <span> </span><span class="NLM_article-title">Effect of noncompetitive proteasome inhibition on bortezomib resistance</span>. <i>J. Natl. Cancer Inst</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">1069</span>– <span class="NLM_lpage">1082</span>, <span class="refDoi"> DOI: 10.1093/jnci/djq198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1093%2Fjnci%2Fdjq198" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=20505154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlWmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2010&pages=1069-1082&author=X.+Liauthor=T.+E.+Woodauthor=R.+Sprangersauthor=G.+Jansenauthor=N.+E.+Frankeauthor=X.+Maoauthor=X.+Wangauthor=Y.+Zhangauthor=S.+E.+Verbruggeauthor=H.+Adomatauthor=Z.+H.+Liauthor=S.+Trudelauthor=C.+Chenauthor=T.+L.+Religaauthor=N.+Jamalauthor=H.+Messnerauthor=J.+Cloosauthor=D.+R.+Roseauthor=A.+Navonauthor=E.+Gunsauthor=R.+A.+Bateyauthor=L.+E.+Kayauthor=A.+D.+Schimmer&title=Effect+of+noncompetitive+proteasome+inhibition+on+bortezomib+resistance&doi=10.1093%2Fjnci%2Fdjq198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Noncompetitive Proteasome Inhibition on Bortezomib Resistance</span></div><div class="casAuthors">Li, Xiaoming; Wood, Tabitha E.; Sprangers, Remco; Jansen, Gerrit; Franke, Niels E.; Mao, Xinliang; Wang, Xiaoming; Zhang, Yi; Verbrugge, Sue Ellen; Adomat, Hans; Li, Zhi Hua; Trudel, Suzanne; Chen, Christine; Religa, Tomasz L.; Jamal, Nazir; Messner, Hans; Cloos, Jacqueline; Rose, David R.; Navon, Ami; Guns, Emma; Batey, Robert A.; Kay, Lewis E.; Schimmer, Aaron D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1069-1082</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: Bortezomib and the other proteasome inhibitors that are currently under clin. investigation bind to the catalytic sites of proteasomes and are competitive inhibitors.  We hypothesized that proteasome inhibitors that act through a noncompetitive mechanism might overcome some forms of bortezomib resistance.  Methods: 5-amino-8-hydroxyquinoline (5AHQ) was identified through a screen of a 27-compd. chem. library based on the quinoline pharmacophore to identify proteasome inhibitors.  Inhibition of proteasome activity by 5AHQ was tested by measuring 7-amino-4-methylcoumarin (AMC) release from the proteasome substrate Suc-LLVY-AMC in intact human and mouse leukemia and myeloma cells and in tumor cell protein exts.  Cytotoxicity was assessed in 5AHQ-treated cell lines and primary cells from myeloma and leukemia patients using AlamarBlue fluorescence and MTS assays, trypan blue staining, and annexin V staining. 5AHQ-proteasome interaction was assessed by NMR. 5AHQ efficacy was evaluated in three leukemia xenograft mouse models (9-10 mice per group per model).  All statistical tests were two-sided.  Results 5AHQ inhibited the proteasome when added to cell exts. and intact cells (the mean concn. inhibiting 50% [IC50] of AMC release in intact cells ranged from 0.57 to 5.03 μM), induced cell death in intact cells from leukemia and myeloma cell lines (mean IC50 values for cell growth ranged from 0.94 to 3.85 μM), and preferentially induced cell death in primary myeloma and leukemia cells compared with normal hematopoietic cells.  5AHQ was equally cytotoxic to human myelomonocytic THP1 cells and to THP1/BTZ500 cells, which are 237-fold more resistant to bortezomib than wild-type THP1 cells because of their overexpression and mutation of the bortezomib-binding β5 proteasome subunit (mean IC50 for cell death in the absence of bortezomib, wild-type THP1: 3.7 μM, 95% confidence interval = 3.4 to 4.0 μM; THP1/BTZ500: 6.6 μM, 95% confidence interval = 5.9 to 7.5 μM).  5AHQ interacted with the α subunits of the 20S proteasome at noncatalytic sites.  Orally administered 5AHQ inhibited tumor growth in all three mouse models of leukemia without overt toxicity (eg, OCI-AML2 model, median tumor wt. [interquartile range], 5AHQ vs control: 95.7 mg [61.4-163.5 mg] vs 247.2 mg [189.4-296.2 mg], P = .002).  Conclusions: 5AHQ is a noncompetitive proteasome inhibitor that is cytotoxic to myeloma and leukemia cells in vitro and inhibits xenograft tumor growth in vivo. 5AHQ can overcome some forms of bortezomib resistance in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW4TcOS6iYs7Vg90H21EOLACvtfcHk0lgOLtlPN13Z2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlWmsbs%253D&md5=45a19957639165d2673f2dc72a0387a4</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjq198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjq198%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWood%26aufirst%3DT.%2BE.%26aulast%3DSprangers%26aufirst%3DR.%26aulast%3DJansen%26aufirst%3DG.%26aulast%3DFranke%26aufirst%3DN.%2BE.%26aulast%3DMao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DVerbrugge%26aufirst%3DS.%2BE.%26aulast%3DAdomat%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DZ.%2BH.%26aulast%3DTrudel%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DReliga%26aufirst%3DT.%2BL.%26aulast%3DJamal%26aufirst%3DN.%26aulast%3DMessner%26aufirst%3DH.%26aulast%3DCloos%26aufirst%3DJ.%26aulast%3DRose%26aufirst%3DD.%2BR.%26aulast%3DNavon%26aufirst%3DA.%26aulast%3DGuns%26aufirst%3DE.%26aulast%3DBatey%26aufirst%3DR.%2BA.%26aulast%3DKay%26aufirst%3DL.%2BE.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26atitle%3DEffect%2520of%2520noncompetitive%2520proteasome%2520inhibition%2520on%2520bortezomib%2520resistance%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst%26date%3D2010%26volume%3D102%26spage%3D1069%26epage%3D1082%26doi%3D10.1093%2Fjnci%2Fdjq198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schrader, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henneberg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mata, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tittmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourenkov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, A.</span></span> <span> </span><span class="NLM_article-title">The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">594</span>– <span class="NLM_lpage">598</span>, <span class="refDoi"> DOI: 10.1126/science.aaf8993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1126%2Fscience.aaf8993" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=27493187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Oks7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2016&pages=594-598&author=J.+Schraderauthor=F.+Hennebergauthor=R.+A.+Mataauthor=K.+Tittmannauthor=T.+R.+Schneiderauthor=H.+Starkauthor=G.+Bourenkovauthor=A.+Chari&title=The+inhibition+mechanism+of+human+20S+proteasomes+enables+next-generation+inhibitor+design&doi=10.1126%2Fscience.aaf8993"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design</span></div><div class="casAuthors">Schrader, Jil; Henneberg, Fabian; Mata, Ricardo A.; Tittmann, Kai; Schneider, Thomas R.; Stark, Holger; Bourenkov, Gleb; Chari, Ashwin</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">6299</span>),
    <span class="NLM_cas:pages">594-598</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The proteasome is a validated target for anticancer therapy, and proteasome inhibition is employed in the clinic for the treatment of tumors and hematol. malignancies.  Here, the authors describe crystal structures of the native human 20S proteasome and its complexes with inhibitors, which either are drugs approved for cancer treatment or are in clin. trials.  The structure of the native human 20S proteasome was detd. at an unprecedented resoln. of 1.8 angstroms.  Addnl., six inhibitor-proteasome complex structures were elucidated at resolns. between 1.9 and 2.1 angstroms.  Collectively, the high-resoln. structures provide new insights into the catalytic mechanisms of inhibition and necessitate a revised description of the proteasome active site.  Knowledge about inhibition mechanisms provides insights into peptide hydrolysis and can guide strategies for the development of next-generation proteasome-based cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZCuIDBbOXPLVg90H21EOLACvtfcHk0lgOLtlPN13Z2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Oks7vL&md5=8216d0007cbf06c352e06fcb05d644a9</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1126%2Fscience.aaf8993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aaf8993%26sid%3Dliteratum%253Aachs%26aulast%3DSchrader%26aufirst%3DJ.%26aulast%3DHenneberg%26aufirst%3DF.%26aulast%3DMata%26aufirst%3DR.%2BA.%26aulast%3DTittmann%26aufirst%3DK.%26aulast%3DSchneider%26aufirst%3DT.%2BR.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DBourenkov%26aufirst%3DG.%26aulast%3DChari%26aufirst%3DA.%26atitle%3DThe%2520inhibition%2520mechanism%2520of%2520human%252020S%2520proteasomes%2520enables%2520next-generation%2520inhibitor%2520design%26jtitle%3DScience%26date%3D2016%26volume%3D353%26spage%3D594%26epage%3D598%26doi%3D10.1126%2Fscience.aaf8993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mushtaq, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoor, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latif, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iftikhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahid, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riaz, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anwer, F.</span></span> <span> </span><span class="NLM_article-title">Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: a systematic review</span>. <i>Crit Rev. Oncol Hematol</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2018.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2Fj.critrevonc.2018.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=29650268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A280%3ADC%252BC1MjitF2gsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2018&pages=1-11&author=A.+Mushtaqauthor=V.+Kapoorauthor=A.+Latifauthor=A.+Iftikharauthor=U.+Zahidauthor=A.+McBrideauthor=I.+Abrahamauthor=I.+B.+Riazauthor=F.+Anwer&title=Efficacy+and+toxicity+profile+of+carfilzomib+based+regimens+for+treatment+of+multiple+myeloma%3A+a+systematic+review&doi=10.1016%2Fj.critrevonc.2018.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review</span></div><div class="casAuthors">Mushtaq Adeela; Kapoor Vikas; Latif Azka; Iftikhar Ahmad; Zahid Umar; McBride Ali; Abraham Ivo; Riaz Irbaz Bin; Anwer Faiz</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-11</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Standard induction therapy for multiple myeloma is three-drug combination based on following classes of drugs: proteasome inhibitors, immunomodulators and steroids.  Despite its notable efficacy, bortezomib has side effects like peripheral neuropathy (PNP) with reported incidence of grade ≥3 PNP between 2%-23% Schlafer et al., 2017.  Carfilzomib (CFZ) has high selectivity and minimal off-target adverse effects including lower rates of PNP.  CFZ is already approved for treatment of relapsed and refractory multiple myeloma (RRMM) as single agent as well as in combination with lenalidomide and/or dexamethasone.  Extensive literature search identified a total of 1839 articles.  Twenty-six articles (n = 5980) met the inclusion criteria, 15 in newly diagnosed multiple myeloma (NDMM) and 11 in RRMM group.  CFZ demonstrates comparable or even better efficacy to bortezomib with much favorable AE profile.  Deep, rapid and sustainable response using KRd with safer toxicity profile supports extension of KRd therapy to frontline therapy for all risk categories of MM.  High incidence of grade ≥3 HTN underscores the importance of serial BP monitoring.  In RRMM, CFZ has documented efficacy with standard 20-27mg/m2 dose.  Further large-scale trials are needed to study benefit-to-risk profile of 20-56 and 20-70 mg/m2 dose of CFZ vs standard 20-27 mg/m2 dose in NDMM and RRMM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTszHATWKJXIBJ5E29YNGvQfW6udTcc2eZUNdmzjqTdX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjitF2gsQ%253D%253D&md5=d39efa7e5c297ac2876197ad300370f3</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2018.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2018.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DMushtaq%26aufirst%3DA.%26aulast%3DKapoor%26aufirst%3DV.%26aulast%3DLatif%26aufirst%3DA.%26aulast%3DIftikhar%26aufirst%3DA.%26aulast%3DZahid%26aufirst%3DU.%26aulast%3DMcBride%26aufirst%3DA.%26aulast%3DAbraham%26aufirst%3DI.%26aulast%3DRiaz%26aufirst%3DI.%2BB.%26aulast%3DAnwer%26aufirst%3DF.%26atitle%3DEfficacy%2520and%2520toxicity%2520profile%2520of%2520carfilzomib%2520based%2520regimens%2520for%2520treatment%2520of%2520multiple%2520myeloma%253A%2520a%2520systematic%2520review%26jtitle%3DCrit%2520Rev.%2520Oncol%2520Hematol%26date%3D2018%26volume%3D125%26spage%3D1%26epage%3D11%26doi%3D10.1016%2Fj.critrevonc.2018.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Federspiel, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codreanu, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albertolle, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teague, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guengerich, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liebler, D. C.</span></span> <span> </span><span class="NLM_article-title">Specificity of protein covalent modification by the electrophilic proteasome inhibitor carfilzomib in human cells</span>. <i>Mol. Cell. Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3233</span>– <span class="NLM_lpage">3242</span>, <span class="refDoi"> DOI: 10.1074/mcp.M116.059709</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1074%2Fmcp.M116.059709" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=27503896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFCnsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=3233-3242&author=J.+D.+Federspielauthor=S.+G.+Codreanuauthor=S.+Goyalauthor=M.+E.+Albertolleauthor=E.+Loweauthor=J.+Teagueauthor=H.+Wongauthor=F.+P.+Guengerichauthor=D.+C.+Liebler&title=Specificity+of+protein+covalent+modification+by+the+electrophilic+proteasome+inhibitor+carfilzomib+in+human+cells&doi=10.1074%2Fmcp.M116.059709"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Specificity of protein covalent modification by the electrophilic proteasome inhibitor carfilzomib in human cells</span></div><div class="casAuthors">Federspiel, Joel D.; Codreanu, Simona G.; Goyal, Sandeep; Albertolle, Matthew E.; Lowe, Eric; Teague, Juli; Wong, Hansen; Guengerich, F. Peter; Liebler, Daniel C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular & Cellular Proteomics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3233-3242</span>CODEN:
                <span class="NLM_cas:coden">MCPOBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-9484</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Carfilzomib (CFZ) is a second-generation proteasome inhibitor that is Food and Drug Administration and European Commission approved for the treatment of relapsed or refractory multiple myeloma.  CFZ is an epoxomicin deriv. with an epoxyketone electrophilic warhead that irreversibly adducts the catalytic threonine residue of the β5 subunit of the proteasome.  Although CFZ produces a highly potent, sustained inactivation of the proteasome, the electrophilic nature of the drug could potentially produce off-target protein adduction.  To address this possibility, we synthesized an alkynyl analog of CFZ and investigated protein adduction by this analog in HepG2 cells.  Using click chem. coupled with streptavidin based IP and shotgun tandem mass spectrometry (MS/MS), we identified two off-target proteins, cytochrome P 450 27A1 (CYP27A1) and glutathione S-transferase omega 1 (GSTO1), as targets of the alkynyl CFZ probe.  We confirmed the adduction of CYP27A1 and GSTO1 by streptavidin capture and immunoblotting methodol. and then site-specifically mapped the adducts with targeted MS/MS methods.  Although CFZ adduction of CYP27A1 and GSTO1 in vitro decreased the activities of these enzymes, the small fraction of these proteins modified by CFZ in intact cells should limit the impact of these offtarget modifications.  The data support the high selectivity of CFZ for covalent modification of its therapeutic targets, despite the presence of a reactive electrophile.  The approach we describe offers a generalizable method to evaluate the safety profile of covalent protein-modifying therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1MWDdlf62B7Vg90H21EOLACvtfcHk0lgqehb-VqYNRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFCnsLs%253D&md5=ff2d31854362ad6b6c7f8ea2129acdc8</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1074%2Fmcp.M116.059709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fmcp.M116.059709%26sid%3Dliteratum%253Aachs%26aulast%3DFederspiel%26aufirst%3DJ.%2BD.%26aulast%3DCodreanu%26aufirst%3DS.%2BG.%26aulast%3DGoyal%26aufirst%3DS.%26aulast%3DAlbertolle%26aufirst%3DM.%2BE.%26aulast%3DLowe%26aufirst%3DE.%26aulast%3DTeague%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DGuengerich%26aufirst%3DF.%2BP.%26aulast%3DLiebler%26aufirst%3DD.%2BC.%26atitle%3DSpecificity%2520of%2520protein%2520covalent%2520modification%2520by%2520the%2520electrophilic%2520proteasome%2520inhibitor%2520carfilzomib%2520in%2520human%2520cells%26jtitle%3DMol.%2520Cell.%2520Proteomics%26date%3D2016%26volume%3D15%26spage%3D3233%26epage%3D3242%26doi%3D10.1074%2Fmcp.M116.059709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span> <span> </span><span class="NLM_article-title">Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">168</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.226993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1124%2Fjpet.115.226993" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=26311812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslals7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2015&pages=168-173&author=L.+Aoauthor=D.+Reichelauthor=D.+Huauthor=H.+Jeongauthor=K.+B.+Kimauthor=Y.+Baeauthor=W.+Lee&title=Polymer+micelle+formulations+of+proteasome+inhibitor+carfilzomib+for+improved+metabolic+stability+and+anticancer+efficacy+in+human+multiple+myeloma+and+lung+cancer+cell+lines&doi=10.1124%2Fjpet.115.226993"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines</span></div><div class="casAuthors">Ao, Lin; Reichel, Derek; Hu, Di; Jeong, Hyunyoung; Kim, Kyung Bo; Bae, Younsoo; Lee, Wooin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">168-173</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Carfilzomib (CFZ) is a second-generation proteasome inhibitor drug approved for the treatment of multiple myeloma.  Contrary to its excellent antimyeloma activity, CFZ has shown only limited efficacy in patients with solid malignancies.  This lack of efficacy has been attributed in part to rapid degrdn. of CFZ in the body, possibly hindering the ability of CFZ to access the proteasome target in solid tumors.  We hypothesized that polymer micelles, a currently Food and Drug Administration-approved nanoparticle drug delivery formulation, may protect CFZ from metabolic degrdn. and thus expand the clin. utility of the drug as an anticancer agent.  To test our hypothesis, we prepd. CFZ-entrapped polymer micelle particles with various compns. and drug release profiles and examd. the extent of the CFZ metab. in vitro using mouse liver homogenates.  We also assessed the cytotoxic activities of the CFZ-entrapped micelle formulations in human cancer cell lines derived from B lymphocytes (RPMI-8226) and the lung (H460).  Our data indicated that polymer micelle-based formulations can improve metabolic stability and cytotoxic effects of CFZ compared with free CFZ in human cancer cell lines tested.  Taken together, these results suggest that polymer micelles may have potential as a delivery system for CFZ with an extended therapeutic utility for nonhematol. malignancies in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqc8dzYgQUzSLVg90H21EOLACvtfcHk0lgqehb-VqYNRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslals7w%253D&md5=3130e9ad61b0b69a1daa9e66c08c6576</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.226993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.226993%26sid%3Dliteratum%253Aachs%26aulast%3DAo%26aufirst%3DL.%26aulast%3DReichel%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DD.%26aulast%3DJeong%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DBae%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DW.%26atitle%3DPolymer%2520micelle%2520formulations%2520of%2520proteasome%2520inhibitor%2520carfilzomib%2520for%2520improved%2520metabolic%2520stability%2520and%2520anticancer%2520efficacy%2520in%2520human%2520multiple%2520myeloma%2520and%2520lung%2520cancer%2520cell%2520lines%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D355%26spage%3D168%26epage%3D173%26doi%3D10.1124%2Fjpet.115.226993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryoo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span> <span> </span><span class="NLM_article-title">Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: anticancer efficacy and pharmacokinetic studies in mice</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e0173247</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0173247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1371%2Fjournal.pone.0173247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=28273121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVGjsbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&author=J.+E.+Parkauthor=S.+E.+Chunauthor=D.+Reichelauthor=J.+S.+Minauthor=S.+C.+Leeauthor=S.+Hanauthor=G.+Ryooauthor=Y.+Ohauthor=S.+H.+Parkauthor=H.+M.+Ryuauthor=K.+B.+Kimauthor=H.+Y.+Leeauthor=S.+K.+Baeauthor=Y.+Baeauthor=W.+Lee&title=Polymer+micelle+formulation+for+the+proteasome+inhibitor+drug+carfilzomib%3A+anticancer+efficacy+and+pharmacokinetic+studies+in+mice&doi=10.1371%2Fjournal.pone.0173247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice</span></div><div class="casAuthors">Park, Ji Eun; Chun, Se-Eun; Reichel, Derek; Min, Jee Sun; Lee, Su-Chan; Han, Songhee; Ryoo, Gongmi; Oh, Yunseok; Park, Shin-Hyung; Ryu, Heon-Min; Kim, Kyung Bo; Lee, Ho-Young; Bae, Soo Kyung; Bae, Younsoo; Lee, Wooin</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e0173247/1-e0173247/12</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Carfilzomib (CFZ) is a peptide epoxyketone proteasome inhibitor approved for the treatment of multiple myeloma (MM).  Despite the remarkable efficacy of CFZ against MM, the clin. trials in patients with solid cancers yielded rather disappointing results with minimal clin. benefits.  Rapid degrdn. of CFZ in vivo and its poor penetration to tumor sites are considered to be major factors limiting its efficacy against solid cancers.  We previously reported that polymer micelles (PMs) composed of biodegradable block copolymers poly(ethylene glycol) (PEG) and poly(caprolactone) (PCL) can improve the metabolic stability of CFZ in vitro.  Here, we prepd. the CFZ-loaded PM, PEG-PCL-deoxycholic acid (CFZ-PM) and assessed its in vivo anticancer efficacy and pharmacokinetic profiles.  Despite in vitro metabolic protection of CFZ, CFZ-PM did not display in vivo anticancer efficacy in mice bearing human lung cancer xenograft (H460) superior to that of the clin. used cyclodextrinbased CFZ (CFZ-CD) formulation.  The plasma pharmacokinetic profiles of CFZ-PM were also comparable to those of CFZ-CD and the residual tumors that persisted in xenograft mice receiving CFZ-PM displayed an incomplete proteasome inhibition.  In summary, our results showed that despite its favorable in vitro performances, the current CFZ-PM formulation did not improve in vivo anticancer efficacy and accessibility of active CFZ to solid cancer tissues over CFZ-CD.  Careful consideration of the current results and potential confounding factors may provide valuable insights into the future efforts to validate the potential of CFZ based therapy for solid cancer and to develop effective CFZ delivery strategies that can be used to treat solid cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1CNICEadpy7Vg90H21EOLACvtfcHk0lgqehb-VqYNRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVGjsbjF&md5=39c80a41e6b90037f31b311a223336a1</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0173247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0173247%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BE.%26aulast%3DChun%26aufirst%3DS.%2BE.%26aulast%3DReichel%26aufirst%3DD.%26aulast%3DMin%26aufirst%3DJ.%2BS.%26aulast%3DLee%26aufirst%3DS.%2BC.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DRyoo%26aufirst%3DG.%26aulast%3DOh%26aufirst%3DY.%26aulast%3DPark%26aufirst%3DS.%2BH.%26aulast%3DRyu%26aufirst%3DH.%2BM.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DLee%26aufirst%3DH.%2BY.%26aulast%3DBae%26aufirst%3DS.%2BK.%26aulast%3DBae%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DW.%26atitle%3DPolymer%2520micelle%2520formulation%2520for%2520the%2520proteasome%2520inhibitor%2520drug%2520carfilzomib%253A%2520anticancer%2520efficacy%2520and%2520pharmacokinetic%2520studies%2520in%2520mice%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26doi%3D10.1371%2Fjournal.pone.0173247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 7 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Deepak Bhattarai, Min Jae Lee, Ahruem Baek, In Jun Yeo, Zachary Miller, Yu Mi Baek, Sukyeong Lee, Dong-Eun Kim, Jin Tae Hong, <span class="NLM_string-name hlFld-ContribAuthor">Kyung Bo Kim</span>. </span><span class="cited-content_cbyCitation_article-title">LMP2 Inhibitors as a Potential Treatment for Alzheimer’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (7)
                                     , 3763-3783. <a href="https://doi.org/10.1021/acs.jmedchem.0c00416" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00416</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00416%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DLMP2%252BInhibitors%252Bas%252Ba%252BPotential%252BTreatment%252Bfor%252BAlzheimer%2525E2%252580%252599s%252BDisease%26aulast%3DBhattarai%26aufirst%3DDeepak%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D11032020%26date%3D30032020%26date%3D19032020%26volume%3D63%26issue%3D7%26spage%3D3763%26epage%3D3783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juan  Wang</span>, <span class="hlFld-ContribAuthor ">Boqiang  Liang</span>, <span class="hlFld-ContribAuthor ">Yiling  Chen</span>, <span class="hlFld-ContribAuthor ">Jasper  Fuk-Woo Chan</span>, <span class="hlFld-ContribAuthor ">Shuofeng  Yuan</span>, <span class="hlFld-ContribAuthor ">Hui  Ye</span>, <span class="hlFld-ContribAuthor ">Linlin  Nie</span>, <span class="hlFld-ContribAuthor ">Jiao  Zhou</span>, <span class="hlFld-ContribAuthor ">Yi  Wu</span>, <span class="hlFld-ContribAuthor ">Meixian  Wu</span>, <span class="hlFld-ContribAuthor ">Lina S.  Huang</span>, <span class="hlFld-ContribAuthor ">Jing  An</span>, <span class="hlFld-ContribAuthor ">Arieh  Warshel</span>, <span class="hlFld-ContribAuthor ">Kwok-Yung  Yuen</span>, <span class="hlFld-ContribAuthor ">Aaron  Ciechanover</span>, <span class="hlFld-ContribAuthor ">Ziwei  Huang</span>, <span class="hlFld-ContribAuthor ">Yan  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">A new class of α-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>215 </em>, 113267. <a href="https://doi.org/10.1016/j.ejmech.2021.113267" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113267</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113267%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bnew%252Bclass%252Bof%252B%2525CE%2525B1-ketoamide%252Bderivatives%252Bwith%252Bpotent%252Banticancer%252Band%252Banti-SARS-CoV-2%252Bactivities%26aulast%3DWang%26aufirst%3DJuan%26date%3D2021%26volume%3D215%26spage%3D113267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Margot S.F.  Roeten</span>, <span class="hlFld-ContribAuthor ">Johan  van Meerloo</span>, <span class="hlFld-ContribAuthor ">Zinia J.  Kwidama</span>, <span class="hlFld-ContribAuthor ">Giovanna  ter Huizen</span>, <span class="hlFld-ContribAuthor ">Wouter H.  Segerink</span>, <span class="hlFld-ContribAuthor ">Sonja  Zweegman</span>, <span class="hlFld-ContribAuthor ">Gertjan J.L.  Kaspers</span>, <span class="hlFld-ContribAuthor ">Gerrit  Jansen</span>, <span class="hlFld-ContribAuthor ">Jacqueline  Cloos</span>. </span><span class="cited-content_cbyCitation_article-title">Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2021,</strong> <em>10 </em>
                                    (3)
                                     , 665. <a href="https://doi.org/10.3390/cells10030665" title="DOI URL">https://doi.org/10.3390/cells10030665</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells10030665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells10030665%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DPre-Clinical%252BEvaluation%252Bof%252Bthe%252BProteasome%252BInhibitor%252BIxazomib%252Bagainst%252BBortezomib-Resistant%252BLeukemia%252BCells%252Band%252BPrimary%252BAcute%252BLeukemia%252BCells%26aulast%3DRoeten%26aufirst%3DMargot%2BS.F.%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D3%26spage%3D665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Grace E.  Hubbell</span>, <span class="hlFld-ContribAuthor ">Jetze J.  Tepe</span>. </span><span class="cited-content_cbyCitation_article-title">Natural product scaffolds as inspiration for the design and synthesis of 20S human proteasome inhibitors. </span><span class="cited-content_cbyCitation_journal-name">RSC Chemical Biology</span><span> <strong>2020,</strong> <em>1 </em>
                                    (5)
                                     , 305-332. <a href="https://doi.org/10.1039/D0CB00111B" title="DOI URL">https://doi.org/10.1039/D0CB00111B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0CB00111B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0CB00111B%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Chemical%2520Biology%26atitle%3DNatural%252Bproduct%252Bscaffolds%252Bas%252Binspiration%252Bfor%252Bthe%252Bdesign%252Band%252Bsynthesis%252Bof%252B20S%252Bhuman%252Bproteasome%252Binhibitors%26aulast%3DHubbell%26aufirst%3DGrace%2BE.%26date%3D2020%26date%3D2020%26volume%3D1%26issue%3D5%26spage%3D305%26epage%3D332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Preye  Agbana</span>, <span class="hlFld-ContribAuthor ">Min Jae  Lee</span>, <span class="hlFld-ContribAuthor ">Piotr  Rychahou</span>, <span class="hlFld-ContribAuthor ">Kyung-Bo  Kim</span>, <span class="hlFld-ContribAuthor ">Younsoo  Bae</span>. </span><span class="cited-content_cbyCitation_article-title">Ternary Polypeptide Nanoparticles with Improved Encapsulation, Sustained Release, and Enhanced In Vitro Efficacy of Carfilzomib. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutical Research</span><span> <strong>2020,</strong> <em>37 </em>
                                    (11)
                                     <a href="https://doi.org/10.1007/s11095-020-02922-9" title="DOI URL">https://doi.org/10.1007/s11095-020-02922-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11095-020-02922-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11095-020-02922-9%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutical%2520Research%26atitle%3DTernary%252BPolypeptide%252BNanoparticles%252Bwith%252BImproved%252BEncapsulation%25252C%252BSustained%252BRelease%25252C%252Band%252BEnhanced%252BIn%252BVitro%252BEfficacy%252Bof%252BCarfilzomib%26aulast%3DAgbana%26aufirst%3DPreye%26date%3D2020%26date%3D2020%26volume%3D37%26issue%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xue  Li</span>, <span class="hlFld-ContribAuthor ">Lingmei  Kong</span>, <span class="hlFld-ContribAuthor ">Qihong  Yang</span>, <span class="hlFld-ContribAuthor ">Aizhu  Duan</span>, <span class="hlFld-ContribAuthor ">Xiaoman  Ju</span>, <span class="hlFld-ContribAuthor ">Bicheng  Cai</span>, <span class="hlFld-ContribAuthor ">Lin  Chen</span>, <span class="hlFld-ContribAuthor ">Tao  An</span>, <span class="hlFld-ContribAuthor ">Yan  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Parthenolide inhibits ubiquitin-specific peptidase 7 (USP7), Wnt signaling, and colorectal cancer cell growth. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biological Chemistry</span><span> <strong>2020,</strong> <em>295 </em>
                                    (11)
                                     , 3576-3589. <a href="https://doi.org/10.1074/jbc.RA119.011396" title="DOI URL">https://doi.org/10.1074/jbc.RA119.011396</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1074/jbc.RA119.011396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1074%2Fjbc.RA119.011396%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biological%2520Chemistry%26atitle%3DParthenolide%252Binhibits%252Bubiquitin-specific%252Bpeptidase%252B7%252B%252528USP7%252529%25252C%252BWnt%252Bsignaling%25252C%252Band%252Bcolorectal%252Bcancer%252Bcell%252Bgrowth%26aulast%3DLi%26aufirst%3DXue%26date%3D2020%26volume%3D295%26issue%3D11%26spage%3D3576%26epage%3D3589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arduino  Mangoni</span>, <span class="hlFld-ContribAuthor ">Jean  Eynde</span>, <span class="hlFld-ContribAuthor ">Josef  Jampilek</span>, <span class="hlFld-ContribAuthor ">Dimitra  Hadjipavlou-Litina</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>, <span class="hlFld-ContribAuthor ">Jóhannes  Reynisson</span>, <span class="hlFld-ContribAuthor ">Maria  Sousa</span>, <span class="hlFld-ContribAuthor ">Paula  Gomes</span>, <span class="hlFld-ContribAuthor ">Katalin  Prokai-Tatrai</span>, <span class="hlFld-ContribAuthor ">Tiziano  Tuccinardi</span>, <span class="hlFld-ContribAuthor ">Jean-Marc  Sabatier</span>, <span class="hlFld-ContribAuthor ">F.  Luque</span>, <span class="hlFld-ContribAuthor ">Jarkko  Rautio</span>, <span class="hlFld-ContribAuthor ">Rafik  Karaman</span>, <span class="hlFld-ContribAuthor ">M.  Vasconcelos</span>, <span class="hlFld-ContribAuthor ">Sandra  Gemma</span>, <span class="hlFld-ContribAuthor ">Stefania  Galdiero</span>, <span class="hlFld-ContribAuthor ">Christopher  Hulme</span>, <span class="hlFld-ContribAuthor ">Simona  Collina</span>, <span class="hlFld-ContribAuthor ">Michael  Gütschow</span>, <span class="hlFld-ContribAuthor ">George  Kokotos</span>, <span class="hlFld-ContribAuthor ">Carlo  Siciliano</span>, <span class="hlFld-ContribAuthor ">Raffaele  Capasso</span>, <span class="hlFld-ContribAuthor ">Luigi  Agrofoglio</span>, <span class="hlFld-ContribAuthor ">Rino  Ragno</span>, <span class="hlFld-ContribAuthor ">Diego  Muñoz-Torrero</span>. </span><span class="cited-content_cbyCitation_article-title">Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–5. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (13)
                                     , 2415. <a href="https://doi.org/10.3390/molecules24132415" title="DOI URL">https://doi.org/10.3390/molecules24132415</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24132415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24132415%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DBreakthroughs%252Bin%252BMedicinal%252BChemistry%25253A%252BNew%252BTargets%252Band%252BMechanisms%25252C%252BNew%252BDrugs%25252C%252BNew%252BHopes%2525E2%252580%2525935%26aulast%3DMangoni%26aufirst%3DArduino%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D13%26spage%3D2415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/medium/jm-2018-019434_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01943&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/medium/jm-2018-019434_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Structures of proteasome inhibitors in clinical use. The gray-colored markings denote the functional groups that are proposed to form favorable interactions with the specificity pockets (S1–4) of a proteasome catalytic subunit. (B) Schematic representation of a prototypical proteasome substrate or substrate-like inhibitor bound to a proteasome catalytic subunit showing the unprimed residues (P1, P2, P3, and P4) located <i>N</i>-terminal to the cleavage site of the proteasome catalytic subunit (shown as an arrow) and the primed P1′ residue located C-terminal to the cleavage site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01943&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/medium/jm-2018-019434_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Ubiquitin-proteasome system (UPS) and its association with various hallmarks of cancer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01943&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/medium/jm-2018-019434_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0009.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis Scheme of <b>5</b> (UK101-OH) and <b>9</b> (Cfz–OH)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01943&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (A) (a) (i) CH<sub>3</sub>PO(OCH<sub>3</sub>)<sub>2</sub>, n-BuLi, THF, −78 °C, 2 h, Boc-serine methylester, THF, −78 °C, 3 h, 55%; (ii) Aqueous solution of formaldehyde, K<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O, rt, 4 h, 59%; (iii) TBDMS-Cl, imidazole, DCM, rt, 30 min, 71% or iodomethane, Ag<sub>2</sub>O, MeCN, rt, 24 h, 51%; (b) benzonitrile, H<sub>2</sub>O<sub>2</sub>, DIEA, MeOH, 0 °C, 3 h, 35–41%; (c) heptanoic acid, HBTU, HOBt, DIEA, DCM, rt, 18 h, 82%; (d) (i) H<sub>2</sub>, Pd/C, methanol, 1 h, (ii) Boc-deprotected 2a, HBTU, HOBt, DIEA, DCM, rt, 18 h, 91%; (e) TBAF, DCM, 2 h, 70%. (B) (a) (i) Phenylalanine benzyl ester hydrochloride, HBTU, HOBt, DIEA, DCM, rt, 18 h, 81%; (ii) TFA, DCM, rt, 1 h then evaporation and drying, Boc-homoPhe-OH, HBTU, HOBt, DIEA, DCM, rt, 18 h, 79%; (iii) TFA, DCM, rt, 1 h then evaporate and dried, morpholin-4-yl-acetic acid hydrochloride, HBTU, HOBt, DIEA, DCM, rt, 18 h, 65%; (b) (i) H<sub>2</sub>/Pd, C, methanol, 1 h; (ii) 2a or 2b, HBTU, HOBt, DIEA, DCM, rt, 18 h, 45% and 48%, respectively; (c) TBAF, DCM, 2 h, 64%; (d) MOM-Cl or MEM-Cl or methanesulfonyl chloride, DIEA, DCM, overnight, 60–64%.</p></p></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/medium/jm-2018-019434_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Structures of UK101 and UK102. (B) Comparison of the cytotoxic potency (72-h IC<sub>50</sub> values) of H727 and H23 cells to carfilzomib, bortezomib, MG-132, UK101, UK102, and lactacystin. Data are reported as the mean ± SD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01943&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/medium/jm-2018-019434_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Effects of carfilzomib (Cfz) on the viability of an RPMI8266 cell line with acquired Cfz resistance (RPMI8266/CfzR) in comparison to the parental cell line. Cell viability was measured by MTS assay after 72 h drug treatment (left). Immunoblotting analysis showing a marked increase of P-gp expression in RPMI8226 Cfz-resistant cells in comparison to parental cells (right). (B) Comparison of the sensitivity (72-h IC<sub>50</sub> values) of RPMI8226 parental and Cfz-resistant cells to Cfz, epoxomicin, UK101, and UK102. Data are reported as the mean ± SD. For epoxomicin and carfilzomib, the SD values were obtained from three independent experiments. For UK101 and UK102, the SD values were from nonlinear regression analysis using three replicates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01943&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/medium/jm-2018-019434_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of carfilzomib (Cfz), UK101, and UK102 on cell viability of primary MM samples from 14 different donors, six from Btz/Cfz-naïve patients and eight from patients relapsed on Btz therapy. Primary MM cells were treated with Cfz (A, 50 nM), UK101 (B, 10 μM), or UK102 (C, 10 μM) for 48 h. Cell viability was measured using an ATP-based luminescent assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01943&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/medium/jm-2018-019434_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Predicted docking models of UK101 and carfilzomib (Cfz) bound to β5 or β1i. The location of UK101’s TBDMS group positioned within putative P1′ pockets is highlighted using a purple-colored circle. β5 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UNB">3UNB</a>) and β1i (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UNF">3UNF</a>) from mammalian 20S proteasomes were used as templates. In cartoon presentation, β1i (gray, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UNF">3UNF</a>) was superposed to β5 (yellow, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UNB">3UNB</a>) and only different amino acid residues are shown in stick model. (B) Comparison of UK101 and <b>5</b>(UK101-OH) in terms of their potency (IC<sub>50</sub> values) against proteasome chymotrypsin-like activity (in RPMI8226 cell lysate), β1i/LMP2 catalytic activity (in 20S purified human immunoproteasome), and against H23, H727, and Cfz-resistant RPMI8226 cells as measured by MTS cell viability assay. Data are reported as the mean ± SD. Docking model of UK101-OH bound to β1i (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UNF">3UNF</a>). The P1′–OH of UK101-OH (<b>5</b>) is perfectly positioned to form hydrogen bonds with Ser168 and Ser21.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01943&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/medium/jm-2018-019434_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0007.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Potency (IC<sub>50</sub> values) for compounds with various substitutions at the P1′site against proteasome chymotrypsin-like activity (RPMI8226 cell lysate), β1i/LMP2 activity (purified human 20S immunoproteasome), and cell viability of H23, H727, and Cfz-resistant RPMI8226 cells. Data reported as the mean ± SD (carfilzomib, <i>n</i> = 3 independent experiments) or from a single experiment (3 replicates, <b>7</b>, <b>9</b>, and <b>12</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01943&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/medium/jm-2018-019434_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0008.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Schematic depicting the rapid metabolism of Cfz by microsomal epoxide hydrolase (mEH) to the inactive diol. (B) Quantification of the remaining levels of Cfz or <b>9</b> following the incubation with rat liver homogenate containing active mEH and peptidase activities for 5, 10, and 20 min, respectively. Data presented as mean ± SD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-9/acs.jmedchem.8b01943/20190502/images/large/jm-2018-019434_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01943&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i46">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61164" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61164" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 50 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergsagel, P. L.</span></span> <span> </span><span class="NLM_article-title">Where we were, where we are, where we are going: progress in multiple myeloma</span>. <i>Am. Soc. Clin Oncol Educ Book</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.14694/EdBook_AM.2014.34.199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.14694%2FEdBook_AM.2014.34.199" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=199-203&author=P.+L.+Bergsagel&title=Where+we+were%2C+where+we+are%2C+where+we+are+going%3A+progress+in+multiple+myeloma&doi=10.14694%2FEdBook_AM.2014.34.199"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.14694%2FEdBook_AM.2014.34.199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14694%252FEdBook_AM.2014.34.199%26sid%3Dliteratum%253Aachs%26aulast%3DBergsagel%26aufirst%3DP.%2BL.%26atitle%3DWhere%2520we%2520were%252C%2520where%2520we%2520are%252C%2520where%2520we%2520are%2520going%253A%2520progress%2520in%2520multiple%2520myeloma%26jtitle%3DAm.%2520Soc.%2520Clin%2520Oncol%2520Educ%2520Book%26date%3D2014%26volume%3D34%26spage%3D199%26epage%3D203%26doi%3D10.14694%2FEdBook_AM.2014.34.199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lonial, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palumbo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San-Miguel, J.</span></span> <span> </span><span class="NLM_article-title">Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">526</span>– <span class="NLM_lpage">535</span>, <span class="refDoi"> DOI: 10.1038/leu.2015.223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1038%2Fleu.2015.223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=26265184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1OnsbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=526-535&author=S.+Lonialauthor=B.+Durieauthor=A.+Palumboauthor=J.+San-Miguel&title=Monoclonal+antibodies+in+the+treatment+of+multiple+myeloma%3A+current+status+and+future+perspectives&doi=10.1038%2Fleu.2015.223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives</span></div><div class="casAuthors">Lonial, S.; Durie, B.; Palumbo, A.; San-Miguel, J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">526-535</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The treatment landscape for patients with multiple myeloma (MM) is constantly evolving.  Over the past decade, the introduction of novel agents such as proteasome inhibitors and immunomodulatory drugs has led to notable changes in therapeutic strategy, and improvements in survival, yet MM remains incurable in the vast majority of cases.  More recently, a targeted approach to MM treatment has emerged, using monoclonal antibodies (mAbs) to target antigens expressed on the surface of MM cells.  MAbs tested to date kill MM cells via the host's immune system and/or by promoting apoptosis, and appear to have generally improved tolerability compared with currently available treatments.  Due to their distinct mode of action, mAbs are promising both for patients who have exhausted current regimens, and as part of first-line treatments in newly diagnosed patients.  This review examines the recent developments in mAb-based therapy for MM, primarily focused on those agents in ongoing clin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2QiypmVuBwLVg90H21EOLACvtfcHk0lh1XRRdXLSGjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1OnsbvO&md5=649a630bbb026c68efe821f0f7ab01e4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.223%26sid%3Dliteratum%253Aachs%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DDurie%26aufirst%3DB.%26aulast%3DPalumbo%26aufirst%3DA.%26aulast%3DSan-Miguel%26aufirst%3DJ.%26atitle%3DMonoclonal%2520antibodies%2520in%2520the%2520treatment%2520of%2520multiple%2520myeloma%253A%2520current%2520status%2520and%2520future%2520perspectives%26jtitle%3DLeukemia%26date%3D2016%26volume%3D30%26spage%3D526%26epage%3D535%26doi%3D10.1038%2Fleu.2015.223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. L.</span></span> <span> </span><span class="NLM_article-title">Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0283-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1186%2Fs13045-016-0283-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=27363983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVGktr7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=51-58&author=L.+Sanchezauthor=Y.+Wangauthor=D.+S.+Siegelauthor=M.+L.+Wang&title=Daratumumab%3A+a+first-in-class+CD38+monoclonal+antibody+for+the+treatment+of+multiple+myeloma&doi=10.1186%2Fs13045-016-0283-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma</span></div><div class="casAuthors">Sanchez, Larysa; Wang, Yucai; Siegel, David S.; Wang, Michael L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51/1-51/8</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells.  Preclin. studies have shown that daratumumab induces MM cell death through several mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis.  Given the encouraging efficacy and acceptable safety profile of daratumumab demonstrated in clin. trials, daratumumab has emerged as a novel treatment option for myeloma and became the first monoclonal antibody approved by the FDA for the treatment of MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_qCAS_SP2S7Vg90H21EOLACvtfcHk0ljEkS-g0QSRGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVGktr7J&md5=d95152cd0036adfd4a0dec28293bed6b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0283-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0283-0%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSiegel%26aufirst%3DD.%2BS.%26aulast%3DWang%26aufirst%3DM.%2BL.%26atitle%3DDaratumumab%253A%2520a%2520first-in-class%2520CD38%2520monoclonal%2520antibody%2520for%2520the%2520treatment%2520of%2520multiple%2520myeloma%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D51%26epage%3D58%26doi%3D10.1186%2Fs13045-016-0283-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">San-Miguel, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hungria, V. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beksac, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimopoulos, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elghandour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jedrzejczak, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunther, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakorn, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siritanaratkul, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlossman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonial, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einsele, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sopala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bengoudifa, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binlich, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span> <span> </span><span class="NLM_article-title">Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial</span>. <i>Lancet Haematol</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e506</span>– <span class="NLM_lpage">e515</span>, <span class="refDoi"> DOI: 10.1016/S2352-3026(16)30147-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2FS2352-3026%2816%2930147-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=27751707" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&pages=e506-e515&author=J.+F.+San-Miguelauthor=V.+T.+Hungriaauthor=S.+S.+Yoonauthor=M.+Beksacauthor=M.+A.+Dimopoulosauthor=A.+Elghandourauthor=W.+W.+Jedrzejczakauthor=A.+Guntherauthor=T.+N.+Nakornauthor=N.+Siritanaratkulauthor=R.+L.+Schlossmanauthor=J.+Houauthor=P.+Moreauauthor=S.+Lonialauthor=J.+H.+Leeauthor=H.+Einseleauthor=M.+Sopalaauthor=B.+R.+Bengoudifaauthor=F.+Binlichauthor=P.+G.+Richardson&title=Overall+survival+of+patients+with+relapsed+multiple+myeloma+treated+with+panobinostat+or+placebo+plus+bortezomib+and+dexamethasone+%28the+PANORAMA+1+trial%29%3A+a+randomised%2C+placebo-controlled%2C+phase+3+trial&doi=10.1016%2FS2352-3026%2816%2930147-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS2352-3026%2816%2930147-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2352-3026%252816%252930147-8%26sid%3Dliteratum%253Aachs%26aulast%3DSan-Miguel%26aufirst%3DJ.%2BF.%26aulast%3DHungria%26aufirst%3DV.%2BT.%26aulast%3DYoon%26aufirst%3DS.%2BS.%26aulast%3DBeksac%26aufirst%3DM.%26aulast%3DDimopoulos%26aufirst%3DM.%2BA.%26aulast%3DElghandour%26aufirst%3DA.%26aulast%3DJedrzejczak%26aufirst%3DW.%2BW.%26aulast%3DGunther%26aufirst%3DA.%26aulast%3DNakorn%26aufirst%3DT.%2BN.%26aulast%3DSiritanaratkul%26aufirst%3DN.%26aulast%3DSchlossman%26aufirst%3DR.%2BL.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DMoreau%26aufirst%3DP.%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DEinsele%26aufirst%3DH.%26aulast%3DSopala%26aufirst%3DM.%26aulast%3DBengoudifa%26aufirst%3DB.%2BR.%26aulast%3DBinlich%26aufirst%3DF.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26atitle%3DOverall%2520survival%2520of%2520patients%2520with%2520relapsed%2520multiple%2520myeloma%2520treated%2520with%2520panobinostat%2520or%2520placebo%2520plus%2520bortezomib%2520and%2520dexamethasone%2520%2528the%2520PANORAMA%25201%2520trial%2529%253A%2520a%2520randomised%252C%2520placebo-controlled%252C%2520phase%25203%2520trial%26jtitle%3DLancet%2520Haematol%26date%3D2016%26volume%3D3%26spage%3De506%26epage%3De515%26doi%3D10.1016%2FS2352-3026%2816%2930147-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanahan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinberg, R. A.</span></span> <span> </span><span class="NLM_article-title">Hallmarks of cancer: the next generation</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">646</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2011.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2Fj.cell.2011.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=21376230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2011&pages=646-674&author=D.+Hanahanauthor=R.+A.+Weinberg&title=Hallmarks+of+cancer%3A+the+next+generation&doi=10.1016%2Fj.cell.2011.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Hallmarks of cancer: the next generation</span></div><div class="casAuthors">Hanahan, Douglas; Weinberg, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">646-674</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The hallmarks of cancer comprise six biol. capabilities acquired during the multistep development of human tumors.  The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease.  They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis.  Underlying these hallmarks are genome instability, which generates the genetic diversity that expedites their acquisition, and inflammation, which fosters multiple hallmark functions.  Conceptual progress in the last decade has added two emerging hallmarks of potential generality to this list-reprogramming of energy metab. and evading immune destruction.  In addn. to cancer cells, tumors exhibit another dimension of complexity: they contain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hallmark traits by creating the "tumor microenvironment.".  Recognition of the widespread applicability of these concepts will increasingly affect the development of new means to treat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTcpqXALcb6LVg90H21EOLACvtfcHk0ljEkS-g0QSRGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFeqtrk%253D&md5=b36f160c417a712e83cb83c577f0018e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DWeinberg%26aufirst%3DR.%2BA.%26atitle%3DHallmarks%2520of%2520cancer%253A%2520the%2520next%2520generation%26jtitle%3DCell%26date%3D2011%26volume%3D144%26spage%3D646%26epage%3D674%26doi%3D10.1016%2Fj.cell.2011.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solimini, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elledge, S. J.</span></span> <span> </span><span class="NLM_article-title">Principles of cancer therapy: oncogene and non-oncogene addiction</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">823</span>– <span class="NLM_lpage">837</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.02.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2Fj.cell.2009.02.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=19269363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltFSnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2009&pages=823-837&author=J.+Luoauthor=N.+L.+Soliminiauthor=S.+J.+Elledge&title=Principles+of+cancer+therapy%3A+oncogene+and+non-oncogene+addiction&doi=10.1016%2Fj.cell.2009.02.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Principles of cancer therapy: oncogene and non-oncogene addiction</span></div><div class="casAuthors">Luo, Ji; Solimini, Nicole L.; Elledge, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">823-837</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Cancer is a complex collection of distinct genetic diseases united by common hallmarks.  Here, we expand upon the classic hallmarks to include the stress phenotypes of tumorigenesis.  We describe a conceptual framework of how oncogene and non-oncogene addictions contribute to these hallmarks and how they can be exploited through stress sensitization and stress overload to selectively kill cancer cells.  In particular, we present evidence for a large class of non-oncogenes that are essential for cancer cell survival and present attractive drug targets.  Finally, we discuss the path ahead to therapeutic discovery and provide theor. considerations for combining orthogonal cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrH3NH_D9W6LVg90H21EOLACvtfcHk0lhQO3C1-uZSaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltFSnsLw%253D&md5=dfbc7a874dcad44f8af947083dab8c33</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.02.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.02.024%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DSolimini%26aufirst%3DN.%2BL.%26aulast%3DElledge%26aufirst%3DS.%2BJ.%26atitle%3DPrinciples%2520of%2520cancer%2520therapy%253A%2520oncogene%2520and%2520non-oncogene%2520addiction%26jtitle%3DCell%26date%3D2009%26volume%3D136%26spage%3D823%26epage%3D837%26doi%3D10.1016%2Fj.cell.2009.02.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Moigne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djakovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss von
Soly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madriaga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kampmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aftab, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakes, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shawver, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wustrow, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, M.</span></span> <span> </span><span class="NLM_article-title">Targeting the AAA ATPase p97 as an approach to treat cancer through disruption of protein homeostasis</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">653</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2Fj.ccell.2015.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=26555175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVSksr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=653-665&author=D.+J.+Andersonauthor=R.+Le+Moigneauthor=S.+Djakovicauthor=B.+Kumarauthor=J.+Riceauthor=S.+Wongauthor=J.+Wangauthor=B.+Yaoauthor=E.+Valleauthor=S.+Kiss+von%0ASolyauthor=A.+Madriagaauthor=F.+Sorianoauthor=M.+K.+Menonauthor=Z.+Y.+Wuauthor=M.+Kampmannauthor=Y.+Chenauthor=J.+S.+Weissmanauthor=B.+T.+Aftabauthor=F.+M.+Yakesauthor=L.+Shawverauthor=H.+J.+Zhouauthor=D.+Wustrowauthor=M.+Rolfe&title=Targeting+the+AAA+ATPase+p97+as+an+approach+to+treat+cancer+through+disruption+of+protein+homeostasis&doi=10.1016%2Fj.ccell.2015.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis</span></div><div class="casAuthors">Anderson, Daniel J.; Le Moigne, Ronan; Djakovic, Stevan; Kumar, Brajesh; Rice, Julie; Wong, Steve; Wang, Jinhai; Yao, Bing; Valle, Eduardo; Kiss von Soly, Szerenke; Madriaga, Antonett; Soriano, Ferdie; Menon, Mary-Kamala; Wu, Zhi Yong; Kampmann, Martin; Chen, Yuwen; Weissman, Jonathan S.; Aftab, Blake T.; Yakes, F. Michael; Shawver, Laura; Zhou, Han-Jie; Wustrow, David; Rolfe, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">653-665</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">P97 is a AAA-ATPase with multiple cellular functions, one of which is crit. regulation of protein homeostasis pathways.  We describe the characterization of CB-5083, a potent, selective, and orally bioavailable inhibitor of p97.  Treatment of tumor cells with CB-5083 leads to accumulation of poly-ubiquitinated proteins, retention of endoplasmic reticulum-assocd. degrdn. (ERAD) substrates, and generation of irresolvable proteotoxic stress, leading to activation of the apoptotic arm of the unfolded protein response.  In xenograft models, CB-5083 causes modulation of key p97-related pathways, induces apoptosis, and has antitumor activity in a broad range of both hematol. and solid tumor models.  Mol. determinants of CB-5083 activity include expression of genes in the ERAD pathway, providing a potential strategy for patient selection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7c4WXhvOlYLVg90H21EOLACvtfcHk0lhQO3C1-uZSaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVSksr%252FN&md5=662df92598397deba1586e8993f2bb7a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DLe%2BMoigne%26aufirst%3DR.%26aulast%3DDjakovic%26aufirst%3DS.%26aulast%3DKumar%26aufirst%3DB.%26aulast%3DRice%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DB.%26aulast%3DValle%26aufirst%3DE.%26aulast%3DKiss%2Bvon%2BSoly%26aufirst%3DS.%26aulast%3DMadriaga%26aufirst%3DA.%26aulast%3DSoriano%26aufirst%3DF.%26aulast%3DMenon%26aufirst%3DM.%2BK.%26aulast%3DWu%26aufirst%3DZ.%2BY.%26aulast%3DKampmann%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWeissman%26aufirst%3DJ.%2BS.%26aulast%3DAftab%26aufirst%3DB.%2BT.%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DShawver%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DH.%2BJ.%26aulast%3DWustrow%26aufirst%3DD.%26aulast%3DRolfe%26aufirst%3DM.%26atitle%3DTargeting%2520the%2520AAA%2520ATPase%2520p97%2520as%2520an%2520approach%2520to%2520treat%2520cancer%2520through%2520disruption%2520of%2520protein%2520homeostasis%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D28%26spage%3D653%26epage%3D665%26doi%3D10.1016%2Fj.ccell.2015.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arcy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">706</span>– <span class="NLM_lpage">716</span>, <span class="refDoi"> DOI: 10.1182/blood-2013-05-500033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1182%2Fblood-2013-05-500033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=24319254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVGqtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2014&pages=706-716&author=Z.+Tianauthor=P.+D%E2%80%99Arcyauthor=X.+Wangauthor=A.+Rayauthor=Y.+T.+Taiauthor=Y.+Huauthor=R.+D.+Carrascoauthor=P.+Richardsonauthor=S.+Linderauthor=D.+Chauhanauthor=K.+C.+Anderson&title=A+novel+small+molecule+inhibitor+of+deubiquitylating+enzyme+USP14+and+UCHL5+induces+apoptosis+in+multiple+myeloma+and+overcomes+bortezomib+resistance&doi=10.1182%2Fblood-2013-05-500033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance</span></div><div class="casAuthors">Tian, Ze; D'Arcy, Padraig; Wang, Xin; Ray, Arghya; Tai, Yu-Tzu; Hu, Yiguo; Carrasco, Ruben D.; Richardson, Paul; Linder, Stig; Chauhan, Dharminder; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">706-716</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Proteasome inhibitors have demonstrated that targeting protein degrdn. is effective therapy in multiple myeloma (MM).  Here we show that deubiquitylating enzymes (DUBs) USP14 and UCHL5 are more highly expressed in MM cells than in normal plasma cells.  USP14 and UCHL5 short interfering RNA knockdown decreases MM cell viability.  A novel 19S regulatory particle inhibitor b-AP15 selectively blocks deubiquitylating activity of USP14 and UCHL5 without inhibiting proteasome activity.  B-AP15 decreases viability in MM cell lines and patient MM cells, inhibits proliferation of MM cells even in the presence of bone marrow stroma cells, and overcomes bortezomib resistance.  Anti-MM activity of b-AP15 is assocd. with growth arrest via downregulation of CDC25C, CDC2, and cyclin B1 as well as induction of caspase-dependent apoptosis and activation of unfolded protein response.  In vivo studies using distinct human MM xenograft models show that b-AP15 is well tolerated, inhibits tumor growth, and prolongs survival.  Combining b-AP15 with suberoylanilide hydroxamic acid, lenalidomide, or dexamethasone induces synergistic anti-MM activity.  Our preclin. data showing efficacy of b-AP15 in MM disease models validates targeting DUBs in the ubiquitin proteasomal cascade to overcome proteasome inhibitor resistance and provides the framework for clin. evaluation of USP14/UCHL5 inhibitors to improve patient outcome in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8aTcAtVqIcbVg90H21EOLACvtfcHk0lhUKPVxX5s9KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVGqtLc%253D&md5=abf0d4ca5dadf6f7bf0cd1de3798702f</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-05-500033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-05-500033%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DZ.%26aulast%3DD%25E2%2580%2599Arcy%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DTai%26aufirst%3DY.%2BT.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DCarrasco%26aufirst%3DR.%2BD.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DLinder%26aufirst%3DS.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DA%2520novel%2520small%2520molecule%2520inhibitor%2520of%2520deubiquitylating%2520enzyme%2520USP14%2520and%2520UCHL5%2520induces%2520apoptosis%2520in%2520multiple%2520myeloma%2520and%2520overcomes%2520bortezomib%2520resistance%26jtitle%3DBlood%26date%3D2014%26volume%3D123%26spage%3D706%26epage%3D716%26doi%3D10.1182%2Fblood-2013-05-500033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Selvaraju, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazurkiewicz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullbo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arcy, P.</span></span> <span> </span><span class="NLM_article-title">Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21–22</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/j.drup.2015.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2Fj.drup.2015.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=26183292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A280%3ADC%252BC28%252Fjsl2rug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21%E2%80%9322&publication_year=2015&pages=20-29&author=K.+Selvarajuauthor=M.+Mazurkiewiczauthor=X.+Wangauthor=J.+Gullboauthor=S.+Linderauthor=P.+D%E2%80%99Arcy&title=Inhibition+of+proteasome+deubiquitinase+activity%3A+a+strategy+to+overcome+resistance+to+conventional+proteasome+inhibitors%3F&doi=10.1016%2Fj.drup.2015.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?</span></div><div class="casAuthors">Selvaraju Karthik; Wang Xin; Mazurkiewicz Magdalena; Gullbo Joachim; Linder Stig; D'Arcy Padraig</div><div class="citationInfo"><span class="NLM_cas:title">Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21-22</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although more traditionally associated with degradation and maintenance of protein homeostasis, the ubiquitin-proteasome system (UPS) has emerged as a critical component in the regulation of cancer cell growth and survival.  The development of inhibitors that block the proteolytic activities of the proteasome have highlighted its suitability as a bona fide anti-cancer drug target.  However, key determinants including the development of drug resistance and dose-limiting toxicity call for the identification of alternative components of the UPS for novel drug targeting.  Recently the deubiquitinases (DUBs), a diverse family of enzymes that catalyze ubiquitin removal, have attracted significant interest as targets for the development of next generation UPS inhibitors.  In particular, pharmacological inhibition of the proteasomal cysteine DUBs (i.e., USP14 and UCHL5) has been shown to be particularly cytotoxic to cancer cells and inhibit tumour growth in several in vivo models.  In the current review we focus on the modes of action of proteasome DUB inhibitors and discus the potential of DUB inhibitors to circumvent acquired drug resistance and provide a therapeutic option for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRZaGfvi-WByzslzEEsg76ufW6udTcc2eaiCRToq0uYwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252Fjsl2rug%253D%253D&md5=3429b630445039d5891d777124fc4f7a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2015.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2015.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DSelvaraju%26aufirst%3DK.%26aulast%3DMazurkiewicz%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGullbo%26aufirst%3DJ.%26aulast%3DLinder%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Arcy%26aufirst%3DP.%26atitle%3DInhibition%2520of%2520proteasome%2520deubiquitinase%2520activity%253A%2520a%2520strategy%2520to%2520overcome%2520resistance%2520to%2520conventional%2520proteasome%2520inhibitors%253F%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2015%26volume%3D21%25E2%2580%259322%26spage%3D20%26epage%3D29%26doi%3D10.1016%2Fj.drup.2015.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulcinniti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodrasov, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kingsbury, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minvielle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">358</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2012.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2Fj.ccr.2012.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=22975377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlCju77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=345-358&author=D.+Chauhanauthor=Z.+Tianauthor=B.+Nicholsonauthor=K.+G.+Kumarauthor=B.+Zhouauthor=R.+Carrascoauthor=J.+L.+McDermottauthor=C.+A.+Leachauthor=M.+Fulcinnitiauthor=M.+P.+Kodrasovauthor=J.+Weinstockauthor=W.+D.+Kingsburyauthor=T.+Hideshimaauthor=P.+K.+Shahauthor=S.+Minvielleauthor=M.+Altunauthor=B.+M.+Kesslerauthor=R.+Orlowskiauthor=P.+Richardsonauthor=N.+Munshiauthor=K.+C.+Anderson&title=A+small+molecule+inhibitor+of+ubiquitin-specific+protease-7+induces+apoptosis+in+multiple+myeloma+cells+and+overcomes+bortezomib+resistance&doi=10.1016%2Fj.ccr.2012.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance</span></div><div class="casAuthors">Chauhan, Dharminder; Tian, Ze; Nicholson, Benjamin; Kumar, K. G. Suresh; Zhou, Bin; Carrasco, Ruben; McDermott, Jeffrey L.; Leach, Craig A.; Fulcinniti, Mariaterresa; Kodrasov, Matthew P.; Weinstock, Joseph; Kingsbury, William D.; Hideshima, Teru; Shah, Parantu K.; Minvielle, Stephane; Altun, Mikael; Kessler, Benedikt M.; Orlowski, Robert; Richardson, Paul; Munshi, Nikhil; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">345-358</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Bortezomib therapy has proven successful for the treatment of relapsed/refractory, relapsed, and newly diagnosed multiple myeloma (MM); however, dose-limiting toxicities and the development of resistance limit its long-term utility.  Here, we show that P5091 is an inhibitor of deubiquitylating enzyme USP7, which induces apoptosis in MM cells resistant to conventional and bortezomib therapies.  Biochem. and genetic studies show that blockade of HDM2 and p21 abrogates P5091-induced cytotoxicity.  In animal tumor model studies, P5091 is well tolerated, inhibits tumor growth, and prolongs survival.  Combining P5091 with lenalidomide, HDAC inhibitor SAHA, or dexamethasone triggers synergistic anti-MM activity.  Our preclin. study therefore supports clin. evaluation of USP7 inhibitor, alone or in combination, as a potential MM therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVKqojA-HcmLVg90H21EOLACvtfcHk0ljS3DYRHsWb9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlCju77F&md5=9c70da62de17591850c1e8195d5f97f7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2012.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2012.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DTian%26aufirst%3DZ.%26aulast%3DNicholson%26aufirst%3DB.%26aulast%3DKumar%26aufirst%3DK.%2BG.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DCarrasco%26aufirst%3DR.%26aulast%3DMcDermott%26aufirst%3DJ.%2BL.%26aulast%3DLeach%26aufirst%3DC.%2BA.%26aulast%3DFulcinniti%26aufirst%3DM.%26aulast%3DKodrasov%26aufirst%3DM.%2BP.%26aulast%3DWeinstock%26aufirst%3DJ.%26aulast%3DKingsbury%26aufirst%3DW.%2BD.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DShah%26aufirst%3DP.%2BK.%26aulast%3DMinvielle%26aufirst%3DS.%26aulast%3DAltun%26aufirst%3DM.%26aulast%3DKessler%26aufirst%3DB.%2BM.%26aulast%3DOrlowski%26aufirst%3DR.%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DMunshi%26aufirst%3DN.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DA%2520small%2520molecule%2520inhibitor%2520of%2520ubiquitin-specific%2520protease-7%2520induces%2520apoptosis%2520in%2520multiple%2520myeloma%2520cells%2520and%2520overcomes%2520bortezomib%2520resistance%26jtitle%3DCancer%2520Cell%26date%3D2012%26volume%3D22%26spage%3D345%26epage%3D358%26doi%3D10.1016%2Fj.ccr.2012.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuiatse, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjorklund, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, R. Z.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the MDM2 E3 ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e103015</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0103015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1371%2Fjournal.pone.0103015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=25181509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yrt7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=D.+Guauthor=S.+Wangauthor=I.+Kuiatseauthor=H.+Wangauthor=J.+Heauthor=Y.+Daiauthor=R.+J.+Jonesauthor=C.+C.+Bjorklundauthor=J.+Yangauthor=S.+Grantauthor=R.+Z.+Orlowski&title=Inhibition+of+the+MDM2+E3+ligase+induces+apoptosis+and+autophagy+in+wild-type+and+mutant+p53+models+of+multiple+myeloma%2C+and+acts+synergistically+with+ABT-737&doi=10.1371%2Fjournal.pone.0103015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the MDM2 E3 ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737</span></div><div class="casAuthors">Gu, Dongmin; Wang, Shuhong; Kuiatse, Isere; Wang, Hua; He, Jin; Dai, Yun; Jones, Richard J.; Bjorklund, Chad C.; Yang, Jing; Grant, Steven; Orlowski, Robert Z.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e103015/1-e103015/12, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Intracellular proteolytic pathways have been validated as rational targets in multiple myeloma with the approval of two proteasome inhibitors in this disease, and with the finding that immunomodulatory agents work through an E3 ubiquitin ligase contg. Cereblon.  Another E3 ligase that could be a rational target is the murine double minute (MDM) 2 protein, which plays a role in p53 turnover.  A novel inhibitor of this complex, MI-63, was found to induce apoptosis in p53 wild-type myeloma models in assocn. with activation of a p53-mediated cell death program.  MI-63 overcame adhesion-mediated drug resistance, showed anti-tumor activity in vivo, enhanced the activity of bortezomib and lenalidomide, and also overcame lenalidomide resistance.  In mutant p53 models, inhibition of MDM2 with MI-63 also activated apoptosis, albeit at higher concns., and this was assocd. with activation of autophagy.  When MI-63 was combined with the BH3 mimetic ABT-737, enhanced activity was seen in both wild-type and mutant p53 models.  Finally, this regimen showed efficacy against primary plasma cells from patients with newly diagnosed and relapsed/refractory myeloma.  These findings support the translation of novel MDM2 inhibitors both alone, and in combination with other novel agents, to the clinic for patients with multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokKNSMvmPF2bVg90H21EOLACvtfcHk0ljS3DYRHsWb9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yrt7jP&md5=d29157fc2b710290b3f7cb6d9c2b6f78</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0103015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0103015%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DKuiatse%26aufirst%3DI.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DDai%26aufirst%3DY.%26aulast%3DJones%26aufirst%3DR.%2BJ.%26aulast%3DBjorklund%26aufirst%3DC.%2BC.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DGrant%26aufirst%3DS.%26aulast%3DOrlowski%26aufirst%3DR.%2BZ.%26atitle%3DInhibition%2520of%2520the%2520MDM2%2520E3%2520ligase%2520induces%2520apoptosis%2520and%2520autophagy%2520in%2520wild-type%2520and%2520mutant%2520p53%2520models%2520of%2520multiple%2520myeloma%252C%2520and%2520acts%2520synergistically%2520with%2520ABT-737%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0103015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masszi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzasko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahlis, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pour, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandhu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganly, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoppa, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gimsing, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palumbo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garderet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Touzeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buadi, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laubach, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Bacco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Velde, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Group, T.-M. S.</span></span> <span> </span><span class="NLM_article-title">Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">1621</span>– <span class="NLM_lpage">1634</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1516282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1056%2FNEJMoa1516282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=27119237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOltLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=1621-1634&author=P.+Moreauauthor=T.+Massziauthor=N.+Grzaskoauthor=N.+J.+Bahlisauthor=M.+Hanssonauthor=L.+Pourauthor=I.+Sandhuauthor=P.+Ganlyauthor=B.+W.+Bakerauthor=S.+R.+Jacksonauthor=A.+M.+Stoppaauthor=D.+R.+Simpsonauthor=P.+Gimsingauthor=A.+Palumboauthor=L.+Garderetauthor=M.+Cavoauthor=S.+Kumarauthor=C.+Touzeauauthor=F.+K.+Buadiauthor=J.+P.+Laubachauthor=D.+T.+Bergauthor=J.+Linauthor=A.+Di+Baccoauthor=A.+M.+Huiauthor=H.+van+de+Veldeauthor=P.+G.+Richardsonauthor=T.-M.+S.+Group&title=Oral+ixazomib%2C+lenalidomide%2C+and+dexamethasone+for+multiple+myeloma&doi=10.1056%2FNEJMoa1516282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma</span></div><div class="casAuthors">Moreau, P.; Masszi, T.; Grzasko, N.; Bahlis, N. J.; Hansson, M.; Pour, L.; Sandhu, I.; Ganly, P.; Baker, B. W.; Jackson, S. R.; Stoppa, A.-M.; Simpson, D. R.; Gimsing, P.; Palumbo, A.; Garderet, L.; Cavo, M.; Kumar, S.; Touzeau, C.; Buadi, F. K.; Laubach, J. P.; Berg, D. T.; Lin, J.; Di Bacco, A.; Hui, A.-M.; van de Velde, H.; Richardson, P. G.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1621-1634</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Ixazomib is an oral proteasome inhibitor that is currently being studied for the treatment of multiple myeloma.  In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 722 patients who had relapsed, refractory, or relapsed and refractory multiple myeloma to receive ixazomib plus lenalidomide-dexamethasone (ixazomib group) or placebo plus lenalidomide-dexamethasone (placebo group).  The primary end point was progression-free survival.  Progression-free survival was significantly longer in the ixazomib group than in the placebo group at a median follow-up of 14.7 mo (median progression-free survival, 20.6 mo vs. 14.7 mo; hazard ratio for disease progression or death in the ixazomib group, 0.74; P = 0.01); a benefit with respect to progression-free survival was obsd. with the ixazomib regimen, as compared with the placebo regimen, in all prespecified patient subgroups, including in patients with high-risk cytogenetic abnormalities.  The overall rates of response were 78% in the ixazomib group and 72% in the placebo group, and the corresponding rates of complete response plus very good partial response were 48% and 39%.  The median time to response was 1.1 mo in the ixazomib group and 1.9 mo in the placebo group and the corresponding median duration of response was 20.5 mo and 15.0 mo.  At a median follow-up of approx. 23 mo, the median overall survival has not been reached in either study group, and follow-up is ongoing.  The rates of serious adverse events were similar in the two study groups (47% in the ixazomib group and 49% in the placebo group), as were the rates of death during the study period (4% and 6%, resp.); adverse events of at least grade 3 severity occurred in 74% and 69% of the patients, resp.  Thrombocytopenia of grade 3 and grade 4 severity occurred more frequently in the ixazomib group (12% and 7% of the patients, resp.) than in the placebo group (5% and 4% of the patients, resp.).  Rash occurred more frequently in the ixazomib group than in the placebo group (36% vs. 23% of the patients), as did gastrointestinal adverse events, which were predominantly low grade.  The incidence of peripheral neuropathy was 27% in the ixazomib group and 22% in the placebo group (grade 3 events occurred in 2% of the patients in each study group).  Patient-reported quality of life was similar in the two study groups.  The addn. of ixazomib to a regimen of lenalidomide and dexamethasone was assocd. with significantly longer progression-free survival; the addnl. toxic effects with this all-oral regimen were limited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe5omTDIjGVLVg90H21EOLACvtfcHk0lh0bOM3InF53g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOltLjN&md5=b71bd9b8d3afd6c02e1c541abdb44c0e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1516282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1516282%26sid%3Dliteratum%253Aachs%26aulast%3DMoreau%26aufirst%3DP.%26aulast%3DMasszi%26aufirst%3DT.%26aulast%3DGrzasko%26aufirst%3DN.%26aulast%3DBahlis%26aufirst%3DN.%2BJ.%26aulast%3DHansson%26aufirst%3DM.%26aulast%3DPour%26aufirst%3DL.%26aulast%3DSandhu%26aufirst%3DI.%26aulast%3DGanly%26aufirst%3DP.%26aulast%3DBaker%26aufirst%3DB.%2BW.%26aulast%3DJackson%26aufirst%3DS.%2BR.%26aulast%3DStoppa%26aufirst%3DA.%2BM.%26aulast%3DSimpson%26aufirst%3DD.%2BR.%26aulast%3DGimsing%26aufirst%3DP.%26aulast%3DPalumbo%26aufirst%3DA.%26aulast%3DGarderet%26aufirst%3DL.%26aulast%3DCavo%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DTouzeau%26aufirst%3DC.%26aulast%3DBuadi%26aufirst%3DF.%2BK.%26aulast%3DLaubach%26aufirst%3DJ.%2BP.%26aulast%3DBerg%26aufirst%3DD.%2BT.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DDi%2BBacco%26aufirst%3DA.%26aulast%3DHui%26aufirst%3DA.%2BM.%26aulast%3Dvan%2Bde%2BVelde%26aufirst%3DH.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DGroup%26aufirst%3DT.-M.%2BS.%26atitle%3DOral%2520ixazomib%252C%2520lenalidomide%252C%2520and%2520dexamethasone%2520for%2520multiple%2520myeloma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D1621%26epage%3D1634%26doi%3D10.1056%2FNEJMoa1516282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gallerani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucchetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marangon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noberasco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delmonte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Braud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsoni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cereda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Incalci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sessa, C.</span></span> <span> </span><span class="NLM_article-title">A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">290</span>– <span class="NLM_lpage">296</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2012.09.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2Fj.ejca.2012.09.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=23058787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSnsbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=290-296&author=E.+Galleraniauthor=M.+Zucchettiauthor=D.+Brunelliauthor=E.+Marangonauthor=C.+Noberascoauthor=D.+Hessauthor=A.+Delmonteauthor=G.+Martinelliauthor=S.+Bohmauthor=C.+Driessenauthor=F.+De+Braudauthor=S.+Marsoniauthor=R.+Ceredaauthor=F.+Salaauthor=M.+D%E2%80%99Incalciauthor=C.+Sessa&title=A+first+in+human+phase+I+study+of+the+proteasome+inhibitor+CEP-18770+in+patients+with+advanced+solid+tumours+and+multiple+myeloma&doi=10.1016%2Fj.ejca.2012.09.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma</span></div><div class="casAuthors">Gallerani, Elisa; Zucchetti, Massimo; Brunelli, Dario; Marangon, Elena; Noberasco, Cristina; Hess, Dagmar; Delmonte, Angelo; Martinelli, Giovanni; Bohm, Steffen; Driessen, Christopher; De Braud, Filippo; Marsoni, Silvia; Cereda, Roberta; Sala, Federica; D'Incalci, Maurizio; Sessa, Cristiana</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">290-296</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The safety, pharmacokinetics (PK) and pharmacodynamics of CEP-18770, a new peptide boronic acid proteasome inhibitor, have been investigated after i.v. administration on days 1, 4, 8 and 11 of every 21 d cycle in patients with solid tumors and multiple myeloma (MM).Thirty-eight patients were treated with CEP-18770 at escalating doses from 0.1 to 1.8 mg/m2 where 2 out of 5 patients showed dose limiting toxicities.  The max. tolerated/recommended dose (MTD/RD) of 1.5 mg/m2 was tested in 12 addnl. patients.  Skin rash was dose-limiting and occurred in 53% of patients; other frequent toxicities were asthenia (29%), stomatitis (21%) and pyrexia (16%).  No significant peripheral neuropathy was obsd.  PK in plasma was linear with a half-life of the elimination phase of 62.0 ± 43.5 h.  Proteasome inhibition in peripheral blood mononuclear cells was dose related in MM patients; it was of 45.4 ± 11.5% at the RD.CEP-18770 showed a favorable safety profile with lack of neurotoxicity and linear plasma PK.  The definition of the optimal biol. dose and schedule of treatment is actively pursued because of the high incidence of skin toxicity of the twice a week schedule.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI8KtW1FW2LrVg90H21EOLACvtfcHk0lh0bOM3InF53g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSnsbvK&md5=29f393ac09aebfb7c0a4758fc9436af7</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2012.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2012.09.009%26sid%3Dliteratum%253Aachs%26aulast%3DGallerani%26aufirst%3DE.%26aulast%3DZucchetti%26aufirst%3DM.%26aulast%3DBrunelli%26aufirst%3DD.%26aulast%3DMarangon%26aufirst%3DE.%26aulast%3DNoberasco%26aufirst%3DC.%26aulast%3DHess%26aufirst%3DD.%26aulast%3DDelmonte%26aufirst%3DA.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DBohm%26aufirst%3DS.%26aulast%3DDriessen%26aufirst%3DC.%26aulast%3DDe%2BBraud%26aufirst%3DF.%26aulast%3DMarsoni%26aufirst%3DS.%26aulast%3DCereda%26aufirst%3DR.%26aulast%3DSala%26aufirst%3DF.%26aulast%3DD%25E2%2580%2599Incalci%26aufirst%3DM.%26aulast%3DSessa%26aufirst%3DC.%26atitle%3DA%2520first%2520in%2520human%2520phase%2520I%2520study%2520of%2520the%2520proteasome%2520inhibitor%2520CEP-18770%2520in%2520patients%2520with%2520advanced%2520solid%2520tumours%2520and%2520multiple%2520myeloma%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2013%26volume%3D49%26spage%3D290%26epage%3D296%26doi%3D10.1016%2Fj.ejca.2012.09.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendelson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendell, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillenwater, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arastu-Kapur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span> <span> </span><span class="NLM_article-title">A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">216</span>– <span class="NLM_lpage">224</span>, <span class="refDoi"> DOI: 10.1007/s10637-016-0327-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1007%2Fs10637-016-0327-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=26924128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC28XjslCrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=216-224&author=J.+R.+Infanteauthor=D.+S.+Mendelsonauthor=H.+A.+Burrisauthor=J.+C.+Bendellauthor=A.+W.+Tolcherauthor=M.+S.+Gordonauthor=H.+H.+Gillenwaterauthor=S.+Arastu-Kapurauthor=H.+L.+Wongauthor=K.+P.+Papadopoulos&title=A+first-in-human+dose-escalation+study+of+the+oral+proteasome+inhibitor+oprozomib+in+patients+with+advanced+solid+tumors&doi=10.1007%2Fs10637-016-0327-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors</span></div><div class="casAuthors">Infante, Jeffrey R.; Mendelson, David S.; Burris, Howard A., III; Bendell, Johanna C.; Tolcher, Anthony W.; Gordon, Michael S.; Gillenwater, Heidi H.; Arastu-Kapur, Shirin; Wong, Hansen L.; Papadopoulos, Kyriakos P.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">216-224</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">To det. the dose-limiting toxicities (DLTs), max. tolerated dose (MTD), safety, and pharmacokinetic and pharmacodynamic profiles of the tripeptide epoxyketone proteasome inhibitor oprozomib in patients with advanced refractory or recurrent solid tumors.  Patients received escalating once daily (QD) or split doses of oprozomib on days 1-5 of 14-day cycles (C).  The split-dose arm was implemented and compared in fasted (C1) and fed (C2) states.  Pharmacokinetic samples were collected during C1 and C2.  Proteasome inhibition was evaluated in red blood cells and peripheral blood mononuclear cells.  Forty-four patients (QD, n = 25; split dose, n = 19) were enrolled.  The most common primary tumor types were non-small cell lung cancer (18 %) and colorectal cancer (16%).  In the 180-mg QD cohort, two patients experienced DLTs: grade 3 vomiting and dehydration; grade 3 hypophosphatemia (n = 1 each).  In the split-dose group, three DLTs were obsd. 180-mg cohort: grade 3 hypophosphatemia; 210-mg cohort: grade 5 gastrointestinal hemorrhage and grade 3 hallucinations (n = 1 each).  In the QD and split-dose groups, the MTD was 150 and 180 mg, resp.  Common adverse events (all grades) included nausea (91%), vomiting (86%), and diarrhea (61%).  Peak concns. and total exposure of oprozomib generally increased with the increasing dose.  Oprozomib induced dose-dependent proteasome inhibition.  Best response was stable disease.  While generally low-grade, clin. relevant gastrointestinal toxicities occurred frequently with this oprozomib formulation.  Despite dose-dependent increases in pharmacokinetics and pharmacodynamics, single-agent oprozomib had minimal antitumor activity in this patient population with advanced solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW2c034hrkubVg90H21EOLACvtfcHk0lhkwNOUuAb78g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjslCrtr0%253D&md5=e54838bb160c0886d08c5d0b8cb81a6a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs10637-016-0327-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-016-0327-x%26sid%3Dliteratum%253Aachs%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DMendelson%26aufirst%3DD.%2BS.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DBendell%26aufirst%3DJ.%2BC.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DGordon%26aufirst%3DM.%2BS.%26aulast%3DGillenwater%26aufirst%3DH.%2BH.%26aulast%3DArastu-Kapur%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DH.%2BL.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26atitle%3DA%2520first-in-human%2520dose-escalation%2520study%2520of%2520the%2520oral%2520proteasome%2520inhibitor%2520oprozomib%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2016%26volume%3D34%26spage%3D216%26epage%3D224%26doi%3D10.1007%2Fs10637-016-0327-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmeister, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpaz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanan-Khan, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laubach, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubowiak, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trikha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052–101 Part 1</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">2693</span>– <span class="NLM_lpage">2700</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-12-686378</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1182%2Fblood-2015-12-686378" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=27009059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1ent7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=2693-2700&author=P.+G.+Richardsonauthor=T.+M.+Zimmermanauthor=C.+C.+Hofmeisterauthor=M.+Talpazauthor=A.+A.+Chanan-Khanauthor=J.+L.+Kaufmanauthor=J.+P.+Laubachauthor=D.+Chauhanauthor=A.+J.+Jakubowiakauthor=S.+Reichauthor=M.+Trikhaauthor=K.+C.+Anderson&title=Phase+1+study+of+marizomib+in+relapsed+or+relapsed+and+refractory+multiple+myeloma%3A+NPI-0052%E2%80%93101+Part+1&doi=10.1182%2Fblood-2015-12-686378"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1</span></div><div class="casAuthors">Richardson, Paul G.; Zimmerman, Todd M.; Hofmeister, Craig C.; Talpaz, Moshe; Chanan-Khan, Asher A.; Kaufman, Jonathan L.; Laubach, Jacob P.; Chauhan, Dharminder; Jakubowiak, Andrzej J.; Reich, Steven; Trikha, Mohit; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2693-2700</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Marizomib (MRZ) is a novel, irreversible proteasome inhibitor in clin. development for the treatment of relapsed or relapsed and refractory multiple myeloma (RRMM).  MRZ inhibits the 3 proteolytic activities of the 20S proteasome with specificity distinct from bortezomib and carfilzomib.  StudyNPI-0052-101 Part 1 enrolled relapsed or RRMMpatients into an open-label, dose-escalation design to det. the max. tolerated dose and recommended phase 2 dose (RP2D) of MRZ administered i.v. on 2 different schedules: scheduleA (0.025-0.7mg/m2 once weekly on days 1, 8, and 15 of 4-wk cycles) and schedule B (0.15-0.6 mg/m2 twice weekly on days 1, 4, 8, and 11 of 3-wk cycles; concomitant dexamethasone was allowed with schedule B).  Patients had received an av. of 4.9 and 7.3 prior treatment regimens (schedules A and B, resp.).  MRZ schedule A was administered to 32 patients, and theRP2D was established as 0.7mg/m2 infused over 10 min.  ScheduleBwas administered to 36 patients, and theRP2Dwas detd. to be 0.5 mg/m2 infused over 2 h.  The most common (>20% of patients) related adverse events were fatigue, headache, nausea, diarrhea, dizziness, and vomiting.Six patients achieved clin. benefit responses (defined as minimal response or better), including 5 partial responses (1 patient on schedule A and 4 on schedule B; 3 of these 4 patients received concomitant dexamethasone).  MRZ was generallywell tolerated, and results suggest activity in previously treated RRMMpatients.  Combination studies using pomalidomide and dexamethasone are now underway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPAcz9tcgETLVg90H21EOLACvtfcHk0lhkwNOUuAb78g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1ent7jE&md5=883effc65e2ed7cbc2a3e870737b4afe</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-12-686378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-12-686378%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DZimmerman%26aufirst%3DT.%2BM.%26aulast%3DHofmeister%26aufirst%3DC.%2BC.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DChanan-Khan%26aufirst%3DA.%2BA.%26aulast%3DKaufman%26aufirst%3DJ.%2BL.%26aulast%3DLaubach%26aufirst%3DJ.%2BP.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DJakubowiak%26aufirst%3DA.%2BJ.%26aulast%3DReich%26aufirst%3DS.%26aulast%3DTrikha%26aufirst%3DM.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DPhase%25201%2520study%2520of%2520marizomib%2520in%2520relapsed%2520or%2520relapsed%2520and%2520refractory%2520multiple%2520myeloma%253A%2520NPI-0052%25E2%2580%2593101%2520Part%25201%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26spage%3D2693%26epage%3D2700%26doi%3D10.1182%2Fblood-2015-12-686378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span> <span> </span><span class="NLM_article-title">New investigational drugs with single-agent activity in multiple myeloma</span>. <i>Blood Cancer J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e451</span> <span class="refDoi"> DOI: 10.1038/bcj.2016.53</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1038%2Fbcj.2016.53" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=27471867" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&author=A.+M.+Rajanauthor=S.+Kumar&title=New+investigational+drugs+with+single-agent+activity+in+multiple+myeloma&doi=10.1038%2Fbcj.2016.53"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fbcj.2016.53&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbcj.2016.53%26sid%3Dliteratum%253Aachs%26aulast%3DRajan%26aufirst%3DA.%2BM.%26aulast%3DKumar%26aufirst%3DS.%26atitle%3DNew%2520investigational%2520drugs%2520with%2520single-agent%2520activity%2520in%2520multiple%2520myeloma%26jtitle%3DBlood%2520Cancer%2520J.%26date%3D2016%26volume%3D6%26doi%3D10.1038%2Fbcj.2016.53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vogl, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vij, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikhael, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delforge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparetto, C.</span></span> <span> </span><span class="NLM_article-title">Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma</span>. <i>Leuk. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1080/10428194.2016.1263842</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1080%2F10428194.2016.1263842" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2017&pages=1-11&author=D.+T.+Voglauthor=T.+G.+Martinauthor=R.+Vijauthor=P.+Hariauthor=J.+R.+Mikhaelauthor=D.+Siegelauthor=K.+L.+Wuauthor=M.+Delforgeauthor=C.+Gasparetto&title=Phase+I%2FII+study+of+the+novel+proteasome+inhibitor+delanzomib+%28CEP-18770%29+for+relapsed+and+refractory+multiple+myeloma&doi=10.1080%2F10428194.2016.1263842"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1080%2F10428194.2016.1263842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428194.2016.1263842%26sid%3Dliteratum%253Aachs%26aulast%3DVogl%26aufirst%3DD.%2BT.%26aulast%3DMartin%26aufirst%3DT.%2BG.%26aulast%3DVij%26aufirst%3DR.%26aulast%3DHari%26aufirst%3DP.%26aulast%3DMikhael%26aufirst%3DJ.%2BR.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DK.%2BL.%26aulast%3DDelforge%26aufirst%3DM.%26aulast%3DGasparetto%26aufirst%3DC.%26atitle%3DPhase%2520I%252FII%2520study%2520of%2520the%2520novel%2520proteasome%2520inhibitor%2520delanzomib%2520%2528CEP-18770%2529%2520for%2520relapsed%2520and%2520refractory%2520multiple%2520myeloma%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2017%26volume%3D58%26spage%3D1%26epage%3D11%26doi%3D10.1080%2F10428194.2016.1263842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harshbarger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diedrich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchettini, J.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human 20S proteasome in complex with carfilzomib</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">418</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1016/j.str.2014.11.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2Fj.str.2014.11.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=25599644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtF2msbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=418-424&author=W.+Harshbargerauthor=C.+Millerauthor=C.+Diedrichauthor=J.+Sacchettini&title=Crystal+structure+of+the+human+20S+proteasome+in+complex+with+carfilzomib&doi=10.1016%2Fj.str.2014.11.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Human 20S Proteasome in Complex with Carfilzomib</span></div><div class="casAuthors">Harshbarger, Wayne; Miller, Chase; Diedrich, Chandler; Sacchettini, James</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">418-424</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Proteasome inhibition is highly effective as a treatment for multiple myeloma, and recently carfilzomib was granted US FDA approval for the treatment of relapsed and refractory multiple myeloma.  Here, we report the X-ray crystal structure of the human constitutive 20S proteasome with and without carfilzomib bound at 2.9 and 2.6 Å, resp.  Our data indicate that the S3 and S4 binding pockets play a pivotal role in carfilzomib's selectivity for chymotrypsin-like sites.  Structural comparison with the mouse immunoproteasome crystal structure reveals amino acid substitutions that explain carfilzomib's slight preference for chymotrypsin-like subunits of constitutive proteasomes.  In addn., comparison of the human proteasome:carfilzomib complex with the mouse proteasome:PR-957 complex reveals new details that explain why PR-957 is selective for immunoproteasomes.  Together, the data presented here support the design of inhibitors for either constitutive or immunoproteasomes, with implications for the treatment of cancers as well as autoimmune and neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQfIgWQjhexbVg90H21EOLACvtfcHk0liUm_1iTZvSYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtF2msbg%253D&md5=0249966770dad6c25b7844fb1cea59b1</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2014.11.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2014.11.017%26sid%3Dliteratum%253Aachs%26aulast%3DHarshbarger%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DC.%26aulast%3DDiedrich%26aufirst%3DC.%26aulast%3DSacchettini%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%252020S%2520proteasome%2520in%2520complex%2520with%2520carfilzomib%26jtitle%3DStructure%26date%3D2015%26volume%3D23%26spage%3D418%26epage%3D424%26doi%3D10.1016%2Fj.str.2014.11.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crotchett, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slaughter, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMartino, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogol, E. P.</span></span> <span> </span><span class="NLM_article-title">Formation of proteasome-PA700 complexes directly correlates with activation of peptidase activity</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">12927</span>– <span class="NLM_lpage">12932</span>, <span class="refDoi"> DOI: 10.1021/bi981482i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi981482i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADyaK1cXlsFSkt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=12927-12932&author=G.+M.+Adamsauthor=B.+Crotchettauthor=C.+A.+Slaughterauthor=G.+N.+DeMartinoauthor=E.+P.+Gogol&title=Formation+of+proteasome-PA700+complexes+directly+correlates+with+activation+of+peptidase+activity&doi=10.1021%2Fbi981482i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Formation of Proteasome-PA700 Complexes Directly Correlates with Activation of Peptidase Activity</span></div><div class="casAuthors">Adams, George M.; Crotchett, Brad; Slaughter, Clive A.; DeMartino, George N.; Gogol, Edward P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">12927-12932</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The proteolytic activity of the eukaryotic 20S proteasome is stimulated by a multisubunit activator, PA700, which forms both 1:1 and 2:1 complexes with the proteasome.  Formation of the complexes is enhanced by an addnl. protein assembly called modulator, which also stimulates the enzymic activity of the proteasome only in the presence of PA700.  Here we show that the binding of PA700 to the proteasome is cooperative, as is the activation of the proteasome's intrinsic peptidase activity.  Modulator increases the extent of complex formation and peptidase activation, while preserving the cooperative kinetics.  Furthermore, the increase in activity is not linear with the no. of PA700 assemblies bound to the proteasome, but rather with the no. of proteasome-PA700 complexes, regardless of the PA700:proteasome stoichiometry.  Hence the stimulation of peptidase activity is fully (or almost fully) effected by the binding of a single PA700 to the 20S proteasome.  The stimulation of peptidase by modulator is explained entirely by the increased no. of proteasome-PA700 complexes formed in its presence, rather than by any substantial direct stimulation of catalysis.  These observations are consistent with a model in which PA700, either alone or assisted by modulator, promotes conformational changes in the proteasome that activate the catalytic sites and/or facilitate access of peptide substrates to these sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMxmr_oOyVTrVg90H21EOLACvtfcHk0lhmypBEONIQ6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlsFSkt7k%253D&md5=b94171e60e10e409a51e74c4a85dc23d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fbi981482i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi981482i%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DG.%2BM.%26aulast%3DCrotchett%26aufirst%3DB.%26aulast%3DSlaughter%26aufirst%3DC.%2BA.%26aulast%3DDeMartino%26aufirst%3DG.%2BN.%26aulast%3DGogol%26aufirst%3DE.%2BP.%26atitle%3DFormation%2520of%2520proteasome-PA700%2520complexes%2520directly%2520correlates%2520with%2520activation%2520of%2520peptidase%2520activity%26jtitle%3DBiochemistry%26date%3D1998%26volume%3D37%26spage%3D12927%26epage%3D12932%26doi%3D10.1021%2Fbi981482i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Micale, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarbaci, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troiano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zappala, M.</span></span> <span> </span><span class="NLM_article-title">Peptide-based proteasome inhibitors in anticancer drug design</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1001</span>– <span class="NLM_lpage">1069</span>, <span class="refDoi"> DOI: 10.1002/med.21312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1002%2Fmed.21312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=24585725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1KisrjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=1001-1069&author=N.+Micaleauthor=K.+Scarbaciauthor=V.+Troianoauthor=R.+Ettariauthor=S.+Grassoauthor=M.+Zappala&title=Peptide-based+proteasome+inhibitors+in+anticancer+drug+design&doi=10.1002%2Fmed.21312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide-Based Proteasome Inhibitors in Anticancer Drug Design</span></div><div class="casAuthors">Micale, Nicola; Scarbaci, Kety; Troiano, Valeria; Ettari, Roberta; Grasso, Silvana; Zappala, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1001-1069</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The identification of the key role of the eukaryotic 26S proteasome in regulated intracellular proteolysis and its importance as a target in many pathol. conditions wherein the proteasomal activity is defective (e.g., malignancies, autoimmune diseases, neurodegenerative diseases, etc.) prompted several research groups to the development of specific inhibitors of this multicatalytic complex with the aim of obtaining valid drug candidates.  In regard to the anticancer therapy, the peptide boronate bortezomib (Velcade) represents the first mol. approved by FDA for the treatment of multiple myeloma in 2003 and mantle cell lymphoma in 2006.  Since then, a plethora of mols. targeting the proteasome have been identified as potential anticancer agents and a few of them reached clin. trials or are already in the market (i.e., carfilzomib; Kyprolis).  In most cases, the design of new proteasome inhibitors (PIs) takes into account a proven peptide or pseudopeptide motif as a base structure and places other chem. entities throughout the peptide skeleton in such a way to create an efficacious network of interactions within the catalytic sites.  The purpose of this review is to provide an in-depth look at the current state of the research in the field of peptide-based PIs, specifically those ones that might find an application as anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvlA1JIUEG-rVg90H21EOLACvtfcHk0lgrku3kJKiSEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1KisrjI&md5=872c775a6c36b1c4d26e39e4a5237ae7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fmed.21312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21312%26sid%3Dliteratum%253Aachs%26aulast%3DMicale%26aufirst%3DN.%26aulast%3DScarbaci%26aufirst%3DK.%26aulast%3DTroiano%26aufirst%3DV.%26aulast%3DEttari%26aufirst%3DR.%26aulast%3DGrasso%26aufirst%3DS.%26aulast%3DZappala%26aufirst%3DM.%26atitle%3DPeptide-based%2520proteasome%2520inhibitors%2520in%2520anticancer%2520drug%2520design%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2014%26volume%3D34%26spage%3D1001%26epage%3D1069%26doi%3D10.1002%2Fmed.21312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattarai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span> <span> </span><span class="NLM_article-title">H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4089</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-40635-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1038%2Fs41598-019-40635-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=30858500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A280%3ADC%252BB3cbivVGktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=4089&author=M.+J.+Leeauthor=Z.+Millerauthor=J.+E.+Parkauthor=D.+Bhattaraiauthor=W.+Leeauthor=K.+B.+Kim&title=H727+cells+are+inherently+resistant+to+the+proteasome+inhibitor+carfilzomib%2C+yet+require+proteasome+activity+for+cell+survival+and+growth&doi=10.1038%2Fs41598-019-40635-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth</span></div><div class="casAuthors">Lee Min Jae; Miller Zachary; Bhattarai Deepak; Kim Kyung Bo; Park Ji Eun; Lee Wooin</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4089</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The second-in-class proteasome inhibitor (PI) carfilzomib (Kyprolis, Cfz) has contributed to a substantial advancement in multiple myeloma treatment by improving patient survival and quality of life.  A considerable portion of patients however display intrinsic resistance to Cfz.  Our mechanistic understanding of intrinsic Cfz resistance is limited due to a lack of suitable cell-based models.  We report that H727 human bronchial carcinoid cells are inherently resistant to Cfz, yet susceptible to other PIs and inhibitors targeting upstream components of the ubiquitin-proteasome system (UPS).  These results indicate that H727 cells remain dependent on the UPS for cell survival and growth despite harboring intrinsic resistance to Cfz.  Alterations in the composition of proteasome catalytic subunits via interferon-γ treatment or siRNA knockdown results in sensitization of H727 cells to Cfz.  We postulate that a potential link may exist between the composition of proteasome catalytic subunits and the cellular response to Cfz.  Overall, H727 cells may serve as a useful cell-based model for de novo Cfz resistance and our results suggest previously unexplored mechanisms of de novo PI resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHLlRY4-lmF3T4ugvCDgnZfW6udTcc2ea3fL8lNVvVX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbivVGktw%253D%253D&md5=2eac99d394dd7fa2e1fe2922cd32b87f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-40635-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-40635-1%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.%2BJ.%26aulast%3DMiller%26aufirst%3DZ.%26aulast%3DPark%26aufirst%3DJ.%2BE.%26aulast%3DBhattarai%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DKim%26aufirst%3DK.%2BB.%26atitle%3DH727%2520cells%2520are%2520inherently%2520resistant%2520to%2520the%2520proteasome%2520inhibitor%2520carfilzomib%252C%2520yet%2520require%2520proteasome%2520activity%2520for%2520cell%2520survival%2520and%2520growth%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26spage%3D4089%26doi%3D10.1038%2Fs41598-019-40635-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cyrus, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span> <span> </span><span class="NLM_article-title">Towards immunoproteasome-specific inhibitors: an improved synthesis of dihydroeponemycin</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2005</i></span>,  <span class="NLM_fpage">4829</span>– <span class="NLM_lpage">4834</span>, <span class="refDoi"> DOI: 10.1002/ejoc.200500437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1002%2Fejoc.200500437" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2005&publication_year=2005&pages=4829-4834&author=A.+Hoauthor=K.+Cyrusauthor=K.+B.+Kim&title=Towards+immunoproteasome-specific+inhibitors%3A+an+improved+synthesis+of+dihydroeponemycin&doi=10.1002%2Fejoc.200500437"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fejoc.200500437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.200500437%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DA.%26aulast%3DCyrus%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DK.%2BB.%26atitle%3DTowards%2520immunoproteasome-specific%2520inhibitors%253A%2520an%2520improved%2520synthesis%2520of%2520dihydroeponemycin%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2005%26volume%3D2005%26spage%3D4829%26epage%3D4834%26doi%3D10.1002%2Fejoc.200500437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span> <span> </span><span class="NLM_article-title">Efficacy of carfilzomib in the treatment of relapsed and (or) refractory multiple myeloma: a meta-analysis of data from clinical trials</span>. <i>Discov Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">199</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=27875670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A280%3ADC%252BC2snpt1Gruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=189-199&author=R.+Chenauthor=B.+Chenauthor=X.+Zhangauthor=C.+Gao&title=Efficacy+of+carfilzomib+in+the+treatment+of+relapsed+and+%28or%29+refractory+multiple+myeloma%3A+a+meta-analysis+of+data+from+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of carfilzomib in the treatment of relapsed and (or) refractory multiple myeloma: a meta-analysis of data from clinical trials</span></div><div class="casAuthors">Chen Runzhe; Chen Baoan; Zhang Xiaoping; Gao Chong</div><div class="citationInfo"><span class="NLM_cas:title">Discovery medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">121</span>),
    <span class="NLM_cas:pages">189-199</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Recently, carfilzomib has become a promising therapeutic approach for relapsed and (or) refractory multiple myeloma (RRMM), but no study has summarized the overall effect of carfilzomib in RRMM.  To explore the role of carfilzomib, we performed a meta-analysis of all known prospective clinical trials to assess the efficacy of carfilzomib in patients with RRMM.  METHODS AND MATERIALS:  A systematic review of publications was performed on December 15, 2015.  Eight studies including 1,446 patients were identified.  Meta-analyses were carried out to calculate the overall response rate (ORR), complete response rate (CRR), and clinical benefit rate (CBR) of carfilzomib for RRMM.  RESULTS:  In patients with RRMM, ORR was 0.44, CRR was 0.13, and CBR was 0.54.  High heterogeneity between studies was observed, and funnel plots were symmetrical, negating publication bias.  Carfilzomib was generally well tolerated by patients reported in the studies though some manageable adverse effects occurred.  CONCLUSION:  Our analysis revealed a promising benefit of carfilzomib in the treatment of RRMM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQIx2Jf5i2yFyCEBeYuoi7AfW6udTcc2ea3WvA2Z18Cdrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snpt1Gruw%253D%253D&md5=72f2e237d747625c19bc4588dc95a5b5</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DC.%26atitle%3DEfficacy%2520of%2520carfilzomib%2520in%2520the%2520treatment%2520of%2520relapsed%2520and%2520%2528or%2529%2520refractory%2520multiple%2520myeloma%253A%2520a%2520meta-analysis%2520of%2520data%2520from%2520clinical%2520trials%26jtitle%3DDiscov%2520Med.%26date%3D2016%26volume%3D22%26spage%3D189%26epage%3D199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hawley, T.
S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riz, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakabayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depalma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawley, R. G.</span></span> <span> </span><span class="NLM_article-title">Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1</span>. <i>Am. J. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1002/ajh.23387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1002%2Fajh.23387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=23475625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC3sXks1GhsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2013&pages=265-272&author=T.%0AS.+Hawleyauthor=I.+Rizauthor=W.+Yangauthor=Y.+Wakabayashiauthor=L.+Depalmaauthor=Y.+T.+Changauthor=W.+Pengauthor=J.+Zhuauthor=R.+G.+Hawley&title=Identification+of+an+ABCB1+%28P-glycoprotein%29-positive+carfilzomib-resistant+myeloma+subpopulation+by+the+pluripotent+stem+cell+fluorescent+dye+CDy1&doi=10.1002%2Fajh.23387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1</span></div><div class="casAuthors">Hawley, Teresa S.; Riz, Irene; Yang, Wenjing; Wakabayashi, Yoshiyuki; DePalma, Louis; Chang, Young-Tae; Peng, Weiqun; Zhu, Jun; Hawley, Robert G.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Hematology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">265-272</span>CODEN:
                <span class="NLM_cas:coden">AJHEDD</span>;
        ISSN:<span class="NLM_cas:issn">0361-8609</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Multiple myeloma (MM) is characterized by the malignant expansion of differentiated plasma cells.  Although many chemotherapeutic agents display cytotoxic activity toward MM cells, patients inevitably succumb to their disease because the tumor cells become resistant to the anticancer drugs.  The cancer stem cell hypothesis postulates that a small subpopulation of chemotherapy-resistant cancer cells is responsible for propagation of the tumor.  Herein we report that efflux of the pluripotent stem cell dye CDy1 identifies a subpopulation in MM cell lines characterized by increased expression of P-glycoprotein, a member of the ABC (ATP-binding cassette) superfamily of transporters encoded by ABCB1.  We also demonstrate that ABCB1-overexpressing MM cells are resistant to the second-generation proteasome inhibitor carfilzomib that recently received accelerated approval for the treatment of therapy-refractive MM by the U.S. Food and Drug Administration.  Moreover, increased resistance to carfilzomib in sensitive MM cells following drug selection was assocd. with upregulation of ABCB1 cell-surface expression which correlated with increased transporter activity as measured by CDy1 efflux.  We further show that chemosensitization of MM cells to carfilzomib could be achieved in vitro by cotreatment with vismodegib, a hedgehog pathway antagonist which is currently in MM clin. trials.  CDy1 efflux may therefore be a useful assay to det. whether high expression of ABCB1 is predictive of poor clin. responses in MM patients treated with carfilzomib.  Our data also suggest that inclusion of vismodegib might be a potential strategy to reverse ABCB1-mediated drug resistance should it occur.  Am. J. Hematol. 88:265-272, 2013. © 2013 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-sWqm6QARJbVg90H21EOLACvtfcHk0lgwUi-CpZvBVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXks1GhsbY%253D&md5=34dbd19b95a258bbbbe123dce1102b58</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fajh.23387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajh.23387%26sid%3Dliteratum%253Aachs%26aulast%3DHawley%26aufirst%3DT.%2BS.%26aulast%3DRiz%26aufirst%3DI.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DWakabayashi%26aufirst%3DY.%26aulast%3DDepalma%26aufirst%3DL.%26aulast%3DChang%26aufirst%3DY.%2BT.%26aulast%3DPeng%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DHawley%26aufirst%3DR.%2BG.%26atitle%3DIdentification%2520of%2520an%2520ABCB1%2520%2528P-glycoprotein%2529-positive%2520carfilzomib-resistant%2520myeloma%2520subpopulation%2520by%2520the%2520pluripotent%2520stem%2520cell%2520fluorescent%2520dye%2520CDy1%26jtitle%3DAm.%2520J.%2520Hematol.%26date%3D2013%26volume%3D88%26spage%3D265%26epage%3D272%26doi%3D10.1002%2Fajh.23387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span> <span> </span><span class="NLM_article-title">Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2197</span>– <span class="NLM_lpage">2205</span>, <span class="refDoi"> DOI: 10.1021/mp300044b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp300044b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC38XptFCju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=2197-2205&author=L.+Aoauthor=Y.+Wuauthor=D.+Kimauthor=E.+R.+Jangauthor=K.+Kimauthor=D.+M.+Leeauthor=K.+B.+Kimauthor=W.+Lee&title=Development+of+peptide-based+reversing+agents+for+p-glycoprotein-mediated+resistance+to+carfilzomib&doi=10.1021%2Fmp300044b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Peptide-Based Reversing Agents for P-Glycoprotein-Mediated Resistance to Carfilzomib</span></div><div class="casAuthors">Ao, Lin; Wu, Ying; Kim, Donghern; Jang, Eun Ryoung; Kim, Kyunghwa; Lee, Do-min; Kim, Kyung Bo; Lee, Wooin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2197-2205</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Carfilzomib is a novel class of peptidyl epoxyketone proteasome inhibitor and has demonstrated promising activity in multiple clin. trials to treat patients with multiple myeloma and other types of cancers.  Here, we investigated mol. mechanisms underlying acquired resistance to carfilzomib and a potential strategy to restore cellular sensitivity to carfilzomib.  H23 and DLD-1 cells (human lung and colon adenocarcinoma cell lines) with acquired resistance to carfilzomib displayed marked cross-resistance to YU-101, a closely related proteasome inhibitor, and paclitaxel, a known substrate of Pgp.  However, carfilzomib-resistant cells remained sensitive to bortezomib, a clin. used dipeptide with boronic acid pharmacophore.  In accordance with these observations, carfilzomib-resistant H23 and DLD-1 cells showed marked upregulation of P-glycoprotein (Pgp) as compared to their parental controls, and coincubation with verapamil, a Pgp inhibitor, led to an almost complete restoration of cellular sensitivity to carfilzomib.  These results indicate that Pgp upregulation plays a major role in the development of carfilzomib resistance in these cell lines.  In developing a potential strategy to overcome carfilzomib resistance, we as a proof of concept prepd. a small library of peptide analogs derived from the peptide backbone of carfilzomib and screened these mols. for their activity to restore carfilzomib sensitivity when cotreated with carfilzomib.  We found that compds. as small as dipeptides are sufficient in restoring carfilzomib sensitivity.  Taken together, we found that Pgp upregulation plays a major role in the development of resistance to carfilzomib in lung and colon adenocarcinoma cell lines and that small peptide analogs lacking the pharmacophore can be used as agents to reverse acquired carfilzomib resistance.  Our findings may provide important information in developing a potential strategy to overcome drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrslgMOfDD53rVg90H21EOLACvtfcHk0ljEmiCUAol_xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptFCju7c%253D&md5=ba90f3b18f9e4cc80cf1fc72d523fb5c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fmp300044b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp300044b%26sid%3Dliteratum%253Aachs%26aulast%3DAo%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DJang%26aufirst%3DE.%2BR.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DD.%2BM.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DLee%26aufirst%3DW.%26atitle%3DDevelopment%2520of%2520peptide-based%2520reversing%2520agents%2520for%2520p-glycoprotein-mediated%2520resistance%2520to%2520carfilzomib%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26spage%3D2197%26epage%3D2205%26doi%3D10.1021%2Fmp300044b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gutman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boise, L. H.</span></span> <span> </span><span class="NLM_article-title">Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2181</span>– <span class="NLM_lpage">2183</span>, <span class="refDoi"> DOI: 10.1038/leu.2009.123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1038%2Fleu.2009.123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=19516276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A280%3ADC%252BD1MjltVyntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=2181-2183&author=D.+Gutmanauthor=A.+A.+Moralesauthor=L.+H.+Boise&title=Acquisition+of+a+multidrug-resistant+phenotype+with+a+proteasome+inhibitor+in+multiple+myeloma&doi=10.1038%2Fleu.2009.123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma</span></div><div class="casAuthors">Gutman D; Morales A A; Boise L H</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2181-3</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT1aBKLYf2evEBuFdjgVNKSfW6udTcc2eZz4_kmBJpe4Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MjltVyntg%253D%253D&md5=7ae86eb631925aa5cc65b409072142bf</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fleu.2009.123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2009.123%26sid%3Dliteratum%253Aachs%26aulast%3DGutman%26aufirst%3DD.%26aulast%3DMorales%26aufirst%3DA.%2BA.%26aulast%3DBoise%26aufirst%3DL.%2BH.%26atitle%3DAcquisition%2520of%2520a%2520multidrug-resistant%2520phenotype%2520with%2520a%2520proteasome%2520inhibitor%2520in%2520multiple%2520myeloma%26jtitle%3DLeukemia%26date%3D2009%26volume%3D23%26spage%3D2181%26epage%3D2183%26doi%3D10.1038%2Fleu.2009.123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vij, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubowiak, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonial, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukreti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahlis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanan-Khan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buadi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reu, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somlo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zonder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmauer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wear, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, R. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagannath, S.</span></span> <span> </span><span class="NLM_article-title">A phase 2 study of single-agent carfilzomib (PX-171–003-A1) in patients with relapsed and refractory multiple myeloma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">2817</span>– <span class="NLM_lpage">2825</span>, <span class="refDoi"> DOI: 10.1182/blood-2012-05-425934</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1182%2Fblood-2012-05-425934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=22833546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFaksLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2012&pages=2817-2825&author=D.+S.+Siegelauthor=T.+Martinauthor=M.+Wangauthor=R.+Vijauthor=A.+J.+Jakubowiakauthor=S.+Lonialauthor=S.+Trudelauthor=V.+Kukretiauthor=N.+Bahlisauthor=M.+Alsinaauthor=A.+Chanan-Khanauthor=F.+Buadiauthor=F.+J.+Reuauthor=G.+Somloauthor=J.+Zonderauthor=K.+Songauthor=A.+K.+Stewartauthor=E.+Stadtmauerauthor=L.+Kunkelauthor=S.+Wearauthor=A.+F.+Wongauthor=R.+Z.+Orlowskiauthor=S.+Jagannath&title=A+phase+2+study+of+single-agent+carfilzomib+%28PX-171%E2%80%93003-A1%29+in+patients+with+relapsed+and+refractory+multiple+myeloma&doi=10.1182%2Fblood-2012-05-425934"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma</span></div><div class="casAuthors">Siegel, David S.; Martin, Thomas; Wang, Michael; Vij, Ravi; Jakubowiak, Andrzej J.; Lonial, Sagar; Trudel, Suzanne; Kukreti, Vishal; Bahlis, Nizar; Alsina, Melissa; Chanan-Khan, Asher; Buadi, Francis; Reu, Frederic J.; Somlo, George; Zonder, Jeffrey; Song, Kevin; Stewart, A. Keith; Stadtmauer, Edward; Kunkel, Lori; Wear, Sandra; Wong, Alvin F.; Orlowski, Robert Z.; Jagannath, Sundar</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2817-2825</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Carfilzomib is a next-generation, selective proteasome inhibitor being evaluated for the treatment of relapsed and refractory multiple myeloma.  In this open-label, single-arm phase 2 study (PX-171-003-A1), patients received single-agent carfilzomib 20 mg/m2 i.v. twice weekly for 3 of 4 wk in cycle 1, then 27 mg/m2 for ≤ 12 cycles.  The primary endpoint was overall response rate (≥ partial response).  Secondary endpoints included clin. benefit response rate (≥ minimal response), duration of response, progression-free survival, overall survival, and safety.  A total of 266 patients were evaluable for safety, 257 for efficacy; 95% were refractory to their last therapy; 80% were refractory or intolerant to both bortezomib and lenalidomide.  Patients had median of 5 prior lines of therapy, including bortezomib, lenalidomide, and thalidomide.  Overall response rate was 23.7% with median duration of response of 7.8 mo.  Median overall survival was 15.6 mo.  Adverse events (AEs) were manageable without cumulative toxicities.  Common AEs were fatigue (49%), anemia (46%), nausea (45%), and thrombocytopenia (39%).  Thirty-three patients (12.4%) experienced peripheral neuropathy, primarily grades 1 or 2.  Thirty-three patients (12.4%) withdrew because of an AE.  Durable responses and an acceptable tolerability profile in this heavily pretreated population demonstrate the potential of carfilzomib to offer meaningful clin. benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptn9sXStS-8LVg90H21EOLACvtfcHk0ljEmiCUAol_xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFaksLbM&md5=f96b01b750ff27ea4097c5aba4453bcb</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1182%2Fblood-2012-05-425934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2012-05-425934%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DD.%2BS.%26aulast%3DMartin%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DVij%26aufirst%3DR.%26aulast%3DJakubowiak%26aufirst%3DA.%2BJ.%26aulast%3DLonial%26aufirst%3DS.%26aulast%3DTrudel%26aufirst%3DS.%26aulast%3DKukreti%26aufirst%3DV.%26aulast%3DBahlis%26aufirst%3DN.%26aulast%3DAlsina%26aufirst%3DM.%26aulast%3DChanan-Khan%26aufirst%3DA.%26aulast%3DBuadi%26aufirst%3DF.%26aulast%3DReu%26aufirst%3DF.%2BJ.%26aulast%3DSomlo%26aufirst%3DG.%26aulast%3DZonder%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DStewart%26aufirst%3DA.%2BK.%26aulast%3DStadtmauer%26aufirst%3DE.%26aulast%3DKunkel%26aufirst%3DL.%26aulast%3DWear%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DA.%2BF.%26aulast%3DOrlowski%26aufirst%3DR.%2BZ.%26aulast%3DJagannath%26aufirst%3DS.%26atitle%3DA%2520phase%25202%2520study%2520of%2520single-agent%2520carfilzomib%2520%2528PX-171%25E2%2580%2593003-A1%2529%2520in%2520patients%2520with%2520relapsed%2520and%2520refractory%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2012%26volume%3D120%26spage%3D2817%26epage%3D2825%26doi%3D10.1182%2Fblood-2012-05-425934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargagna-Mohan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span> <span> </span><span class="NLM_article-title">LMP2-specific inhibitors: Novel chemical genetic tools for proteasome biology</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2007.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2Fj.chembiol.2007.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=17462577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkslaitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=419-430&author=Y.+K.+Hoauthor=P.+Bargagna-Mohanauthor=R.+Mohanauthor=K.+B.+Kim&title=LMP2-specific+inhibitors%3A+Novel+chemical+genetic+tools+for+proteasome+biology&doi=10.1016%2Fj.chembiol.2007.03.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">LMP2-Specific Inhibitors: Chemical Genetic Tools for Proteasome Biology</span></div><div class="casAuthors">Ho, Yik Khuan; Bargagna-Mohan, Paola; Wehenkel, Marie; Mohan, Royce; Kim, Kyung-Bo</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">419-430</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The immunoproteasome, having been linked to neurodegenerative diseases and hematol. cancers, has been shown to play an important role in MHC class I antigen presentation.  However, its other pathophysiol. functions are still not very well understood.  This can be attributed mainly to a lack of appropriate mol. probes that can selectively modulate the immunoproteasome catalytic subunits.  Herein, the authors report the development of mol. probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome.  The authors show that these compds. irreversibly modify the LMP2 subunit with high specificity.  Importantly, LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of malignant tumors that highly express LMP2.  Thus, the development of the immunoproteasome catalytic subunit LMP2-specific inhibitors may not only hold great potential as a therapeutic agent for certain diseases but can also provide a valuable chem. genetic probe to investigate immunoproteasome biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDvEUufIJ3K7Vg90H21EOLACvtfcHk0livD7Ts9AqsVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkslaitbY%253D&md5=d12fa5065f6bdd4aee8ad12491a1c072</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2007.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2007.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DY.%2BK.%26aulast%3DBargagna-Mohan%26aufirst%3DP.%26aulast%3DMohan%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DK.%2BB.%26atitle%3DLMP2-specific%2520inhibitors%253A%2520Novel%2520chemical%2520genetic%2520tools%2520for%2520proteasome%2520biology%26jtitle%3DChem.%2520Biol.%26date%3D2007%26volume%3D14%26spage%3D419%26epage%3D430%26doi%3D10.1016%2Fj.chembiol.2007.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Bruin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Rooden, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Ayed, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisselev, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Stelt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Marel, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of beta1i or beta5i specific inhibitors of human immunoproteasomes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">6197</span>– <span class="NLM_lpage">6209</span>, <span class="refDoi"> DOI: 10.1021/jm500716s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500716s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6197-6209&author=G.+de%0ABruinauthor=E.+M.+Huberauthor=B.+T.+Xinauthor=E.+J.+van+Roodenauthor=K.+Al-Ayedauthor=K.+B.+Kimauthor=A.+F.+Kisselevauthor=C.+Driessenauthor=M.+van+der+Steltauthor=G.+A.+van+der+Marelauthor=M.+Grollauthor=H.+S.+Overkleeft&title=Structure-based+design+of+beta1i+or+beta5i+specific+inhibitors+of+human+immunoproteasomes&doi=10.1021%2Fjm500716s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm500716s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500716s%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BBruin%26aufirst%3DG.%26aulast%3DHuber%26aufirst%3DE.%2BM.%26aulast%3DXin%26aufirst%3DB.%2BT.%26aulast%3Dvan%2BRooden%26aufirst%3DE.%2BJ.%26aulast%3DAl-Ayed%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DKisselev%26aufirst%3DA.%2BF.%26aulast%3DDriessen%26aufirst%3DC.%26aulast%3Dvan%2Bder%2BStelt%26aufirst%3DM.%26aulast%3Dvan%2Bder%2BMarel%26aufirst%3DG.%2BA.%26aulast%3DGroll%26aufirst%3DM.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26atitle%3DStructure-based%2520design%2520of%2520beta1i%2520or%2520beta5i%2520specific%2520inhibitors%2520of%2520human%2520immunoproteasomes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6197%26epage%3D6209%26doi%3D10.1021%2Fjm500716s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huber, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinemeyer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groettrup, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span> <span> </span><span class="NLM_article-title">Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">738</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2011.12.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2Fj.cell.2011.12.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=22341445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtV2qsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2012&pages=727-738&author=E.+M.+Huberauthor=M.+Baslerauthor=R.+Schwabauthor=W.+Heinemeyerauthor=C.+J.+Kirkauthor=M.+Groettrupauthor=M.+Groll&title=Immuno-+and+constitutive+proteasome+crystal+structures+reveal+differences+in+substrate+and+inhibitor+specificity&doi=10.1016%2Fj.cell.2011.12.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity</span></div><div class="casAuthors">Huber, Eva M.; Basler, Michael; Schwab, Ricarda; Heinemeyer, Wolfgang; Kirk, Christopher J.; Groettrup, Marcus; Groll, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">727-738</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Constitutive proteasomes and immunoproteasomes shape the peptide repertoire presented by major histocompatibility complex class I (MHC-I) mols. by harboring different sets of catalytically active subunits.  Here, we present the crystal structures of constitutive proteasomes and immunoproteasomes from mouse in the presence and absence of the epoxyketone inhibitor PR-957 (ONX 0914) at 2.9 Å resoln.  Based on our X-ray data, we propose a unique catalytic feature for the immunoproteasome subunit β5i/LMP7.  Comparison of ligand-free and ligand-bound proteasomes reveals conformational changes in the S1 pocket of β5c/X but not β5i, thereby explaining the selectivity of PR-957 for β5i.  Time-resolved structures of yeast proteasome:PR-957 complexes indicate that ligand docking to the active site occurs only via the reactive head group and the P1 side chain.  Together, our results support structure-guided design of inhibitory lead structures selective for immunoproteasomes that are linked to cytokine prodn. and diseases like cancer and autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2OWN02GZMFbVg90H21EOLACvtfcHk0livD7Ts9AqsVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtV2qsL8%253D&md5=ee9f24ec6a0720808e4baf27bf87fcad</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.12.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.12.030%26sid%3Dliteratum%253Aachs%26aulast%3DHuber%26aufirst%3DE.%2BM.%26aulast%3DBasler%26aufirst%3DM.%26aulast%3DSchwab%26aufirst%3DR.%26aulast%3DHeinemeyer%26aufirst%3DW.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DGroettrup%26aufirst%3DM.%26aulast%3DGroll%26aufirst%3DM.%26atitle%3DImmuno-%2520and%2520constitutive%2520proteasome%2520crystal%2520structures%2520reveal%2520differences%2520in%2520substrate%2520and%2520inhibitor%2520specificity%26jtitle%3DCell%26date%3D2012%26volume%3D148%26spage%3D727%26epage%3D738%26doi%3D10.1016%2Fj.cell.2011.12.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul Hameed, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehenkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muzyka, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, C. G.</span></span> <span> </span><span class="NLM_article-title">Molecular basis of the selectivity of the immunoproteasome catalytic subunit LMP2-specific inhibitor revealed by molecular modeling and dynamics simulations</span>. <i>J. Phys. Chem. B</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">12333</span>– <span class="NLM_lpage">12339</span>, <span class="refDoi"> DOI: 10.1021/jp1058098</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp1058098" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2010&pages=12333-12339&author=B.+Leiauthor=M.+D.+Abdul+Hameedauthor=A.+Hamzaauthor=M.+Wehenkelauthor=J.+L.+Muzykaauthor=X.+J.+Yaoauthor=K.+B.+Kimauthor=C.+G.+Zhan&title=Molecular+basis+of+the+selectivity+of+the+immunoproteasome+catalytic+subunit+LMP2-specific+inhibitor+revealed+by+molecular+modeling+and+dynamics+simulations&doi=10.1021%2Fjp1058098"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjp1058098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp1058098%26sid%3Dliteratum%253Aachs%26aulast%3DLei%26aufirst%3DB.%26aulast%3DAbdul%2BHameed%26aufirst%3DM.%2BD.%26aulast%3DHamza%26aufirst%3DA.%26aulast%3DWehenkel%26aufirst%3DM.%26aulast%3DMuzyka%26aufirst%3DJ.%2BL.%26aulast%3DYao%26aufirst%3DX.%2BJ.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DZhan%26aufirst%3DC.%2BG.%26atitle%3DMolecular%2520basis%2520of%2520the%2520selectivity%2520of%2520the%2520immunoproteasome%2520catalytic%2520subunit%2520LMP2-specific%2520inhibitor%2520revealed%2520by%2520molecular%2520modeling%2520and%2520dynamics%2520simulations%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D2010%26volume%3D114%26spage%3D12333%26epage%3D12339%26doi%3D10.1021%2Fjp1058098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bomba, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">230</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.047662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1124%2Fdmd.112.047662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=23118326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1Ontg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=230-237&author=Z.+Wangauthor=J.+Yangauthor=C.+Kirkauthor=Y.+Fangauthor=M.+Alsinaauthor=A.+Badrosauthor=K.+Papadopoulosauthor=A.+Wongauthor=T.+Wooauthor=D.+Bombaauthor=J.+Liauthor=J.+R.+Infante&title=Clinical+pharmacokinetics%2C+metabolism%2C+and+drug-drug+interaction+of+carfilzomib&doi=10.1124%2Fdmd.112.047662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib</span></div><div class="casAuthors">Wang, Zhengping; Yang, Jinfu; Kirk, Christopher; Fang, Ying; Alsina, Melissa; Badros, Ashraf; Papadopoulos, Kyriakos; Wong, Alvin; Woo, Tina; Bomba, Darrin; Li, Jin; Infante, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">230-237</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM).  Here we summarize the clin. pharmacokinetics (PK), metab., and drug-drug interaction (DDI) profile of carfilzomib.  The PK of carfilzomib, infused over 2-10 min, was evaluated in patients with solid tumors or MM.  Metabolites of carfilzomib were characterized in patient plasma and urine samples.  In vitro drug metab. and DDI studies were conducted in human liver microsomes and hepatocytes.  A clin. DDI study was conducted in patients with solid tumors to evaluate the effect of carfilzomib on CYP3A activity.  Plasma concns. of carfilzomib declined rapidly and in a biphasic manner after i.v. administration.  The systemic half-life was short and the systemic clearance rate was higher than hepatic blood flow.  Carfilzomib was cleared largely extrahepatically via peptidase cleavage and epoxide hydrolysis.  Cytochrome P 450-mediated metab. played a minor role, suggesting that coadministration of P 450 inhibitors or inducers is unlikely to change its PK profile.  Carfilzomib showed direct and time-dependent inhibition of CYP3A in human liver microsome prepns. and exposure to carfilzomib resulted in redns. in CYP3A and 1A2 gene expression in cultured human hepatocytes.  However, administration of carfilzomib did not affect the PK of midazolam in patients with solid tumors, and there were no safety signals indicative of potential drug interactions.  We conclude that the rapid systemic clearance and short half-life of carfilzomib limit clin. significant DDI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBFQz6vn1lHbVg90H21EOLACvtfcHk0ljTAuPBKIG9jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1Ontg%253D%253D&md5=f3f74eb39c59681aadf7a10b3af45510</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.047662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.047662%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DKirk%26aufirst%3DC.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DAlsina%26aufirst%3DM.%26aulast%3DBadros%26aufirst%3DA.%26aulast%3DPapadopoulos%26aufirst%3DK.%26aulast%3DWong%26aufirst%3DA.%26aulast%3DWoo%26aufirst%3DT.%26aulast%3DBomba%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26atitle%3DClinical%2520pharmacokinetics%252C%2520metabolism%252C%2520and%2520drug-drug%2520interaction%2520of%2520carfilzomib%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2013%26volume%3D41%26spage%3D230%26epage%3D237%26doi%3D10.1124%2Fdmd.112.047662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausville, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutler, R. E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span> <span> </span><span class="NLM_article-title">A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">861</span>– <span class="NLM_lpage">868</span>, <span class="refDoi"> DOI: 10.1007/s00280-013-2267-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1007%2Fs00280-013-2267-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=23975329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlOrtrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2013&pages=861-868&author=K.+P.+Papadopoulosauthor=H.+A.+Burrisauthor=M.+Gordonauthor=P.+Leeauthor=E.+A.+Sausvilleauthor=P.+J.+Rosenauthor=A.+Patnaikauthor=R.+E.+Cutlerauthor=Z.+Wangauthor=S.+Leeauthor=S.+F.+Jonesauthor=J.+R.+Infante&title=A+phase+I%2FII+study+of+carfilzomib+2%E2%80%9310-min+infusion+in+patients+with+advanced+solid+tumors&doi=10.1007%2Fs00280-013-2267-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors</span></div><div class="casAuthors">Papadopoulos, Kyriakos P.; Burris, Howard A.; Gordon, Michael; Lee, Peter; Sausville, Edward A.; Rosen, Peter J.; Patnaik, Amita; Cutler, Richard E., Jr.; Wang, Zhengping; Lee, Susan; Jones, Suzanne F.; Infante, Jeffery R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">861-868</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Tolerability, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of carfilzomib, a selective proteasome inhibitor, administered twice weekly by 2-10-min i.v. (IV) infusion on days 1, 2, 8, 9, 15, and 16 in 28-day cycles, were assessed in patients with advanced solid tumors in this phase I/II study.  Methods: Adult patients with solid tumors progressing after ≥1 prior therapies were enrolled.  The dose was 20 mg/m2 in week 1 of cycle 1 and 20, 27, or 36 mg/m2 thereafter.  The max. tolerated dose or protocol-defined max. planned dose (MPD) identified during dose escalation was administered to an expansion cohort and to patients with small cell lung, non-small cell lung, ovarian, and renal cancer in phase II tumor-specific cohorts.  Results: Fourteen patients received carfilzomib during dose escalation.  The single dose-limiting toxicity at 20/36 mg/m2 was grade 3 fatigue, establishing the MPD as the expansion and phase II dose.  Sixty-five addnl. patients received carfilzomib at the MPD.  Adverse events included fatigue, nausea, anorexia, and dyspnea.  Carfilzomib PK was dose proportional with a half-life <1 h.  All doses resulted in at least 80 % proteasome inhibition in blood.  Partial responses occurred in two patients in phase I, with 21.5 % stable disease after four cycles in evaluable patients in the expansion and phase II cohorts.  Conclusion: Carfilzomib 20/36 mg/m2 was well tolerated when administered twice weekly by 2-10-min IV infusion.  At this dose and infusion rate, carfilzomib inhibited the proteasome in blood but demonstrated limited antitumor activity in patients with advanced solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw4kZY9JrtI7Vg90H21EOLACvtfcHk0ljTAuPBKIG9jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlOrtrvN&md5=bebfbc6be14861a4d25f9402dfea67b8</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1007%2Fs00280-013-2267-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-013-2267-x%26sid%3Dliteratum%253Aachs%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DGordon%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DP.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DRosen%26aufirst%3DP.%2BJ.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DCutler%26aufirst%3DR.%2BE.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DS.%2BF.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26atitle%3DA%2520phase%2520I%252FII%2520study%2520of%2520carfilzomib%25202%25E2%2580%259310-min%2520infusion%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2013%26volume%3D72%26spage%3D861%26epage%3D868%26doi%3D10.1007%2Fs00280-013-2267-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teague, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rock, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">In vitro metabolism of oprozomib, an oral proteasome inhibitor: role of epoxide hydrolases and cytochrome P450s</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">712</span>– <span class="NLM_lpage">720</span>, <span class="refDoi"> DOI: 10.1124/dmd.117.075226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1124%2Fdmd.117.075226" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=712-720&author=Z.+Wangauthor=Y.+Fangauthor=J.+Teagueauthor=H.+Wongauthor=C.+Morisseauauthor=B.+D.+Hammockauthor=D.+A.+Rockauthor=Z.+Wang&title=In+vitro+metabolism+of+oprozomib%2C+an+oral+proteasome+inhibitor%3A+role+of+epoxide+hydrolases+and+cytochrome+P450s&doi=10.1124%2Fdmd.117.075226"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1124%2Fdmd.117.075226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.117.075226%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DTeague%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DRock%26aufirst%3DD.%2BA.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DIn%2520vitro%2520metabolism%2520of%2520oprozomib%252C%2520an%2520oral%2520proteasome%2520inhibitor%253A%2520role%2520of%2520epoxide%2520hydrolases%2520and%2520cytochrome%2520P450s%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2017%26volume%3D45%26spage%3D712%26epage%3D720%26doi%3D10.1124%2Fdmd.117.075226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saenz-Mendez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Kempner, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ventura, O. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, M.</span></span> <span> </span><span class="NLM_article-title">Structural insights into human microsomal epoxide hydrolase by combined homology modeling, molecular dynamics simulations, and molecular docking calculations</span>. <i>Proteins: Struct., Funct., Genet.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">720</span>– <span class="NLM_lpage">730</span>, <span class="refDoi"> DOI: 10.1002/prot.25251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1002%2Fprot.25251" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2017&pages=720-730&author=P.+Saenz-Mendezauthor=A.+Katzauthor=M.+L.+Perez-Kempnerauthor=O.+N.+Venturaauthor=M.+Vazquez&title=Structural+insights+into+human+microsomal+epoxide+hydrolase+by+combined+homology+modeling%2C+molecular+dynamics+simulations%2C+and+molecular+docking+calculations&doi=10.1002%2Fprot.25251"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fprot.25251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.25251%26sid%3Dliteratum%253Aachs%26aulast%3DSaenz-Mendez%26aufirst%3DP.%26aulast%3DKatz%26aufirst%3DA.%26aulast%3DPerez-Kempner%26aufirst%3DM.%2BL.%26aulast%3DVentura%26aufirst%3DO.%2BN.%26aulast%3DVazquez%26aufirst%3DM.%26atitle%3DStructural%2520insights%2520into%2520human%2520microsomal%2520epoxide%2520hydrolase%2520by%2520combined%2520homology%2520modeling%252C%2520molecular%2520dynamics%2520simulations%252C%2520and%2520molecular%2520docking%2520calculations%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D2017%26volume%3D85%26spage%3D720%26epage%3D730%26doi%3D10.1002%2Fprot.25251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1789</span>– <span class="NLM_lpage">1808</span>, <span class="refDoi"> DOI: 10.1021/jm201468j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201468j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ajtrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1789-1808&author=H.+C.+Shenauthor=B.+D.+Hammock&title=Discovery+of+inhibitors+of+soluble+epoxide+hydrolase%3A+a+target+with+multiple+potential+therapeutic+indications&doi=10.1021%2Fjm201468j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Inhibitors of Soluble Epoxide Hydrolase: A Target with Multiple Potential Therapeutic Indications</span></div><div class="casAuthors">Shen, Hong C.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1789-1808</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The inhibition of sol. epoxide hydrolase (sEH) by small mols. has been shown to increase the levels of fatty acid epoxides such as epoxyeicosatrienoic acids (EETs), and decrease the levels of the corresponding fatty acid diols including dihydroxyeicosatrienoic acids (DHETs).  Due to numerous beneficial effects of EETs, the elevation of their levels, as a result of sEH inhibition, may eventually lead to new therapeutic approaches for multiple diseases.  Specifically, it has been shown, largely in rodent models, that sEH inhibitors can be used to treat heart failure, hypertension, diabetes, stroke, dyslipidemia, inflammatory and neuropathic pain, immunol. disorders, eye diseases, neurol. diseases, and other indications.  Medicinal chem. strategies, key biol. data of benchmark compds., and possible paths for sEH inhibitors to reach the clinic will be reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBjFZ7QGkOVbVg90H21EOLACvtfcHk0liqejyIfmmjLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ajtrzK&md5=1a2ba726f26b7e207df467f67685cf2d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm201468j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201468j%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DH.%2BC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520inhibitors%2520of%2520soluble%2520epoxide%2520hydrolase%253A%2520a%2520target%2520with%2520multiple%2520potential%2520therapeutic%2520indications%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1789%26epage%3D1808%26doi%3D10.1021%2Fjm201468j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hosagrahara, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettie, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassett, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omiecinski, C. J.</span></span> <span> </span><span class="NLM_article-title">Functional analysis of human microsomal epoxide hydrolase genetic variants</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1016/j.cbi.2004.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2Fj.cbi.2004.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=15535985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVKnsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2004&pages=149-159&author=V.+P.+Hosagraharaauthor=A.+E.+Rettieauthor=C.+Hassettauthor=C.+J.+Omiecinski&title=Functional+analysis+of+human+microsomal+epoxide+hydrolase+genetic+variants&doi=10.1016%2Fj.cbi.2004.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Functional analysis of human microsomal epoxide hydrolase genetic variants</span></div><div class="casAuthors">Hosagrahara, Vinayak P.; Rettie, Allan E.; Hassett, Christopher; Omiecinski, Curtis J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">149-159</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Human microsomal epoxide hydrolase (EPHX1) is active in the metab. of many potentially carcinogenic or otherwise genotoxic epoxides, such as those derived from the oxidn. of polyarom. hydrocarbons.  EPHX1 is polymorphic and encodes allelic variation at least two amino acid positions, Y113H and H139R.  In a no. of recent mol. epidemiol. investigations, EPHX1 polymorphism has been suggested as a susceptibility factor for several human diseases.  To better evaluate the functional contribution of EPHX1 genetic polymorphism, we characterized the enzymic properties assocd. with each of the resp. variant proteins.  Enzymic profiles were evaluated with cis-stilbene oxide (cSO) and benzo[a]pyrene-4,5-epoxide (BaPO), two prototypical substrates for the hydrolase.  In one series of expts., activities of recombinant EPHX1 proteins were analyzed subsequent to their expression using the pFastbac baculovirus vector in Spodoptera frugiperda-9 (Sf9) insect cells, and purifn. by column chromatog.  In parallel studies, EPHX1 activities were evaluated with human liver microsomes derived from individuals of known EPHX1 genotype.  Using the purified protein prepns., rates of cSO and BaPO hydrolysis for the ref. protein, Y113/H139, were approx. 2-fold greater than those measured with the other EPHX1 allelic variants.  However, when activities were analyzed using human liver microsomal fractions, no major differences were evident in the reaction rates generated among prepns. representing the different EPHX1 alleles.  Collectively, these results suggest that the structural differences encoded by the Y113H and H139R variant alleles exert only modest impact on EPHX1-specific enzymic activities in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO9BXOsS5nNbVg90H21EOLACvtfcHk0liqejyIfmmjLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVKnsLk%253D&md5=6e945c146c9c6ad5e6681012d2b4edd8</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2004.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2004.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DHosagrahara%26aufirst%3DV.%2BP.%26aulast%3DRettie%26aufirst%3DA.%2BE.%26aulast%3DHassett%26aufirst%3DC.%26aulast%3DOmiecinski%26aufirst%3DC.%2BJ.%26atitle%3DFunctional%2520analysis%2520of%2520human%2520microsomal%2520epoxide%2520hydrolase%2520genetic%2520variants%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2004%26volume%3D150%26spage%3D149%26epage%3D159%26doi%3D10.1016%2Fj.cbi.2004.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verbrugge, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assaraf, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niewerth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Meerloo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cloos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Veer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffer, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderl, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zweegman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dijkmans, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lems, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheper, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Gruijl, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, G.</span></span> <span> </span><span class="NLM_article-title">Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors</span>. <i>Exp. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1186/2162-3619-2-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1186%2F2162-3619-2-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=23305345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivFGktLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=2-13&author=S.+E.+Verbruggeauthor=M.+Alauthor=Y.+G.+Assarafauthor=D.+Niewerthauthor=J.+van+Meerlooauthor=J.+Cloosauthor=M.+van+der+Veerauthor=G.+L.+Schefferauthor=G.+J.+Petersauthor=E.+T.+Chanauthor=J.+L.+Anderlauthor=C.+J.+Kirkauthor=S.+Zweegmanauthor=B.+A.+Dijkmansauthor=W.+F.+Lemsauthor=R.+J.+Scheperauthor=T.+D.+de+Gruijlauthor=G.+Jansen&title=Overcoming+bortezomib+resistance+in+human+B+cells+by+anti-CD20%2Frituximab-mediated+complement-dependent+cytotoxicity+and+epoxyketone-based+irreversible+proteasome+inhibitors&doi=10.1186%2F2162-3619-2-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors</span></div><div class="casAuthors">Verbrugge, Sue Ellen; Al, Marjon; Assaraf, Yehuda G.; Niewerth, Denise; van Meerloo, Johan; Cloos, Jacqueline; van der Veer, Michael; Scheffer, George L.; Peters, Godefridus J.; Chan, Elena T.; Andrerl, Janet L.; Kirk, Christopher J.; Zweegman, Sonja; Dijkmans, Ben A. C.; Lems, Willem F.; Scheper, Rik J.; de Gruijl, Tanja D.; Jansen, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Hematology & Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2</span>CODEN:
                <span class="NLM_cas:coden">EHOXAU</span>;
        ISSN:<span class="NLM_cas:issn">2162-3619</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: In clin. and exptl. settings, antibody-based anti-CD20/rituximab and small mol. proteasome inhibitor (PI) bortezomib (BTZ) treatment proved effective modalities for B cell depletion in lymphoproliferative disorders as well as autoimmune diseases.  However, the chronic nature of these diseases requires either prolonged or re-treatment, often with acquired resistance as a consequence.  Methods: Here we studied the mol. basis of acquired resistance to BTZ in JY human B lymphoblastic cells following prolonged exposure to this drug and examd. possibilities to overcome resistance by next generation PIs and anti-CD20/rituximab-mediated complement-dependent cytotoxicity (CDC).  Results: Characterization of BTZ-resistant JY/BTZ cells compared to parental JY/WT cells revealed the following features: (a) 10-12 fold resistance to BTZ assocd. with the acquisition of a mutation in the PSMB5 gene (encoding the constitutive β5 proteasome subunit) introducing an amino acid substitution (Met45Ile) in the BTZ-binding pocket, (b) a significant 2-4 fold increase in the mRNA and protein levels of the constitutive β5 proteasome subunit along with unaltered immunoproteasome expression, (c) full sensitivity to the irreversible epoxyketone-based PIs carfilzomib and (to a lesser extent) the immunoproteasome inhibitor ONX 0914.  Finally, in assocn. with impaired ubiquitination and attenuated breakdown of CD20, JY/BTZ cells harbored a net 3-fold increase in CD20 cell surface expression, which was functionally implicated in conferring a significantly increased anti-CD20/rituximab-mediated CDC.  Conclusions: These results demonstrate that acquired resistance to BTZ in B cells can be overcome by next generation PIs and by anti-CD20/rituximab-induced CDC, thereby paving the way for salvage therapy in BTZ-resistant disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9mBdftcNY5LVg90H21EOLACvtfcHk0liqejyIfmmjLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivFGktLs%253D&md5=acf3434db935d0a06c6704aa21da4c21</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1186%2F2162-3619-2-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2162-3619-2-2%26sid%3Dliteratum%253Aachs%26aulast%3DVerbrugge%26aufirst%3DS.%2BE.%26aulast%3DAl%26aufirst%3DM.%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26aulast%3DNiewerth%26aufirst%3DD.%26aulast%3Dvan%2BMeerloo%26aufirst%3DJ.%26aulast%3DCloos%26aufirst%3DJ.%26aulast%3Dvan%2Bder%2BVeer%26aufirst%3DM.%26aulast%3DScheffer%26aufirst%3DG.%2BL.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26aulast%3DChan%26aufirst%3DE.%2BT.%26aulast%3DAnderl%26aufirst%3DJ.%2BL.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DZweegman%26aufirst%3DS.%26aulast%3DDijkmans%26aufirst%3DB.%2BA.%26aulast%3DLems%26aufirst%3DW.%2BF.%26aulast%3DScheper%26aufirst%3DR.%2BJ.%26aulast%3Dde%2BGruijl%26aufirst%3DT.%2BD.%26aulast%3DJansen%26aufirst%3DG.%26atitle%3DOvercoming%2520bortezomib%2520resistance%2520in%2520human%2520B%2520cells%2520by%2520anti-CD20%252Frituximab-mediated%2520complement-dependent%2520cytotoxicity%2520and%2520epoxyketone-based%2520irreversible%2520proteasome%2520inhibitors%26jtitle%3DExp.%2520Hematol.%2520Oncol.%26date%3D2013%26volume%3D2%26spage%3D2%26epage%3D13%26doi%3D10.1186%2F2162-3619-2-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verbrugge, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assaraf, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dijkmans, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffer, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">den Uyl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oerlemans, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Heijden, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Gruijl, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheper, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, G.</span></span> <span> </span><span class="NLM_article-title">Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">174</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.187542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1124%2Fjpet.111.187542" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=22235146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVagtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2012&pages=174-182&author=S.+E.+Verbruggeauthor=Y.+G.+Assarafauthor=B.+A.+Dijkmansauthor=G.+L.+Schefferauthor=M.+Alauthor=D.+den+Uylauthor=R.+Oerlemansauthor=E.+T.+Chanauthor=C.+J.+Kirkauthor=G.+J.+Petersauthor=J.+W.+van+der+Heijdenauthor=T.+D.+de+Gruijlauthor=R.+J.+Scheperauthor=G.+Jansen&title=Inactivating+PSMB5+mutations+and+P-glycoprotein+%28multidrug+resistance-associated+protein%2FATP-binding+cassette+B1%29+mediate+resistance+to+proteasome+inhibitors%3A+ex+vivo+efficacy+of+%28immuno%29proteasome+inhibitors+in+mononuclear+blood+cells+from+patients+with+rheumatoid+arthritis&doi=10.1124%2Fjpet.111.187542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis</span></div><div class="casAuthors">Verbrugge, Sue Ellen; Assaraf, Yehuda G.; Dijkmans, Ben A. C.; Scheffer, George L.; Al, Marjon; den Uyl, Debby; Oerlemans, Ruud; Chan, Elena T.; Kirk, Christopher J.; Peters, Godefridus J.; van der Heijden, Joost W.; de Gruijl, Tanja D.; Scheper, Rik J.; Jansen, Gerrit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">174-182</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bortezomib (BTZ), a registered proteasome inhibitor (PI) for multiple myeloma, has also been proposed as a potential antirheumatic agent.  Its reported side effects, however, make it unappealing for long-term administration, and resistance may also develop.  To overcome this, second-generation PIs became available.  Here, we investigated whether a novel class of peptide epoxyketone-based PIs, including carfilzomib, N-((S)-3-methoxy-1-(((S)-3-methoxy-1-(((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)-2-methylthiazole-5-carboxamide (ONX0912), and (S)-3-(4-methoxyphenyl)-N-((S)-1-((S)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide (ONX0914), might escape two established BTZ-resistance mechanisms: (1) mutations in the proteasome β5 subunit (PSMB5) targeted by these PIs, and (2) drug efflux mediated by ATP-binding cassette transporters.  THP1 myeloid sublines with acquired resistance to BTZ (54- to 235-fold) caused by mutations in the PSMB5 gene displayed marked cross-resistance but less pronounced cross-resistance to carfilzomib (9- to 32-fold), ONX0912 (39- to 62-fold), and ONX0914 (27- to 97-fold).  As for ATP-binding cassette transporter-mediated efflux, lymphoid CEM/VLB cells with P-glycoprotein (Pgp)/multidrug resistance 1 overexpression exhibited substantial resistance to carfilzomib (114-fold), ONX0912 (23-fold), and ONX0914 (162-fold), whereas less resistance to BTZ (4.5-fold) was obsd.  Consistently, β5 subunit-assocd. chymotrypsin-like proteasome activity was significantly less inhibited in these CEM/VLB cells.  Ex vivo anal. of peripheral blood mononuclear cells from therapy-naive patients with rheumatoid arthritis revealed that, although basal Pgp levels were low, P-glycoprotein expression compromised the inhibitory effect of carfilzomib and ONX0914.  However, the use of P121 (reversin 121), a Pgp transport inhibitor, restored parental cell inhibitory levels in both CEM/VLB cells and peripheral blood mononuclear cells.  These results indicate that the pharmacol. activity of these PIs may be hindered by drug resistance mechanisms involving PSMBS mutations and PI extrusion via Pgp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLjyDKKBsD_7Vg90H21EOLACvtfcHk0li7XG86NYq9gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVagtr8%253D&md5=5b87626879dfdca4f1003e35833af2e0</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.187542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.187542%26sid%3Dliteratum%253Aachs%26aulast%3DVerbrugge%26aufirst%3DS.%2BE.%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26aulast%3DDijkmans%26aufirst%3DB.%2BA.%26aulast%3DScheffer%26aufirst%3DG.%2BL.%26aulast%3DAl%26aufirst%3DM.%26aulast%3Dden%2BUyl%26aufirst%3DD.%26aulast%3DOerlemans%26aufirst%3DR.%26aulast%3DChan%26aufirst%3DE.%2BT.%26aulast%3DKirk%26aufirst%3DC.%2BJ.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26aulast%3Dvan%2Bder%2BHeijden%26aufirst%3DJ.%2BW.%26aulast%3Dde%2BGruijl%26aufirst%3DT.%2BD.%26aulast%3DScheper%26aufirst%3DR.%2BJ.%26aulast%3DJansen%26aufirst%3DG.%26atitle%3DInactivating%2520PSMB5%2520mutations%2520and%2520P-glycoprotein%2520%2528multidrug%2520resistance-associated%2520protein%252FATP-binding%2520cassette%2520B1%2529%2520mediate%2520resistance%2520to%2520proteasome%2520inhibitors%253A%2520ex%2520vivo%2520efficacy%2520of%2520%2528immuno%2529proteasome%2520inhibitors%2520in%2520mononuclear%2520blood%2520cells%2520from%2520patients%2520with%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D174%26epage%3D182%26doi%3D10.1124%2Fjpet.111.187542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung-Hagesteijn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdmann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reece, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiedemann, R. E.</span></span> <span> </span><span class="NLM_article-title">Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">304</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2013.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2Fj.ccr.2013.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=24029229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVahsb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=289-304&author=C.+Leung-Hagesteijnauthor=N.+Erdmannauthor=G.+Cheungauthor=J.+J.+Keatsauthor=A.+K.+Stewartauthor=D.+E.+Reeceauthor=K.+C.+Chungauthor=R.+E.+Tiedemann&title=Xbp1s-negative+tumor+B+cells+and+pre-plasmablasts+mediate+therapeutic+proteasome+inhibitor+resistance+in+multiple+myeloma&doi=10.1016%2Fj.ccr.2013.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma</span></div><div class="casAuthors">Leung-Hagesteijn, Chungyee; Erdmann, Natalie; Cheung, Grace; Keats, Jonathan J.; Stewart, A. Keith; Reece, Donna E.; Chung, Kim Chan; Tiedemann, Rodger E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">289-304</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Proteasome inhibitor (PI) resistance mechanisms in multiple myeloma (MM) remain controversial.  We report the existence of a progenitor organization in primary MM that recapitulates maturation stages between B cells and plasma cells and that contributes to clin. PI resistance.  Xbp1s- tumor B cells and pre-plasmablasts survive therapeutic PI, preventing cure, while maturation arrest of MM before the plasmablast stage enables progressive disease on PI treatment.  Mechanistically, suppression of Xbp1s in MM is shown to induce bortezomib resistance via de-commitment to plasma cell maturation and Ig prodn., diminishing endoplasmic reticulum (ER) front-loading and cytotoxic susceptibility to PI-induced inhibition of ER-assocd. degrdn.  These results reveal the tumor progenitor structure in MM and highlight its role in therapeutic failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_GJzGqektqrVg90H21EOLACvtfcHk0li7XG86NYq9gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVahsb%252FK&md5=8a493f4178b5a53a257e991b3d02e742</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2013.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2013.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DLeung-Hagesteijn%26aufirst%3DC.%26aulast%3DErdmann%26aufirst%3DN.%26aulast%3DCheung%26aufirst%3DG.%26aulast%3DKeats%26aufirst%3DJ.%2BJ.%26aulast%3DStewart%26aufirst%3DA.%2BK.%26aulast%3DReece%26aufirst%3DD.%2BE.%26aulast%3DChung%26aufirst%3DK.%2BC.%26aulast%3DTiedemann%26aufirst%3DR.%2BE.%26atitle%3DXbp1s-negative%2520tumor%2520B%2520cells%2520and%2520pre-plasmablasts%2520mediate%2520therapeutic%2520proteasome%2520inhibitor%2520resistance%2520in%2520multiple%2520myeloma%26jtitle%3DCancer%2520Cell%26date%3D2013%26volume%3D24%26spage%3D289%26epage%3D304%26doi%3D10.1016%2Fj.ccr.2013.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niewerth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assaraf, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zweegman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaspers, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cloos, J.</span></span> <span> </span><span class="NLM_article-title">Molecular basis of resistance to proteasome inhibitors in hematological malignancies</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">18</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1016/j.drup.2014.12.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2Fj.drup.2014.12.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=25670156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A280%3ADC%252BC2MrksFOrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2015&pages=18-35&author=D.+Niewerthauthor=G.+Jansenauthor=Y.+G.+Assarafauthor=S.+Zweegmanauthor=G.+J.+Kaspersauthor=J.+Cloos&title=Molecular+basis+of+resistance+to+proteasome+inhibitors+in+hematological+malignancies&doi=10.1016%2Fj.drup.2014.12.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis of resistance to proteasome inhibitors in hematological malignancies</span></div><div class="casAuthors">Niewerth Denise; Kaspers Gertjan J L; Jansen Gerrit; Assaraf Yehuda G; Zweegman Sonja; Cloos Jacqueline</div><div class="citationInfo"><span class="NLM_cas:title">Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18-35</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Over the past decade, the proteasome inhibitor bortezomib (Velcade) has not only gained a cornerstone position in the treatment of hematological malignancies, particularly multiple myeloma and mantle cell lymphoma, but also in experimental therapeutics of acute leukemia.  However, the therapeutic efficacy of bortezomib is hampered by the emergence of acquired resistance, for which multifactorial mechanisms have been identified.  This review summarizes the current status of the molecular mechanisms underlying resistance to proteasome inhibitors that emerged in preclinical therapeutic studies, and discusses these findings in the clinical perspective of novel therapeutic modalities of hematological malignancies.  The specific topics that will be addressed in the current review include the recently established mechanisms of resistance to proteasome inhibitors: the role of constitutive and immunoproteasomes, mutations in proteasome subunits, unfolded protein response, XBP1 and MARCKS proteins, multidrug efflux transporters, aggresomes and autophagy, as well as the impact of pro-survival signaling pathways and bone marrow microenvironment.  The growing knowledge of the determinants that confer bortezomib resistance and/or toxicity has provided the basis for the rational development of second generation proteasome inhibitors, some of which were recently approved or that are undergoing clinical evaluation as novel strategies to overcome bortezomib resistance as well as to enhance clinical therapeutic efficacy along with minimal side effects.  Collectively, these combined approaches should enhance therapeutic efficacy and outcome in patients with hematological malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsj6vKDkCfumyYR5VtavbzfW6udTcc2eZk9e4D_LqzJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MrksFOrsA%253D%253D&md5=f015e1bdf6c2b1ac7247beac331c02eb</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2014.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2014.12.001%26sid%3Dliteratum%253Aachs%26aulast%3DNiewerth%26aufirst%3DD.%26aulast%3DJansen%26aufirst%3DG.%26aulast%3DAssaraf%26aufirst%3DY.%2BG.%26aulast%3DZweegman%26aufirst%3DS.%26aulast%3DKaspers%26aufirst%3DG.%2BJ.%26aulast%3DCloos%26aufirst%3DJ.%26atitle%3DMolecular%2520basis%2520of%2520resistance%2520to%2520proteasome%2520inhibitors%2520in%2520hematological%2520malignancies%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2015%26volume%3D18%26spage%3D18%26epage%3D35%26doi%3D10.1016%2Fj.drup.2014.12.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunsucker, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voorhees, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, R. Z.</span></span> <span> </span><span class="NLM_article-title">Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">4667</span>– <span class="NLM_lpage">4676</span>, <span class="refDoi"> DOI: 10.1182/blood-2008-07-171637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1182%2Fblood-2008-07-171637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=19050304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnvVyqurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=4667-4676&author=D.+J.+Kuhnauthor=S.+A.+Hunsuckerauthor=Q.+Chenauthor=P.+M.+Voorheesauthor=M.+Orlowskiauthor=R.+Z.+Orlowski&title=Targeted+inhibition+of+the+immunoproteasome+is+a+potent+strategy+against+models+of+multiple+myeloma+that+overcomes+resistance+to+conventional+drugs+and+nonspecific+proteasome+inhibitors&doi=10.1182%2Fblood-2008-07-171637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors</span></div><div class="casAuthors">Kuhn, Deborah J.; Hunsucker, Sally A.; Chen, Qing; Voorhees, Peter M.; Orlowski, Marian; Orlowski, Robert Z.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4667-4676</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Proteasome inhibition is a validated strategy for therapy of multiple myeloma, but this disease remains challenging as relapses are common, and often assocd. with increasing chemoresistance.  Moreover, nonspecific proteasome inhibitors such as bortezomib can induce peripheral neuropathy and other toxicities that may compromise the ability to deliver therapy at full doses, thereby decreasing efficacy.  One novel approach may be to target the immunoproteasome, a proteasomal variant found predominantly in cells of hematopoietic origin that differs from the constitutive proteasome found in most other cell types.  Using purified prepns. of constitutive and immunoproteasomes, we screened a rationally designed series of peptidyl-aldehydes and identified several with relative specificity for the immunoproteasome.  The most potent immunoproteasome-specific inhibitor, IPSI-001, preferentially targeted the β1i subunit of the immunoproteasome in vitro and in cellulo in a dose-dependent manner.  This agent induced accumulation of ubiquitin-protein conjugates, proapoptotic proteins, and activated caspase-mediated apoptosis.  IPSI-001 potently inhibited proliferation in myeloma patient samples and other hematol. malignancies.  Importantly, IPSI-001 was able to overcome conventional and novel drug resistance, including resistance to bortezomib.  These findings provide a rationale for the translation of IPSIs to the clinic, where they may provide antimyeloma activity with greater specificity and less toxicity than current inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyFUysXTzcsrVg90H21EOLACvtfcHk0lgscBWnggRu0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnvVyqurk%253D&md5=6753f40ae6057eeadbbde2f6650828fc</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-07-171637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-07-171637%26sid%3Dliteratum%253Aachs%26aulast%3DKuhn%26aufirst%3DD.%2BJ.%26aulast%3DHunsucker%26aufirst%3DS.%2BA.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DVoorhees%26aufirst%3DP.%2BM.%26aulast%3DOrlowski%26aufirst%3DM.%26aulast%3DOrlowski%26aufirst%3DR.%2BZ.%26atitle%3DTargeted%2520inhibition%2520of%2520the%2520immunoproteasome%2520is%2520a%2520potent%2520strategy%2520against%2520models%2520of%2520multiple%2520myeloma%2520that%2520overcomes%2520resistance%2520to%2520conventional%2520drugs%2520and%2520nonspecific%2520proteasome%2520inhibitors%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D4667%26epage%3D4676%26doi%3D10.1182%2Fblood-2008-07-171637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruckrich, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kammer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovaa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessen, C.</span></span> <span> </span><span class="NLM_article-title">Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1038/sj.leu.2404414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1038%2Fsj.leu.2404414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=17024115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlSqurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=84-92&author=M.+Krausauthor=T.+Ruckrichauthor=M.+Reichauthor=J.+Gogelauthor=A.+Beckauthor=W.+Kammerauthor=C.+R.+Berkersauthor=D.+Burgauthor=H.+Overkleeftauthor=H.+Ovaaauthor=C.+Driessen&title=Activity+patterns+of+proteasome+subunits+reflect+bortezomib+sensitivity+of+hematologic+malignancies+and+are+variable+in+primary+human+leukemia+cells&doi=10.1038%2Fsj.leu.2404414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells</span></div><div class="casAuthors">Kraus, M.; Rueckrich, T.; Reich, M.; Gogel, J.; Beck, A.; Kammer, W.; Berkers, C. R.; Burg, D.; Overkleeft, H.; Ovaa, H.; Driessen, C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-92</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Proteasomal proteolysis relies on the activity of six catalytically active proteasomal subunits (β1, β2, β5, β1i, β2i and β5i).  Applying a functional proteomics approach, we used a recently developed activity-based, cell-permeable proteasome-specific probe that for the first time allows differential visualization of individual active proteasomal subunits in intact primary cells.  In primary leukemia samples, we obsd. remarkable variability in the amts. of active β1/1i-, β2/2i- and β5/5i-type of subunits, contrasting with their const. protein expression.  Bortezomib inhibited β5- and β1-type, but to a lesser extend β2-type of subunits in live primary cells in vitro and in vivo.  When we adapted the bortezomib-sensitive human acute myeloid leukemia cell line HL-60 to bortezomib 40 nM (HL-60a), proteasomal activity profiling revealed an upregulation of active subunits, and residual β1/β5-type of activity could be visualized in the presence of bortezomib 20 nM, in contrast to control cells.  In a panel of cell lines from hematol. malignancies, the ratio between β2-type and (β1+β5)-type of active proteasomal polypeptides mirrored different degrees of bortezomib sensitivity.  We thus conclude that the proteasomal activity profile varies in primary leukemia cells, and that the pattern of proteasomal subunit activity influences the sensitivity of hematol. malignancies toward bortezomib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhSfjpxWwrmrVg90H21EOLACvtfcHk0lgscBWnggRu0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlSqurzL&md5=a7e3c1e5930d38f7359836967ee8c066</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2404414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2404414%26sid%3Dliteratum%253Aachs%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DRuckrich%26aufirst%3DT.%26aulast%3DReich%26aufirst%3DM.%26aulast%3DGogel%26aufirst%3DJ.%26aulast%3DBeck%26aufirst%3DA.%26aulast%3DKammer%26aufirst%3DW.%26aulast%3DBerkers%26aufirst%3DC.%2BR.%26aulast%3DBurg%26aufirst%3DD.%26aulast%3DOverkleeft%26aufirst%3DH.%26aulast%3DOvaa%26aufirst%3DH.%26aulast%3DDriessen%26aufirst%3DC.%26atitle%3DActivity%2520patterns%2520of%2520proteasome%2520subunits%2520reflect%2520bortezomib%2520sensitivity%2520of%2520hematologic%2520malignancies%2520and%2520are%2520variable%2520in%2520primary%2520human%2520leukemia%2520cells%26jtitle%3DLeukemia%26date%3D2007%26volume%3D21%26spage%3D84%26epage%3D92%26doi%3D10.1038%2Fsj.leu.2404414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geurink, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weyburne, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirabella, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silzle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shabaneh, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Linden, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bruin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haile, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Rooden, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appenzeller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisselev, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessen, C.</span></span> <span> </span><span class="NLM_article-title">The novel beta2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">1350</span>– <span class="NLM_lpage">1360</span>, <span class="refDoi"> DOI: 10.3324/haematol.2014.109421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.3324%2Fhaematol.2014.109421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=26069288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVKitrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2015&pages=1350-1360&author=M.+Krausauthor=J.+Baderauthor=P.+P.+Geurinkauthor=E.+S.+Weyburneauthor=A.+C.+Mirabellaauthor=T.+Silzleauthor=T.+B.+Shabanehauthor=W.+A.+van+der+Lindenauthor=G.+de+Bruinauthor=S.+R.+Haileauthor=E.+van+Roodenauthor=C.+Appenzellerauthor=N.+Liauthor=A.+F.+Kisselevauthor=H.+Overkleeftauthor=C.+Driessen&title=The+novel+beta2-selective+proteasome+inhibitor+LU-102+synergizes+with+bortezomib+and+carfilzomib+to+overcome+proteasome+inhibitor+resistance+of+myeloma+cells&doi=10.3324%2Fhaematol.2014.109421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells</span></div><div class="casAuthors">Kraus, Marianne; Bader, Juergen; Geurink, Paul P.; Weyburne, Emily S.; Mirabella, Anne C.; Silzle, Tobias; Shabaneh, Tamer B.; van der Linden, Wouter A.; de Bruin, Gerjan; Haile, Sarah R.; van Rooden, Eva; Appenzeller, Christina; Li, Nan; Kisselev, Alexei F.; Overkleeft, Herman; Driessen, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1350-1360</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">1592-8721</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">Proteasome inhibitor resistance is a challenge for myeloma therapy.  Bortezomib targets the β5 and β1 activity, but not the β2 activity of the proteasome.  Bortezomib-resistant myeloma cells down-regulate the activation status of the unfolded protein response, and up-regulate β2 proteasome activity.  To improve proteasome inhibition in bortezomib-resistant myeloma and to achieve more efficient UPR activation, we have developed LU-102, a selective inhibitor of the β2 proteasome activity.  LU-102 inhibited the β2 activity in intact myeloma cells at low micromolar concns. without relevant co-inhibition of β1 and β5 proteasome subunits.  In protea-some inhibitor-resistant myeloma cells, significantly more potent proteasome inhibition was achieved by bortezomib or carfilzomib in combination with LU-102, compared to bortezomib/carfilzomib alone, resulting in highly synergistic cytotoxic activity of the drug combination via endoplasmatic reticulum stress-induced apoptosis.  Combining bortezomib/carfilzomib with LU-102 significantly prolonged proteasome inhibition and increased activation of the unfolded protein response and IRE1-α activity.  IRE1-α has recently been shown to control myeloma cell differentiation and bortezomib sensitivity (Leung-Hagesteijn, Cancer Cell 24:3, 289-304).  Thus, β2-selective proteasome inhibition by LU-102 in combination with bortezomib or carfilzomib re-sults in synergistic proteasome inhibition, activation of the unfolded protein response, and cytotoxicity, and overcomes bortezomib/carfilzomib resistance in myeloma cells in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhWaSEQ0aXHbVg90H21EOLACvtfcHk0lgEuJVeKEGrkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVKitrjE&md5=7895da9ac823a56178903ca149c8d39f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2014.109421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2014.109421%26sid%3Dliteratum%253Aachs%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DBader%26aufirst%3DJ.%26aulast%3DGeurink%26aufirst%3DP.%2BP.%26aulast%3DWeyburne%26aufirst%3DE.%2BS.%26aulast%3DMirabella%26aufirst%3DA.%2BC.%26aulast%3DSilzle%26aufirst%3DT.%26aulast%3DShabaneh%26aufirst%3DT.%2BB.%26aulast%3Dvan%2Bder%2BLinden%26aufirst%3DW.%2BA.%26aulast%3Dde%2BBruin%26aufirst%3DG.%26aulast%3DHaile%26aufirst%3DS.%2BR.%26aulast%3Dvan%2BRooden%26aufirst%3DE.%26aulast%3DAppenzeller%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DKisselev%26aufirst%3DA.%2BF.%26aulast%3DOverkleeft%26aufirst%3DH.%26aulast%3DDriessen%26aufirst%3DC.%26atitle%3DThe%2520novel%2520beta2-selective%2520proteasome%2520inhibitor%2520LU-102%2520synergizes%2520with%2520bortezomib%2520and%2520carfilzomib%2520to%2520overcome%2520proteasome%2520inhibitor%2520resistance%2520of%2520myeloma%2520cells%26jtitle%3DHaematologica%26date%3D2015%26volume%3D100%26spage%3D1350%26epage%3D1360%26doi%3D10.3324%2Fhaematol.2014.109421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprangers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franke, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbrugge, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adomat, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Religa, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cloos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guns, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batey, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimmer, A. D.</span></span> <span> </span><span class="NLM_article-title">Effect of noncompetitive proteasome inhibition on bortezomib resistance</span>. <i>J. Natl. Cancer Inst</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">1069</span>– <span class="NLM_lpage">1082</span>, <span class="refDoi"> DOI: 10.1093/jnci/djq198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1093%2Fjnci%2Fdjq198" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=20505154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlWmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2010&pages=1069-1082&author=X.+Liauthor=T.+E.+Woodauthor=R.+Sprangersauthor=G.+Jansenauthor=N.+E.+Frankeauthor=X.+Maoauthor=X.+Wangauthor=Y.+Zhangauthor=S.+E.+Verbruggeauthor=H.+Adomatauthor=Z.+H.+Liauthor=S.+Trudelauthor=C.+Chenauthor=T.+L.+Religaauthor=N.+Jamalauthor=H.+Messnerauthor=J.+Cloosauthor=D.+R.+Roseauthor=A.+Navonauthor=E.+Gunsauthor=R.+A.+Bateyauthor=L.+E.+Kayauthor=A.+D.+Schimmer&title=Effect+of+noncompetitive+proteasome+inhibition+on+bortezomib+resistance&doi=10.1093%2Fjnci%2Fdjq198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of Noncompetitive Proteasome Inhibition on Bortezomib Resistance</span></div><div class="casAuthors">Li, Xiaoming; Wood, Tabitha E.; Sprangers, Remco; Jansen, Gerrit; Franke, Niels E.; Mao, Xinliang; Wang, Xiaoming; Zhang, Yi; Verbrugge, Sue Ellen; Adomat, Hans; Li, Zhi Hua; Trudel, Suzanne; Chen, Christine; Religa, Tomasz L.; Jamal, Nazir; Messner, Hans; Cloos, Jacqueline; Rose, David R.; Navon, Ami; Guns, Emma; Batey, Robert A.; Kay, Lewis E.; Schimmer, Aaron D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1069-1082</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: Bortezomib and the other proteasome inhibitors that are currently under clin. investigation bind to the catalytic sites of proteasomes and are competitive inhibitors.  We hypothesized that proteasome inhibitors that act through a noncompetitive mechanism might overcome some forms of bortezomib resistance.  Methods: 5-amino-8-hydroxyquinoline (5AHQ) was identified through a screen of a 27-compd. chem. library based on the quinoline pharmacophore to identify proteasome inhibitors.  Inhibition of proteasome activity by 5AHQ was tested by measuring 7-amino-4-methylcoumarin (AMC) release from the proteasome substrate Suc-LLVY-AMC in intact human and mouse leukemia and myeloma cells and in tumor cell protein exts.  Cytotoxicity was assessed in 5AHQ-treated cell lines and primary cells from myeloma and leukemia patients using AlamarBlue fluorescence and MTS assays, trypan blue staining, and annexin V staining. 5AHQ-proteasome interaction was assessed by NMR. 5AHQ efficacy was evaluated in three leukemia xenograft mouse models (9-10 mice per group per model).  All statistical tests were two-sided.  Results 5AHQ inhibited the proteasome when added to cell exts. and intact cells (the mean concn. inhibiting 50% [IC50] of AMC release in intact cells ranged from 0.57 to 5.03 μM), induced cell death in intact cells from leukemia and myeloma cell lines (mean IC50 values for cell growth ranged from 0.94 to 3.85 μM), and preferentially induced cell death in primary myeloma and leukemia cells compared with normal hematopoietic cells.  5AHQ was equally cytotoxic to human myelomonocytic THP1 cells and to THP1/BTZ500 cells, which are 237-fold more resistant to bortezomib than wild-type THP1 cells because of their overexpression and mutation of the bortezomib-binding β5 proteasome subunit (mean IC50 for cell death in the absence of bortezomib, wild-type THP1: 3.7 μM, 95% confidence interval = 3.4 to 4.0 μM; THP1/BTZ500: 6.6 μM, 95% confidence interval = 5.9 to 7.5 μM).  5AHQ interacted with the α subunits of the 20S proteasome at noncatalytic sites.  Orally administered 5AHQ inhibited tumor growth in all three mouse models of leukemia without overt toxicity (eg, OCI-AML2 model, median tumor wt. [interquartile range], 5AHQ vs control: 95.7 mg [61.4-163.5 mg] vs 247.2 mg [189.4-296.2 mg], P = .002).  Conclusions: 5AHQ is a noncompetitive proteasome inhibitor that is cytotoxic to myeloma and leukemia cells in vitro and inhibits xenograft tumor growth in vivo. 5AHQ can overcome some forms of bortezomib resistance in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW4TcOS6iYs7Vg90H21EOLACvtfcHk0lgEuJVeKEGrkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlWmsbs%253D&md5=45a19957639165d2673f2dc72a0387a4</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjq198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjq198%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWood%26aufirst%3DT.%2BE.%26aulast%3DSprangers%26aufirst%3DR.%26aulast%3DJansen%26aufirst%3DG.%26aulast%3DFranke%26aufirst%3DN.%2BE.%26aulast%3DMao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DVerbrugge%26aufirst%3DS.%2BE.%26aulast%3DAdomat%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DZ.%2BH.%26aulast%3DTrudel%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DReliga%26aufirst%3DT.%2BL.%26aulast%3DJamal%26aufirst%3DN.%26aulast%3DMessner%26aufirst%3DH.%26aulast%3DCloos%26aufirst%3DJ.%26aulast%3DRose%26aufirst%3DD.%2BR.%26aulast%3DNavon%26aufirst%3DA.%26aulast%3DGuns%26aufirst%3DE.%26aulast%3DBatey%26aufirst%3DR.%2BA.%26aulast%3DKay%26aufirst%3DL.%2BE.%26aulast%3DSchimmer%26aufirst%3DA.%2BD.%26atitle%3DEffect%2520of%2520noncompetitive%2520proteasome%2520inhibition%2520on%2520bortezomib%2520resistance%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst%26date%3D2010%26volume%3D102%26spage%3D1069%26epage%3D1082%26doi%3D10.1093%2Fjnci%2Fdjq198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schrader, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henneberg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mata, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tittmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourenkov, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chari, A.</span></span> <span> </span><span class="NLM_article-title">The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">594</span>– <span class="NLM_lpage">598</span>, <span class="refDoi"> DOI: 10.1126/science.aaf8993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1126%2Fscience.aaf8993" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=27493187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Oks7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2016&pages=594-598&author=J.+Schraderauthor=F.+Hennebergauthor=R.+A.+Mataauthor=K.+Tittmannauthor=T.+R.+Schneiderauthor=H.+Starkauthor=G.+Bourenkovauthor=A.+Chari&title=The+inhibition+mechanism+of+human+20S+proteasomes+enables+next-generation+inhibitor+design&doi=10.1126%2Fscience.aaf8993"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design</span></div><div class="casAuthors">Schrader, Jil; Henneberg, Fabian; Mata, Ricardo A.; Tittmann, Kai; Schneider, Thomas R.; Stark, Holger; Bourenkov, Gleb; Chari, Ashwin</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">6299</span>),
    <span class="NLM_cas:pages">594-598</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The proteasome is a validated target for anticancer therapy, and proteasome inhibition is employed in the clinic for the treatment of tumors and hematol. malignancies.  Here, the authors describe crystal structures of the native human 20S proteasome and its complexes with inhibitors, which either are drugs approved for cancer treatment or are in clin. trials.  The structure of the native human 20S proteasome was detd. at an unprecedented resoln. of 1.8 angstroms.  Addnl., six inhibitor-proteasome complex structures were elucidated at resolns. between 1.9 and 2.1 angstroms.  Collectively, the high-resoln. structures provide new insights into the catalytic mechanisms of inhibition and necessitate a revised description of the proteasome active site.  Knowledge about inhibition mechanisms provides insights into peptide hydrolysis and can guide strategies for the development of next-generation proteasome-based cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZCuIDBbOXPLVg90H21EOLACvtfcHk0lgEuJVeKEGrkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Oks7vL&md5=8216d0007cbf06c352e06fcb05d644a9</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1126%2Fscience.aaf8993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aaf8993%26sid%3Dliteratum%253Aachs%26aulast%3DSchrader%26aufirst%3DJ.%26aulast%3DHenneberg%26aufirst%3DF.%26aulast%3DMata%26aufirst%3DR.%2BA.%26aulast%3DTittmann%26aufirst%3DK.%26aulast%3DSchneider%26aufirst%3DT.%2BR.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DBourenkov%26aufirst%3DG.%26aulast%3DChari%26aufirst%3DA.%26atitle%3DThe%2520inhibition%2520mechanism%2520of%2520human%252020S%2520proteasomes%2520enables%2520next-generation%2520inhibitor%2520design%26jtitle%3DScience%26date%3D2016%26volume%3D353%26spage%3D594%26epage%3D598%26doi%3D10.1126%2Fscience.aaf8993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mushtaq, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoor, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latif, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iftikhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahid, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riaz, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anwer, F.</span></span> <span> </span><span class="NLM_article-title">Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: a systematic review</span>. <i>Crit Rev. Oncol Hematol</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2018.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1016%2Fj.critrevonc.2018.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=29650268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A280%3ADC%252BC1MjitF2gsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2018&pages=1-11&author=A.+Mushtaqauthor=V.+Kapoorauthor=A.+Latifauthor=A.+Iftikharauthor=U.+Zahidauthor=A.+McBrideauthor=I.+Abrahamauthor=I.+B.+Riazauthor=F.+Anwer&title=Efficacy+and+toxicity+profile+of+carfilzomib+based+regimens+for+treatment+of+multiple+myeloma%3A+a+systematic+review&doi=10.1016%2Fj.critrevonc.2018.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review</span></div><div class="casAuthors">Mushtaq Adeela; Kapoor Vikas; Latif Azka; Iftikhar Ahmad; Zahid Umar; McBride Ali; Abraham Ivo; Riaz Irbaz Bin; Anwer Faiz</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-11</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Standard induction therapy for multiple myeloma is three-drug combination based on following classes of drugs: proteasome inhibitors, immunomodulators and steroids.  Despite its notable efficacy, bortezomib has side effects like peripheral neuropathy (PNP) with reported incidence of grade ≥3 PNP between 2%-23% Schlafer et al., 2017.  Carfilzomib (CFZ) has high selectivity and minimal off-target adverse effects including lower rates of PNP.  CFZ is already approved for treatment of relapsed and refractory multiple myeloma (RRMM) as single agent as well as in combination with lenalidomide and/or dexamethasone.  Extensive literature search identified a total of 1839 articles.  Twenty-six articles (n = 5980) met the inclusion criteria, 15 in newly diagnosed multiple myeloma (NDMM) and 11 in RRMM group.  CFZ demonstrates comparable or even better efficacy to bortezomib with much favorable AE profile.  Deep, rapid and sustainable response using KRd with safer toxicity profile supports extension of KRd therapy to frontline therapy for all risk categories of MM.  High incidence of grade ≥3 HTN underscores the importance of serial BP monitoring.  In RRMM, CFZ has documented efficacy with standard 20-27mg/m2 dose.  Further large-scale trials are needed to study benefit-to-risk profile of 20-56 and 20-70 mg/m2 dose of CFZ vs standard 20-27 mg/m2 dose in NDMM and RRMM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTszHATWKJXIBJ5E29YNGvQfW6udTcc2eai6cfg8Rl8Urntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjitF2gsQ%253D%253D&md5=d39efa7e5c297ac2876197ad300370f3</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2018.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2018.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DMushtaq%26aufirst%3DA.%26aulast%3DKapoor%26aufirst%3DV.%26aulast%3DLatif%26aufirst%3DA.%26aulast%3DIftikhar%26aufirst%3DA.%26aulast%3DZahid%26aufirst%3DU.%26aulast%3DMcBride%26aufirst%3DA.%26aulast%3DAbraham%26aufirst%3DI.%26aulast%3DRiaz%26aufirst%3DI.%2BB.%26aulast%3DAnwer%26aufirst%3DF.%26atitle%3DEfficacy%2520and%2520toxicity%2520profile%2520of%2520carfilzomib%2520based%2520regimens%2520for%2520treatment%2520of%2520multiple%2520myeloma%253A%2520a%2520systematic%2520review%26jtitle%3DCrit%2520Rev.%2520Oncol%2520Hematol%26date%3D2018%26volume%3D125%26spage%3D1%26epage%3D11%26doi%3D10.1016%2Fj.critrevonc.2018.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Federspiel, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codreanu, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albertolle, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teague, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guengerich, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liebler, D. C.</span></span> <span> </span><span class="NLM_article-title">Specificity of protein covalent modification by the electrophilic proteasome inhibitor carfilzomib in human cells</span>. <i>Mol. Cell. Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3233</span>– <span class="NLM_lpage">3242</span>, <span class="refDoi"> DOI: 10.1074/mcp.M116.059709</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1074%2Fmcp.M116.059709" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=27503896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFCnsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=3233-3242&author=J.+D.+Federspielauthor=S.+G.+Codreanuauthor=S.+Goyalauthor=M.+E.+Albertolleauthor=E.+Loweauthor=J.+Teagueauthor=H.+Wongauthor=F.+P.+Guengerichauthor=D.+C.+Liebler&title=Specificity+of+protein+covalent+modification+by+the+electrophilic+proteasome+inhibitor+carfilzomib+in+human+cells&doi=10.1074%2Fmcp.M116.059709"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Specificity of protein covalent modification by the electrophilic proteasome inhibitor carfilzomib in human cells</span></div><div class="casAuthors">Federspiel, Joel D.; Codreanu, Simona G.; Goyal, Sandeep; Albertolle, Matthew E.; Lowe, Eric; Teague, Juli; Wong, Hansen; Guengerich, F. Peter; Liebler, Daniel C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular & Cellular Proteomics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3233-3242</span>CODEN:
                <span class="NLM_cas:coden">MCPOBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-9484</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Carfilzomib (CFZ) is a second-generation proteasome inhibitor that is Food and Drug Administration and European Commission approved for the treatment of relapsed or refractory multiple myeloma.  CFZ is an epoxomicin deriv. with an epoxyketone electrophilic warhead that irreversibly adducts the catalytic threonine residue of the β5 subunit of the proteasome.  Although CFZ produces a highly potent, sustained inactivation of the proteasome, the electrophilic nature of the drug could potentially produce off-target protein adduction.  To address this possibility, we synthesized an alkynyl analog of CFZ and investigated protein adduction by this analog in HepG2 cells.  Using click chem. coupled with streptavidin based IP and shotgun tandem mass spectrometry (MS/MS), we identified two off-target proteins, cytochrome P 450 27A1 (CYP27A1) and glutathione S-transferase omega 1 (GSTO1), as targets of the alkynyl CFZ probe.  We confirmed the adduction of CYP27A1 and GSTO1 by streptavidin capture and immunoblotting methodol. and then site-specifically mapped the adducts with targeted MS/MS methods.  Although CFZ adduction of CYP27A1 and GSTO1 in vitro decreased the activities of these enzymes, the small fraction of these proteins modified by CFZ in intact cells should limit the impact of these offtarget modifications.  The data support the high selectivity of CFZ for covalent modification of its therapeutic targets, despite the presence of a reactive electrophile.  The approach we describe offers a generalizable method to evaluate the safety profile of covalent protein-modifying therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1MWDdlf62B7Vg90H21EOLACvtfcHk0litTl2GuLSh7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFCnsLs%253D&md5=ff2d31854362ad6b6c7f8ea2129acdc8</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1074%2Fmcp.M116.059709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fmcp.M116.059709%26sid%3Dliteratum%253Aachs%26aulast%3DFederspiel%26aufirst%3DJ.%2BD.%26aulast%3DCodreanu%26aufirst%3DS.%2BG.%26aulast%3DGoyal%26aufirst%3DS.%26aulast%3DAlbertolle%26aufirst%3DM.%2BE.%26aulast%3DLowe%26aufirst%3DE.%26aulast%3DTeague%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DGuengerich%26aufirst%3DF.%2BP.%26aulast%3DLiebler%26aufirst%3DD.%2BC.%26atitle%3DSpecificity%2520of%2520protein%2520covalent%2520modification%2520by%2520the%2520electrophilic%2520proteasome%2520inhibitor%2520carfilzomib%2520in%2520human%2520cells%26jtitle%3DMol.%2520Cell.%2520Proteomics%26date%3D2016%26volume%3D15%26spage%3D3233%26epage%3D3242%26doi%3D10.1074%2Fmcp.M116.059709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span> <span> </span><span class="NLM_article-title">Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">168</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.226993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1124%2Fjpet.115.226993" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=26311812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslals7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2015&pages=168-173&author=L.+Aoauthor=D.+Reichelauthor=D.+Huauthor=H.+Jeongauthor=K.+B.+Kimauthor=Y.+Baeauthor=W.+Lee&title=Polymer+micelle+formulations+of+proteasome+inhibitor+carfilzomib+for+improved+metabolic+stability+and+anticancer+efficacy+in+human+multiple+myeloma+and+lung+cancer+cell+lines&doi=10.1124%2Fjpet.115.226993"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines</span></div><div class="casAuthors">Ao, Lin; Reichel, Derek; Hu, Di; Jeong, Hyunyoung; Kim, Kyung Bo; Bae, Younsoo; Lee, Wooin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">168-173</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Carfilzomib (CFZ) is a second-generation proteasome inhibitor drug approved for the treatment of multiple myeloma.  Contrary to its excellent antimyeloma activity, CFZ has shown only limited efficacy in patients with solid malignancies.  This lack of efficacy has been attributed in part to rapid degrdn. of CFZ in the body, possibly hindering the ability of CFZ to access the proteasome target in solid tumors.  We hypothesized that polymer micelles, a currently Food and Drug Administration-approved nanoparticle drug delivery formulation, may protect CFZ from metabolic degrdn. and thus expand the clin. utility of the drug as an anticancer agent.  To test our hypothesis, we prepd. CFZ-entrapped polymer micelle particles with various compns. and drug release profiles and examd. the extent of the CFZ metab. in vitro using mouse liver homogenates.  We also assessed the cytotoxic activities of the CFZ-entrapped micelle formulations in human cancer cell lines derived from B lymphocytes (RPMI-8226) and the lung (H460).  Our data indicated that polymer micelle-based formulations can improve metabolic stability and cytotoxic effects of CFZ compared with free CFZ in human cancer cell lines tested.  Taken together, these results suggest that polymer micelles may have potential as a delivery system for CFZ with an extended therapeutic utility for nonhematol. malignancies in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqc8dzYgQUzSLVg90H21EOLACvtfcHk0litTl2GuLSh7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslals7w%253D&md5=3130e9ad61b0b69a1daa9e66c08c6576</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.226993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.226993%26sid%3Dliteratum%253Aachs%26aulast%3DAo%26aufirst%3DL.%26aulast%3DReichel%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DD.%26aulast%3DJeong%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DBae%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DW.%26atitle%3DPolymer%2520micelle%2520formulations%2520of%2520proteasome%2520inhibitor%2520carfilzomib%2520for%2520improved%2520metabolic%2520stability%2520and%2520anticancer%2520efficacy%2520in%2520human%2520multiple%2520myeloma%2520and%2520lung%2520cancer%2520cell%2520lines%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D355%26spage%3D168%26epage%3D173%26doi%3D10.1124%2Fjpet.115.226993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryoo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span> <span> </span><span class="NLM_article-title">Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: anticancer efficacy and pharmacokinetic studies in mice</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e0173247</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0173247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=10.1371%2Fjournal.pone.0173247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=28273121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVGjsbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&author=J.+E.+Parkauthor=S.+E.+Chunauthor=D.+Reichelauthor=J.+S.+Minauthor=S.+C.+Leeauthor=S.+Hanauthor=G.+Ryooauthor=Y.+Ohauthor=S.+H.+Parkauthor=H.+M.+Ryuauthor=K.+B.+Kimauthor=H.+Y.+Leeauthor=S.+K.+Baeauthor=Y.+Baeauthor=W.+Lee&title=Polymer+micelle+formulation+for+the+proteasome+inhibitor+drug+carfilzomib%3A+anticancer+efficacy+and+pharmacokinetic+studies+in+mice&doi=10.1371%2Fjournal.pone.0173247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice</span></div><div class="casAuthors">Park, Ji Eun; Chun, Se-Eun; Reichel, Derek; Min, Jee Sun; Lee, Su-Chan; Han, Songhee; Ryoo, Gongmi; Oh, Yunseok; Park, Shin-Hyung; Ryu, Heon-Min; Kim, Kyung Bo; Lee, Ho-Young; Bae, Soo Kyung; Bae, Younsoo; Lee, Wooin</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e0173247/1-e0173247/12</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Carfilzomib (CFZ) is a peptide epoxyketone proteasome inhibitor approved for the treatment of multiple myeloma (MM).  Despite the remarkable efficacy of CFZ against MM, the clin. trials in patients with solid cancers yielded rather disappointing results with minimal clin. benefits.  Rapid degrdn. of CFZ in vivo and its poor penetration to tumor sites are considered to be major factors limiting its efficacy against solid cancers.  We previously reported that polymer micelles (PMs) composed of biodegradable block copolymers poly(ethylene glycol) (PEG) and poly(caprolactone) (PCL) can improve the metabolic stability of CFZ in vitro.  Here, we prepd. the CFZ-loaded PM, PEG-PCL-deoxycholic acid (CFZ-PM) and assessed its in vivo anticancer efficacy and pharmacokinetic profiles.  Despite in vitro metabolic protection of CFZ, CFZ-PM did not display in vivo anticancer efficacy in mice bearing human lung cancer xenograft (H460) superior to that of the clin. used cyclodextrinbased CFZ (CFZ-CD) formulation.  The plasma pharmacokinetic profiles of CFZ-PM were also comparable to those of CFZ-CD and the residual tumors that persisted in xenograft mice receiving CFZ-PM displayed an incomplete proteasome inhibition.  In summary, our results showed that despite its favorable in vitro performances, the current CFZ-PM formulation did not improve in vivo anticancer efficacy and accessibility of active CFZ to solid cancer tissues over CFZ-CD.  Careful consideration of the current results and potential confounding factors may provide valuable insights into the future efforts to validate the potential of CFZ based therapy for solid cancer and to develop effective CFZ delivery strategies that can be used to treat solid cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1CNICEadpy7Vg90H21EOLACvtfcHk0ljSd0drCLah4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVGjsbjF&md5=39c80a41e6b90037f31b311a223336a1</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0173247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0173247%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BE.%26aulast%3DChun%26aufirst%3DS.%2BE.%26aulast%3DReichel%26aufirst%3DD.%26aulast%3DMin%26aufirst%3DJ.%2BS.%26aulast%3DLee%26aufirst%3DS.%2BC.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DRyoo%26aufirst%3DG.%26aulast%3DOh%26aufirst%3DY.%26aulast%3DPark%26aufirst%3DS.%2BH.%26aulast%3DRyu%26aufirst%3DH.%2BM.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DLee%26aufirst%3DH.%2BY.%26aulast%3DBae%26aufirst%3DS.%2BK.%26aulast%3DBae%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DW.%26atitle%3DPolymer%2520micelle%2520formulation%2520for%2520the%2520proteasome%2520inhibitor%2520drug%2520carfilzomib%253A%2520anticancer%2520efficacy%2520and%2520pharmacokinetic%2520studies%2520in%2520mice%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26doi%3D10.1371%2Fjournal.pone.0173247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UNB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UNB','PDB','3UNB'); return false;">PDB: 3UNB</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UNF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UNF','PDB','3UNF'); return false;">PDB: 3UNF</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i42"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01943">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_02246"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b01943">10.1021/acs.jmedchem.8b01943</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Cell viability data of H727 and H23 cells for carfilzomib; effect of reversin-121 on carfilzomib sensitivity in RPMI 8226 with acquired carfilzomib resistance; <sup>1</sup>H NMR, <sup>13</sup>C NMR spectra; LC–MS profiles and molecular formula strings of <b>5</b> and <b>7</b>–<b>12</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01943/suppl_file/jm8b01943_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular docking models in PDB format (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01943/suppl_file/jm8b01943_si_002.pdf">PDF</a>)</p></li><li><p class="inline">Compound data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01943/suppl_file/jm8b01943_si_003.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01943/suppl_file/jm8b01943_si_001.pdf">jm8b01943_si_001.pdf (3.1 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01943/suppl_file/jm8b01943_si_002.pdf">jm8b01943_si_002.pdf (636.58 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01943/suppl_file/jm8b01943_si_003.csv">jm8b01943_si_003.csv (1.12 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b01943&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b01943%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-9" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b01943" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a40e89de53dbe","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
